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A doença de Alzheimer (AD) é uma doença neurodegenerativa devastadora, de 
causa ainda desconhecida e para a qual não existe cura.  Afecta principalmente pessoas 
idosas e, com o aumento gradual da esperança média de vida, tornou-se um dos mais 
graves problemas de saúde pública.  O período médio de sobrevivência do indivíduo 
doente, após o diagnóstico, é de apenas 8 anos.  Caracteriza-se por originar uma perda 
progressiva da memória e da capacidade de raciocínio, mudanças de humor, mudanças de 
personalidade e perda de independência.  As mutações responsáveis por AD e pelas 
formas familiares da doença representam apenas 5% do total de casos.  Embora raras, 
essas mutações estão muito bem estudadas e definidas.  As primeiras mutações que foram 
identificadas situam-se no gene da proteína precursora do péptido β amilóide (Aβ), o qual 
se localiza no cromossoma 21.  As formas mutantes do Aβ, ao contrário da sua forma 
nativa, têm a particularidade de serem bastante agressivas para as células endoteliais 
vasculares do cérebro, originando a chamada angiopatia amilóide cerebral.  Em termos 
fisiopatológicos, a AD caracteriza-se, ainda, pela perda massiva de neurónios, o que 
origina perturbações na função sináptica.  Esta perda de neurónios começa no hipocampo, 
numa área que desempenha uma função primordial na formação de novas memórias, e 
rapidamente atinge outras zonas do cérebro.  As placas amilóides e as tranças 
neurofibrilhares, resultantes da hiperfosforilação da proteína tau, são os únicos elementos 
discriminadores da doença, utilizados para realizar o seu diagnóstico definitivo aquando 
da autópsia. 
Estudar e compreender o fenómeno da morte celular programada é de todo 
imperativo.  A apoptose é um processo altamente regulado, que envolve vários organitos 
e, como tal, pode ser iniciado em diversos locais da célula.  Na realidade, cada organito 
possui sensores que lhes permitem aferir a homeostasia dos processos bioquímicos que 
regula.  Sempre que a homeostasia esteja comprometida, de uma forma que coloque em 
risco a sobrevivência da célula, os organitos comunicam sinais de morte celular entre si, 
para que a célula seja removida, sem comprometer as células adjacentes.  Assim, a 
descodificação da complexa rede de sinalização intracelular, responsável pela morte 
celular programada do tipo apoptótico, pode representar a chave para retardar, ou até 
prevenir, a neurodegenerescência associada à AD.  O conceito de que a morte celular não 
é meramente aleatória e caótica, mas antes pode seguir um processo programado e 
regulado, representou um estímulo para desenvolver o trabalho apresentado nesta tese.  
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Sabendo que a aplicação aguda de formas solúveis do péptido Aβ mimetiza a 
toxicidade observada na AD, estudaram-se os efeitos do Aβ na morte celular.  
Inicialmente, procurámos entender o papel da agregação do Aβ na morte celular e, para 
isso, tirámos partido do facto de os péptidos mutantes de Aβ terem características 
particulares de agregação, para além de uma afinidade selectiva para as células 
vasculares.  Assim, usando células primárias de endotélio vascular humano, 
determinámos que o péptido mutante AβE22Q apresenta um estado conformacional 
intermédio, entre o observado para a formas nativas de Aβ40 e Aβ42.  Além disso, 
mostrámos que, ao contrário das formas nativas, o péptido mutante AβE22Q activa a 
apoptose nestas células através da translocação da Bax para a mitocôndria, com a 
consequente libertação do citocromo c para o citosol.  Este efeito conseguiu ser revertido 
com a pré-incubação das células com um agente anti-apoptótico, o ácido tauro-
ursodesoxicólico (TUDCA).  Contudo, apesar do seu potente efeito anti-apoptótico, o 
TUDCA não interferiu directamente com as propriedades de agregação características do 
Aβ in vitro.  Estes resultados demonstram que a agregação, por si só, não é suficiente para 
induzir toxicidade.  Sugerem, antes, que os efeitos tóxicos são devidos a conformações 
específicas que os péptidos adquirem e que estas, sim, conseguem danificar a célula e 
despoletar a via mitocondrial de apoptose.  
Tendo em conta que durante o processo de agregação do péptido Aβ, este forma 
espécies desnaturadas e que o retículo endoplasmático (ER) é o organito responsável pela 
conformação espacial das proteínas, estudámos em que medida o Aβ solúvel afecta o ER.  
A exposição de células PC12 do tipo neuronal ao Aβ provocou uma resposta imediata de 
sinalização molecular, que envolveu a caspase-12, independentemente da activação da via 
do stresse do ER e que culminou na morte celular.  Assim, observaram-se níveis proteicos 
diminuídos dos marcadores de stresse do ER, incluindo o GRP94, ATF-6α, CHOP e 
eIF2α.  Este efeito mostrou-se independente de mecanismos de degradação proteica, 
mediados pelo protessoma ou pela autofagia, tendo sido parcialmente contrariado pelo 
TUDCA.  Por sua vez, com a inibição das calpaínas conseguiu-se bloquear a activação da 
caspase-12 e a diminuição do ATF-6α.  Muito interessante foi, ainda, o facto de ser 
possível bloquear a diminuição dos níveis da proteína GRP94 através da inibição da via 
secretória de proteínas, pela utilização da geldanamicina e brefeldina.  Este mecanismo de 
sinalização pelo péptido Aβ coloca o GRP94 no meio extracelular, abrindo uma 
oportunidade única para o desenvolvimento de novas estratégias terapêuticas. 
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Para finalizar, tendo em conta que a cinase do terminal amínico da proteína c-Jun 
(JNK) é um sensor primordial do stresse celular, activado na presença do Aβ, bem como 
o facto de a JNK activar a caspase-12 e poder ser activada por vias despoletadas no ER, 
realizámos estudos para compreender o envolvimento desta cinase no contexto de 
exposição de células PC12 do tipo neuronal ao péptido Aβ solúvel.  Os nossos resultados 
mostraram que a JNK é indispensável à apoptose induzida pelo Aβ e que está localizada 
no núcleo, no seu pico de actividade.  Além disso, através do silenciamento da JNK, 
confirmámos que a caspase-2 é um alvo específico da JNK, quando activada pelo Aβ.  
Demonstrámos, ainda, que a caspase-2 activa está localizada no complexo de Golgi, 
através da clivagem do seu substrato específico, a golgina 160, que é uma proteína 
estrutural do complexo de Golgi.  Através da pré-incubação com TUDCA, conseguiu-se, 
também aqui, reverter a activação da JNK e a sua translocação para o núcleo, tendo sido 
ainda possível reverter a activação da caspase-2.  Estes resultados sugerem que o 
complexo de Golgi possa desempenhar um papel fundamental na descodificação da 
sinalização de morte induzida pelo péptido Aβ. 
Os estudos incluídos nesta tese enfatizam a noção de que a AD é uma patologia 
complexa, que envolve uma rede de sinalização entre vários organitos celulares, para 
além de contribuirem para uma melhor compreensão da comunicação subcelular, no que 
respeita aos efeitos tóxicos desencadeados pelo Aβ.  A caracterização destas vias de 
sinalização e de formas de as modular, abrem novas perspectivas para a regulação da 
disfunção celular e degenerescência induzidas pelo Aβ.  
 
Palavras chave: Ácido tauro-ursodesoxicólico; Apoptose; GRP94; JNK; Organitos 
celulares; Péptidos β amilóide 
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Alzheimer‟s disease (AD) is a devastating neurological disorder characterized by 
massive loss of neurons and disruption of synaptic function.  Cell death appears to 
involve several organelles, and decoding this complex signaling network of inter-
organellar cross-talk might represent the key for delaying or preventing AD. 
We first compared aggregation/fibrillization properties, secondary structure, and 
cell death pathways of wild-type amyloid β (Aβ) peptides and AβE22Q Dutch variant, 
both in the presence and absence of anti-apoptotic tauroursodeoxycholic acid (TUDCA).  
Our data dissociate the apoptotic properties of Aβ peptides in human cerebral endothelial 
cells from their distinct mechanisms of aggregation in vitro, while confirming the 
perspectives for modulation of amyloid-induced mitochondrial apoptosis by TUDCA. 
Next, we investigated the ability of the endoplasmic reticulum (ER) to sense 
stress directly caused by the Aβ toxic core.  Aβ exposure triggered an early signaling 
response by the ER, and caspase-12-mediated apoptosis in PC12 neuronal-like cells, 
independently of the ER-stress pathway.  Indeed, ER stress markers, including GRP94, 
ATF-6α, CHOP and eIF2α were strongly donwregulated by Aβ, in a protein degradation-
independent manner, and partially restored by TUDCA.  Calpain inhibition prevented 
caspase-12 activation and ATF-6α downregulation.  However, GRP94 downregulation 
was associated with protein secretion, which in turn was partially rescued by inhibition of 
the secretory pathway.  Thus, Aβ triggers an ER response beyond the usual ER stress. 
Finally, we further investigated the role of the c-Jun N-terminal kinase (JNK) as 
early stress sensor of Aβ toxicity that is activated by ER pathways.  We reported that JNK 
acted as the proximal stress sensor, which translocated to the nucleus and activated 
caspase-2 in PC12 neuronal-like cells.  Caspase-2 then cleaved golgin-160, suggesting a 
unique signaling through the Golgi complex.  Importantly, TUDCA modulated the 
JNK/caspase-2 apoptotic pathway triggered by Aβ. 
In conclusion, these studies contribute to the understanding of the complex sub-
cellular communication involved in Aβ toxicity.  Further characterization of these 
signaling pathways and exact targets are likely to provide new perspectives for 
modulation of amyloid-induced cellular dysfunction and degeneration. 
 
Keywords: Amyloid-β peptides; Apoptosis; Cell organelles; GRP94; JNK; 
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1.1 Alzheimer's disease 
Alzheimer‟s disease (AD) is a fatal progressive neurodegenerative illness, and 
the most common form of dementia.  It is, therefore, a fundamental disorder of cognitive 
awareness, integrating reasoning, abstraction, language, and memory, one of the defining 
components of human consciousness (Nussbaum and Ellis, 2003).  This condition was 
first described by Alois Alzheimer in 1906.  He presented a clinical/pathological report of 
a 51-year old woman, Auguste Deter, who had died of what came to be termed “dementia 
praecox.”  At autopsy, it was noted that there were extracellular deposits, termed 
“plaques”, and intracellular deposits or “tangles”, in the neocortex of the brain.  Tangles 
are a common hallmark of brain injury and are seen after a variety of other insults, such 
as stroke and head trauma.  Hence, their presence does not give any clue as to the etiology 
of the cognitive decline seen in AD.  On the other hand, the plaque deposits, although 
also seen with other injuries, do appear to bear a relationship to the underlying cause of 
the dementia (Holtzman, 2010). 
 
1.1.1 Epidemiology 
The onset of AD is inevitably followed by increasing mental and physical 
incapacitation, including loss of ability to look after one‟s own daily needs, followed by 
institutionalization and death.  AD is the most common cause (60-80%) of dementia 
worldwide.  The prevalence of AD is less than 1% in individuals aged 60-64 years, but 
the probability of developing the disorder increases with age.  The estimated rates of 
occurrence in various age groups are as follows: 65-74 years, 2.5%; 75-79 years, 4%; 80-
84 years, 11%; and 85-93 years, 24%.  It has been estimated that 4.6 million new cases 
will appear every year, at a rate of one new case every 7 seconds.  With life expectancy 
increasing, the numbers are predicted to double every 20 years to 81.1 million by 2040 
(Ferri et al., 2005).  In Portugal, there are ~ 60,000 patients with AD, although this may 
represent an under estimation, given the difficulty of diagnosis. 
AD is fourth in the list of leading causes of death in industrialized societies, 
preceded only by heart disease, cancer, and stroke.  It affects individuals of all races and 
ethnic groups, occurring slightly more commonly in women than in men.  Although AD 
is emerging as the most prevalent and socially disruptive illness of aging populations, its 
causes and cure remain enigmas (Aguzzi and O'Connor, 2010). 
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1.1.2 Molecular neuropathology 
AD is characterized by two neuropathological hallmarks, including extracellular 
deposits, known as amyloid or “senile” plaques, and intracellular neurofibrillary tangles 
(NFTs) (Spillantini and Goedert, 1998).  In addition to these deposits, the AD brain is 
characterized by a dramatic loss of neurons and synapses in many areas of the central 
nervous system, particularly in regions involving higher-order cognitive functions, such 
as learning and memory.  Because memory loss may occur by other causes, definitive 
diagnosis of AD requires postmortem examination of the brain, which must contain 
sufficient numbers of plaques and tangles to qualify as affected by AD (Braak and Braak, 
1998; Dickson, 1997). 
Brain regions, such as the basal forebrain and hippocampus that exhibit plaques, 
typically possess a reduced number of synapses.  Neurites found associated with the 
plaques are also often damaged, suggesting a toxic effect for amyloid β (Aβ) peptide, the 
major constituent of amyloid plaques (Mattson, 2004).  In addition, the levels of many 
neurotransmitters are greatly reduced, including serotonin, noradrenaline, dopamine, 
glutamate, and especially acetylcholine.  Reduced neurotransmitter levels are thought to 
be responsible for the broad and profound clinical symptoms of AD (Nussbaum and Ellis, 
2003). 
 
1.1.2.1 Amyloid plaques 
Amyloid plaques are primarily composed of a 4.3-kDa amyloid peptide, first 
isolated from the brains of patients with AD in 1984.  The Aβ peptide is a 39-43 amino 
acid sequence that forms extraneuronal aggregates with a fibrillar, β-pleated structure.  
Moreover, Aβ peptide accumulation can be observed both in brain and blood vessels. 
Aβ is cleaved from the amyloid precursor protein (APP) (Fig. 1.1), a 695-770 
amino acid transmembrane protein found in virtually all peripheral and brain cells (Selkoe 
and Schenk, 2003).  Although there is no conclusive evidence of the function of APP, an 
increasing body of data suggests its involvement in regulating neurite outgrowth, synaptic 
plasticity, and cell adhesion (Mattson, 2004). 
APP is normally cleaved within the Aβ domain by α-secretase, liberating a 
soluble N-terminal fragment (sAPPα) and a membrane-bound C-terminal fragment (C83).  
Alternatively, APP can be cleaved by β-secretase at the N-terminus of the Aβ domain, 
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yielding s-APPβ and C99.  The latter membrane-bound fragment, then undergoes 
intramembrane cleavage by γ-secretase at the C-terminus of Aβ, resulting in the liberation 
of Aβ into the cell (Yamazaki and Ihara, 1998).  The secretion of Aβ follows, allowing 
the peptide to participate in extracellular aggregation and to become incorporated into 
growing plaques. 
The β-site of APP cleaving enzyme (BACE1) is responsible for the β-secretase 
activity; γ-secretase is composed of four essential subunits, including presenilin-1 (PS1) 
or presenilin-2 (PS2), together with nicastrin, anterior pharynx-defective 1 (APH-1), and 
presenilin enhancer 2 (PEN-2) (Thinakaran and Koo, 2008).  The γ-secretase complex 
cleaves at multiple sites within the transmembrane domain of APP, generating Aβ 
peptides ranging in length from 38 to 42 residues (Selkoe and Wolfe, 2007).  Nearly 90% 
of secreted Aβ ends at residue 40, giving Aβ40, whereas Aβ42 accounts for only less than 
10%, and peptides ending at residues 38 are minor components (Thinakaran and Koo, 
2008).  Notably, the pattern and distribution of these species varies among the different 
topographical lesions.  Parenchymal deposits consist of Aβ42 as the major component, 
whereas vascular Aβ, particularly in the large leptomeningeal vessels, is primarily 
composed of Aβ40 species, organized in large concentric sheets and replacing the smooth 
muscle cell layer (Roher et al., 1993).  Amyloid associated with arterioles and small 
cortical arteries contains a mixture of Aβ40 and Aβ42, while deposits affecting the 
capillary network are mainly composed of Aβ42 (Kokjohn and Roher, 2009).  The 
reasons for this selectivity as well as its importance for the pathogenesis of the disease 
remain largely unclear (Rostagno et al., 2010). 
The term “soluble Aβ” is generally applied either to newly generated, cell-
secreted Aβ or to that fraction of tissue or synthetic Aβ that is taken into the aqueous 
phase of a non-detergent containing extraction buffer.  “Misfolded” and “aggregated” Aβ 
are terms used to describe very early, nonspecific changes in Aβ folding states or 
solubility states, respectively (e.g., aggregated Aβ solutions usually scatter light to a 
greater extent than do solutions of soluble Aβ).  “Oligomeric” Aβ refers to peptide 
assemblies with limited stoichiometry (e.g., dimers, trimers, etc.), while protofibrils are 
structures of intermediate order between aggregates and fibrils (Fig. 1.1) (Gandy, 2005). 
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Querfurth and LaFerla, 2010 
Figure 1.1.  Processing of APP.  (A) Non-amyloidogenic processing of APP, with sequential 
cleavage by membrane-bound α- and γ-secretase.  α-secretase cleaves within the Aβ sequence, 
thus preventing the generation of intact Aβ peptide.  sAPPα ectodomain is secreted to 
extracellular milieu and C83 is released.  C83 is then processed by γ-secretase, releasing 
extracellular p3 (3 kDa) fragment.  Alternatively, amyloidogenic processing starts by β-secretase 
cleavage at the N-terminus of Aβ, releasing a shorter sAPPβ and C99 fragments.  The C99 
fragment is subsequently cleaved within the transmembrane domain by γ-secretase to originate 
Aβ and AICD.  AICD is targeted to the nucleus, signaling transcription activation.  Soluble Aβ is 
a hydophobic peptide that is prone to aggregation.  (B) Protofibrils (upper left) and annular or 
porelike profiles (lower left) are transient structures observed during in vitro formation of mature 
amyloid fibrils.  In the right panel, self-association of 2 to 14 Aβ monomers into oligomers is 
dependent on concentration (right, left immunoblot).  In the right immunoblot, oligomerization is 
promoted by oxidizing conditions (lane 2) and divalent metal conditions (lane 3).  AICD, APP 
intracellular domain; GPI, glycophosphatidylinositol.   
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Numerous mutations have been identified in the gene encoding APP, which alter 
its expression or processing (Rocchi et al., 2003).  These mutations are associated with 
early onset AD and are implicated in the autosomal dominant form of the disease, which 
constitutes ~ 5% of all cases.  Patients with Down‟s syndrome, who have three copies of 
the APP gene, show diffuse Aβ deposits as early as in the second decade of life.  These 
eventually develop into mature neuritic plaques that are indistinguishable from those 
found in the brains of patients with AD. 
 
1.1.2.2 Neurofibrillary tangles 
The chief component of intracellular NFTs is tau, a microtubule-associated 
protein abundant in six different isoforms in the adult brain.  In AD, highly 
phosphorylated and glycosylated tau protein forms paired, helically wound fragments 
(paired helical filaments), ~ 10 nm in diameter, which associate to give insoluble tangles 
in nerve cell bodies and dendrites (Fig. 1.2) (Spillantini and Goedert, 1998).  Tangles are 
a hallmark of many dementia-related diseases, including corticobasal ganglionic 
degeneration, frontotemporal dementia, myotonic dystrophy, Niemann-Pick disease, and 
progressive supranuclear palsy.  The wide variety of neurological disorders in which 
NFTs occur suggests that paired helical filament formation is a nonspecific marker of 
certain types of neuronal injury. 
 
1.1.3 Risk factors 
Besides ageing, which is the most obvious risk factor for AD, no specific 
environmental toxin has been found to be consistently associated with the disease, and 
there have been no randomized clinical trials as yet to support any specific dietary 
intervention.  Some evidence suggests that dietary intake of homocysteine-related 
vitamins, vitamin B12 and folate; antioxidants, such as vitamin C and E; unsaturated fatty 
acids; and also moderate alcohol intake, especially wine, could reduce the risk of AD.  
Epidemiological studies point to depression, traumatic head injury and cardiovascular and 
cerebrovascular factors, including cigarette smoking, midlife high blood pressure, 
obesity, hypercholesterolaemia, atherosclerosis, coronary heart disease and diabetes as 
increasing disease risk, while anti-inflammatory medications seem to reduce risk.  Some 
studies even suggest a beneficial role of psychosocial factors as though, higher education, 
physical exercise and mental activity (reviewed in Selkoe and Schenk, 2003).  Such 
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reports may point to a role of previously unconsidered pathways in the etiology of the 
disease, but the mechanistic interpretation of retrospective epidemiological studies is 
challenging (Citron, 2010). 
 
Querfurth and LaFerla, 2010 
Figure 1.2. Tau structure and function.  Tau is a highly soluble microtubule-binding protein 
that contributes to microtubule assembly and cohesion.  Four repeat sequences (R1-R4) make up 
the microtubule-binding domain (MBD) of tau.  Tau is abnormally hyperphosphorylated in AD by 
numerous kinases, leading to the formation of NFTs.  Normal phosphorylation of tau occurs on 
serine (S; inset) and threonine (T; inset) residues, numbered according to their position in the full 
tau sequence.  Between the N‑terminal portion of the protein (projection domain) and the MBD 
lies a basic proline-rich region (P); these amino acids are phosphorylated by GSK-3β, CDK5 and 
its activator subunit p25, or MAPK.  Non proline-directed kinases, such as Akt, Fyn, PKA, 
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CaMKII, and MARK are also shown.  By activating these kinases, certain inflammatory cytokines 
can also trigger tau hyperphosphorylation.  Hyperphosphorylated sites specific to paired helical 
filament tau in AD tend to flank the MBD.  Excessive kinase, reduced phosphatase activities, or 
both cause hyperphosphorylated tau.  Hyperphosphorylation of tau, particularly that mediated by 
MARK, CDK5 and GSK-3β destabilizes microtubules, causing impairments in axonal transport 
and neuronal dysfunction.  CDK5, cyclin-dependent kinase 5; MAPK, mitogen-activated protein 
kinase; PKA, protein kinase A; CaMKII, calcium-calmodulin protein kinase 2; MARK, 
microtubule affinity-regulating kinase.  From Querfurth and LaFerla, 2010. 
 
1.1.3.1 Genetics 
Family history is the second-greatest risk factor for AD after age, and the 
increasing understanding of its genetics has been vital to the knowledge of the pathogenic 
mechanisms that cause the disease.  Genetically, AD is complex and heterogeneous and 
appears to follow an age-related dichotomy: rare and highly penetrant early-onset familial 
AD mutations in different genes are transmitted in an autosomal dominant fashion, and 
late-onset AD that represents the vast majority of the cases and is absent of obvious 
familial segregation (Bertram and Tanzi, 2005). 
 
1.1.3.1.1 Sporadic disease 
The designation of late-onset AD is used when the onset of the disease occurs 
at 65 years or older, and represents ≥ 95% of all AD cases.  Although genetic analysis of 
segregation and twin studies have suggested a major role of genetic factors in this form of 
AD (Mayeux et al., 1991), until now, only one factor has been effectively established, the 
4 allele of the apolipoprotein E (APOE-4) gene on chromosome 19q13 (Schmechel et 
al., 1993; Strittmatter et al., 1993).  In contrast to all other association-based observations 
in AD, the risk outcome of APOE-4 has been consistently replicated by different 
laboratories that developed several studies transversal to numerous ethnic groups (for 
meta-analysis, see Farrer et al., 1997).  The APOE-4 genotype, which occurs in 16% of 
the population (Roses, 1997) is the major susceptibility gene identified for both rare 
early-onset and sporadic late-onset AD (Coon et al., 2007).  In addition to the increased 
risk by 4-allele, it has also been reported in several studies a weak, albeit significant, 
protective effect for the minor allele, 2.  Contrasting to mutations in the known early-
onset familial AD genes, APOE-4 is neither necessary nor sufficient to cause AD, since 
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many 4-positive individuals do not develop AD, and many AD patients do not carry 
these genes.  Instead, APOE-4 operates as a genetic risk modifier by decreasing the age 
of onset in a dose-dependent manner.  Despite its long-known and well-established 
genetic association, the molecular effects of APOE-4 in AD pathogenesis are not yet 
fully understood, but are expected to include Aβ-aggregation/clearance and/or cholesterol 
homeostasis (Bertram and Tanzi, 2005).  
 
1.1.3.1.2 Familial disease 
Early-onset familial AD (FAD) represents only a small fraction of ≤ 5% of all 
AD cases.  This designation is used when onset ages are younger than 65 years, showing 
autosomal dominant transmission within affected families.  To date, more than 160 
mutations in 3 genes have been reported to cause early-onset FAD.  These genes include 
the APP on chromosome 21 (Goate et al., 1991), PS1 on chromosome 14 (Sherrington et 
al., 1995), and PS2 on chromosome 1 (Levy-Lahad et al., 1995; Rogaev et al., 1995).  
PS1 represents the most frequently mutated gene and accounts for the majority of AD 
cases with onset prior to age of 50 (Bertram and Tanzi, 2005).  Of the genes directly 
related to the development of familial AD, PS1 and PS2 mutations affect the levels of 
Aβ42 production, whereas nucleotide changes within the APP molecule have a 
differential effect depending on the location of the mutated residue (Fig. 1.3). 
Alterations in Aβ domain that result from amino acid replacement in regions 
adjacent to β-secretase cleavage site change the kinetics of APP enzymatic processing.  
As a consequence, increased production of Aβ42 and Aβ40 is observed, maintaining the 
ratio Aβ42/Aβ40 unaffected, which manifests in a classic early-onset AD clinical 
phenotype (Revesz et al., 2009).  Two examples are Swedish double mutation 
(K670N/M671L) (Mullan et al., 1992) that increases the production of Aβ40 and Aβ42 by 
> 5-fold, and Italian mutation (A673V) (Di Fede et al., 2009) that shows enhanced 
production of both Aβ species by ~ 2-fold, maintaining the ratio Aβ42/Aβ40 unaltered.  
However, different processing is observed for mutations in regions adjacent to the γ-
secretase cleavage sites.  These mutations are typically associated with increased 
production of Aβ42 and lower levels of Aβ40, analogous to what is observed for 
mutations in the presenilin genes (Suzuki et al., 1994).  As a result, the ratio of 
Aβ42/Aβ40 is several fold elevated, reaching in some cases ~ 18-fold values.  Amino acid 
General Introduction 
11 
substitutions within residues 21-23 and 34 of the Aβ peptide are, with few exceptions 
(Wakutani et al., 2004), associated with prominent vascular compromise. 
 
 
 
Gandy, 2005 
Figure 1.3.  Structure of APP.  (A) Schematic structure and topography of APP.  (B) Area 
surrounding the Aβ domain, α-, β- and γ-secretase cleavage sites, and amino acid location in 
selected FAD missense mutations.   
 
1.1.3.2 Cerebral amyloid angiopathy 
Cerebral amyloid angiopathy (CAA) due to Aβ deposition is a key pathological 
feature of FAD.  It is an age-associated condition, characterized by deposition of Aβ in 
the medial layer of cerebral blood vessels (Coria and Rubio, 1996).  It is also a significant 
cause of intracerebral hemorrhage in patients with AD and certain related disorders (Coria 
and Rubio, 1996; Melchor et al., 2000).  Specific missense mutations in the APP gene 
occurring inside the Aβ region comprising residues 21-23 is considered a „„hot spot‟‟ for 
mutations due to the high number of genetic variants reported in this area of the molecule.  
Mutations within this amino acid cluster typically show strong vascular compromise and 
primarily associate with CAA, hemorrhagic strokes and dementia.  Mutations in the Aβ 
sequence are concentrated at positions 21-23 and are termed Dutch (E22Q) (Miravalle et 
al., 2000), Italian (E22K) (Miravalle et al., 2000), Iowa (D23N) (Van Nostrand et al., 
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2001) , Arctic (E22G) (Nilsberth et al., 2001) , Flemish (A21G) (Demeester et al., 2001) 
and New Italian (L34V) (Obici et al., 2005) mutations.  In general, all mutants are 
thought to have stronger neurotoxicity than wild-type Aβ, which may correlate with their 
ability to form protofibrils.  However, not all mutants have the same capacity to induce 
neurotoxic effects.  This suggests that the substitution of different amino acids may confer 
distinct structural properties, influencing the onset and aggressiveness of the disease.  
The first mutation inside Aβ domain was described in a condition known as 
hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D), an 
autosomal dominant disorder clinically defined by recurrent strokes, vascular dementia, 
and fatal cerebral bleeding in the fifth to sixth decades of life.  In this missense mutation, 
a Gln replaces a Glu residue at position 22 (AβE22Q) resulting from a single nucleotide 
transversion (G for C) at codon 693 (Levy et al., 1990).  The clinical manifestations for 
the carriers of this mutation include periodic episodes of cerebral hemorrhages that are 
associated with massive amyloid deposition in the walls of leptomeningeal and cortical 
arteries and arterioles, as well as in vessels in the brainstem and cerebellum (Bornebroek 
et al., 1999).  Besides the vascular involvement, Dutch familial cases also develop 
parenchymal amyloid deposits resembling the diffuse preamyloid lesions seen in AD.  
However, dense-core plaques and NFTs are rare or even not present at all (Levy et al., 
1990).  The non-fibrillar diffuse plaques show differences in the extent of fibrillary 
material, ranging from fine diffuse plaques in young patients to more fibrillar, dense 
content in old patients (Maat-Schieman et al., 2000).  Thus, the non-fibrillar diffuse 
plaques, variably associated with reactive astrocytes and activated microglia (Maat-
Schieman et al., 2004) evolve into more fibrillar, dense lesions (Maat-Schieman et al., 
2000).  Nevertheless, the degree of dementia appears to be independent of plaque 
involvement and neurofibrillary degeneration, which is absent or limited, and 
contrastingly correlates with the severity of CAA (Natte et al., 2001). 
Aβ40 is the predominant Aβ species of HCHWA-D vascular amyloid, with wild-
type and Dutch-type mutated sequences present at a 1:1 molar ratio.  In contrast, Aβ42 is 
only a minor component of the vascular deposits (Herzig et al., 2004) and is uniquely 
associated with species bearing the mutation, and not with those originated from the 
normal allele (Prelli et al., 1990).  So far, it has not been possible to identify Aβ42 wild- 
type or carrying the E22Q substitution in the cortex by Western blot, and ELISA results 
show an Aβ42/Aβ40 considerably lower than in AD cases (Herzig et al., 2004). 
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In vitro cell culture studies show that E22Q has potent toxic effects on 
cerebrovascular endothelial and smooth muscle cells (Davis and Van Nostrand, 1996; 
Miravalle et al., 2000), likely reflecting the in vivo hemorrhage-associated phenotype.  
The E22Q mutant is also a potent angiogenesis inhibitor, disturbing the fibroblast growth 
factor 2 (FGF-2) signaling pathway, downregulating phosphorylation of the FGF-2 
receptor, and the Akt survival signaling (Solito et al., 2009).  Altogheter, these effects 
lead to endothelial dysfunction and probably contribute, solely or partially, to the 
disturbances in membrane permeability and hemorrhagic manifestations in the family 
members (Rostagno et al., 2010).  
 
1.1.4 Amyloid precursor protein 
APP in mammals belongs to a family of conserved type I membrane proteins 
that include APP (Goldgaber et al., 1987), APP like protein 1 (APLP1) (Wasco et al., 
1992) and 2 (APLP2) (Slunt et al., 1994).  Importantly, the Aβ peptide domain is not 
conserved and is only present in APP and not in any of the other APP-related genes.  
Although APP family is abundantly expressed in the brain, and APLP1 expression is 
restricted to neurons (Lorent et al., 1995), APP and APLP2 can also be found in the 
majority of other tissues as well.  The human APP gene is located on the long arm of 
chromosome 21 (Lamb et al., 1993).  The expression results in alternative splicing that 
generates APP mRNAs encoding isoforms that go from 365 to 770 amino acid residues.  
The most important Aβ peptide encoding proteins have 695, 751 and 770 amino acids, 
and are denominate as APP695, APP751 and APP770 (Zheng and Koo, 2006).  
The exact physiological role of APP is not clearly understood.  However, several 
functions have been recognized based on the variety of APP extracellular subdomains, 
such as cell surface receptor (Lorenzo et al., 2000), cell adhesion (Soba et al., 2005), 
neurite outgrowth and synaptogenesis (Herard et al., 2006).  Furthermore, the APP 
intracellular domain presents a high degree of sequence conservation between the 
intracellular domain of APP, APLP1, and APLP2, predicting that it is a critical domain 
for regulation of APP function (Zheng and Koo, 2006).   
In fact, APP can be phosphorylated at multiple sites in both extracellular and 
intracellular domains (Hung and Selkoe, 1994).  Among these, the phosphorylation at the 
threonine residue (Thr668) in APP intracellular domain has received most attention.  
Several kinases have been implicated in this phosphorylation event, including the cyclin-
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dependent kinase 5 (CDK5), c-Jun N-terminal kinase 3 (JNK3), and glycogen synthase 
kinase 3β (GSK-3β) (Iijima et al., 2000; Kimberly et al., 2005; Muresan and Muresan, 
2005a).  APP Thr668 phosphorylation has been described to control APP localization to 
the growth cones and neurites (Muresan and Muresan, 2005a).  Notably, Thr668 
phosphorylated APP is preferentially transported to the nerve terminals (Muresan and 
Muresan, 2005b), and Thr668 phosphorylated APP fragments are increased in AD, but 
not in control subjects (Lee et al., 2003).  This evidence supports the theory that APP 
Thr668 phosphorylation participate in AD pathogenesis by controling Aβ production.  
The preceding facts relate to the positive or beneficial functions of APP.  Interestingly, 
there is also extensive research about the cytotoxic apoptotic properties of APP, 
particularly when APP or the β-cleaved C-terminal fragment of APP ("C99" or "C100") 
are upregulated (Yankner et al., 1989).  Overexpression of the C100 APP C-terminal 
fragment (CTF) is related with neuronal degeneration (Oster-Granite et al., 1996), 
possibly through alteration of APP signal transduction.  Furthermore, APP CTF may be 
cytotoxic through amyloid precursor protein intracellular domain (AICD), and  appears to 
require an intact caspase site within the cytosolic tail (Lu et al., 2003). 
Finally, APP has also been strongly involved in axonal transport regulation, at 
least in part through adaptor protein JIP-1 (Sisodia, 2002), a member of the c-Jun N-
terminal kinase-interacting protein (JIP) family.  This fact has particular significance, 
since APP is transported in axons via the fast anterograde transport machinery, and 
protein processing or modifications are known to take place during transit in axons 
(Zheng and Koo, 2006). 
 
1.1.4.1 Subcellular trafficking, maturation and processing 
APP processing takes place in various organelles, during its normal secretory 
pathway, and also at the cell surface.  In both neuronal and non-neuronal cells, APP is 
recognized to be transported through the secretory pathway, a continuum transport in 
separate membrane-enclosed organelles that ultimately reach the cell surface (Fig. 1.4).  
Throughout this secretory transport, post-translational modifications of the newly 
synthesized APP proteins are prone to occur, which may influence APP cleavage and Aβ 
production. 
During its trafficking through the different subcellular organelles, APP can be 
processed originating different APP fragments.  Although most cell types seem to 
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metabolize APP using the same basic molecular mechanisms, the relative influence of the 
different pathways is considerably different, particularly between neurons and non-
neuronal cell lines (Hartmann, 1999).   
 
 
 
Thinakaran and Koo, 2008 
Figure 1.4.  Intracellular trafficking of APP.  After synthesis, APP enters the endoplasmatic 
reticulum followed by the Golgi complex, and is transported via the constitutive secretory 
pathway to the cell membrane (black bars) in the basolateral surface of the cell (route 1).  Once in 
the plasma membrane, APP is rapidly internalized (route 2), and then shuttled through endocytic 
and recycling compartments back to the cell surface (route 3), or degraded in the lysosome.  
Amyloidogenic processing involves transit through the endocytic organelles, where APP 
encounters β- and γ-secretases.  Non degradable lysosomal Aβ42 is recycled back to the cell 
surface. In AD, this process is enhanced by the overproduction of Aβ42 in the endossomes, or the 
protection of APOE4 over Aβ42 against lysosomal degradation, resulting in accumulation of 
excessive Aβ42 (toxic forms) at the cell membrane.  Non-amyloidogenic processing is thought to 
be located near the plasma membrane, where α-secretase is present.   
 
Most of the APP processing occurs after complete maturation of the protein, 
even though some immature APP may also be cleaved by secretases at a low rate in the 
endoplasmatic reticulum (ER) or the cis-Golgi complex subcellular compartments.  
Mature APP is processed rapidly, with turnover of ~ 30-45 min, as it is transported to or 
from the cell surface via the secretory or endocytic pathways, respectively (Koo et al., 
1996; Kuentzel et al., 1993; Yamazaki et al., 1996).  Moreover, only small amounts of 
APP were detected at the cell surface when compared to the total cellular pool (Kuentzel 
et al., 1993).  This is consequence of rapid removal of APP at the cell surface.  APP half-
life was reported to be shorter than 10 min (Lai et al., 1995), either by APP proteolytic 
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cleavage or endocytosis.  Around 30% of cell surface APP is processed to sAPP and 
secreted (Koo et al., 1996), while the remaining cell surface CTFs may be cleaved by γ-
secretase locally, or in the endocytic pathway in endosomes, or further degraded in 
lysosomes (Kaether et al., 2006).  Both cell surface CTF cleavage product and 
unprocessed full-length APP are re-internalized through coated pits and vesicles by 
receptor-mediated endocytosis (Yamazaki et al., 1996).  If endocytosed, internalized APP 
half life is ~ 30 min (Koo et al., 1996), with a pool of endosomal APP being delivered to 
lysosomes. 
 
1.1.4.2 Pathological role of intracellular Aβ 
There is substantial evidence from transgenic mouse models that intracellular Aβ 
initiates cellular dysfunction, before it accumulates in extracellular plaques (Hsia et al., 
1999).  Moreover, a recent study characterizing intracellular accumulation of Aβ in 
humans, including patients with AD, concluded that intracellular Aβ was abundantly 
present, but did not correlate with plaque load or NFT formation (Wegiel et al., 2007).  In 
addition, the disease-associated isoform Aβ42 seems to be more prone to intracellular 
accumulation than Aβ40.  Also, intracellular Aβ occurs most frequently in the 
hippocampus and entorhinal cortex, which are the brain regions to be affected first in AD 
(Gouras et al., 2000).  Expression of APOE-4 also increases intracellular Aβ (Zerbinatti 
et al., 2006).  Within neurons, Aβ42 seems to localize in multivesicular bodies (MVBs), 
which are considered late endosomes and are generated from the early endosome system.  
Immunogold electron microscopy in brains of patients with AD demonstrated that Aβ42 
is localized to the external membrane of MVBs (Takahashi et al., 2002).  The 
accumulation of non-fibrillar Aβ within neuronal MVBs has since been shown in 
APPxPS1 transgenic mice (Langui et al., 2004), and Aβ-containing MVBs were 
frequently in the perinuclear region.  Neurons from APPxPS1 transgenic mice also  
exhibited Aβ-positive granules within the peri-nuclear region of the cell body, which was 
double labeled largely with lamp 2, a lysosomal membrane protein, cathepsin D, another 
lysosomal hydrolase, and MG160, a Golgi complex marker (Langui et al., 2004). 
Recent studies have demonstrated that Aβ accumulation within MVBs is 
pathological, leading to disrupted MVB organization through impairment of the 
ubiquitin-proteasome system (Almeida et al., 2006).  Inhibition of the proteasome by Aβ 
has been demonstrated in animal models and cell lines (Almeida et al., 2006; Oh et al., 
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2005).  Proteasome inhibition in the 3xTg-AD mice showed oligomeric Aβ accumulation 
within neuronal cell bodies (Oddo et al., 2006; Tseng et al., 2008).  Taken together, these 
findings suggest that oligomeric Aβ accumulation within neuronal cell bodies has 
pathological consequences, such as proteasome impairment that leads to the increase of 
tau protein.  In addition, proteasome inhibition, both in vivo and in vitro, result inelevated 
Aβ levels, suggestive that the proteasome degrades Aβ, and that Aβ must be within the 
cytosolic compartment for this degradation to occur (LaFerla et al., 2007). 
In Tg2576 mice, accumulation of Aβ has also been reported to take place in 
mitochondria (Manczak et al., 2006), where all subunits of the γ-secretase have been 
located (Hansson et al., 2004).  Progressive accumulation of intracellular Aβ in 
mitochondria is associated with reduced enzymatic activity of respiratory chain 
complexes III and IV, and decreased rate of oxygen consumption (Fig. 1.5) (Caspersen et 
al., 2005).  These observations facilitate the understanding of the large number of 
mitochondrial alterations described in AD (Keil et al., 2006). 
 
 
Querfurth and LaFerla, 2010 
Figure 1.5.  Oxidative stress and mitochondrial failure.  Mitochondrial dysfunction has been 
implicated in the etiology and development of AD.  APP may be targeted to mitochondria and 
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interfere with protein import.  Mitochondria have been reported to contain active γ-secretase 
complexes, which are involved in cleaving APP to form Aβ, and contain also PS1.  ROS and 
reactive nitrogen species (RNS) are generated from respiratory complexes I, II, and III.  The 
resulting free radicals attack the cell and organelle membrane lipids, increasing the levels of toxic 
aldehydes hydroxynonenal (HNE) and malondialdehyde, and inhibit the mitochondrial aldehyde 
dehydrogenase.  Oxidative damage to membrane-bound, ion-specific ATPases and stimulation of 
calcium (Ca2+) entry mechanisms, such as glutamate N-methyl-D-aspartate (NMDA) receptors, 
membrane-attack complex of complement, and ion-selective amyloid pore formation, cause 
cytosolic and mitochondrial Ca2+ overload.  Cellular Aβ binds to alcohol dehydrogenase and 
directly targets the respiratory chain complex IV (cytochrome c oxidase), and key Krebs-cycle 
enzymes, leading to increased ROS levels and ATP depletion.  Aβ also promotes damage in 
mitochondrial DNA (mtDNA), which results in augmented dysfunction in respiratory chain 
complexes and further increase in ROS.  Lipid peroxidation products also promote tau 
phosphorylation and aggregation, which in turn inhibit complex I.  As the mitochondrial 
membrane potential collapses and the mitochondrial permeability-transition pore (MPP) opens, 
caspases are activated and ROS are released to the cytosol.  Cytosolic ROS/RNS in turn were 
demonstrated to activate KATP channels, which causes alterations in mitochondrial membrane 
potential (Ψm) and further augments ROS levels.  Aβ also induces the stress activated protein 
kinases p38 and JNK, as well as p53, which are further linked with apoptosis.  Substrate 
deficiencies, notably NADH and glucose, combine with electron transport uncoupling to further 
diminish ATP production. GLUT1, 4 , glucose transporter 1, 4.   
 
Intraneuronal Aβ is associated with synaptic dysfunction (Fig. 1.6), which could 
underlie cognitive deficits.  The 3xTg-AD mouse model of AD exhibits intraneuronal 
accumulation of Aβ at 4 months of age, when cognitive deficits are first detected (Billings 
et al., 2005).  Accordingly, these mice show no plaque formation, little somatodendritic 
tau and no hyperphosphorylated tau species.  Finally, the depletion of intraneuronal Aβ 
with immunotherapy restores cognition to control non-transgenic levels (Billings et al., 
2005). 
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Querfurth and LaFerla, 2010 
Figure 1.6.  Synaptic dysfunction in AD.  Aβ is thought to have a physiological role in 
modulating synaptic activity, the disruption of which probably underlies cognitive dysfunction.  
Excess build-up of Aβ and synaptotoxic Aβ oligomers induce neurotransmitter receptor 
internalization and inhibition.  Aβligomers, impair synaptic plasticity by altering the balance 
between long-term potentiation (LTP) and long-term depression (LTD) and reducing the numbers 
of dendritic spines.  At high concentrations, oligomers may suppress basal synaptic transmission.  
Because Aβ oligomers can also enhance LTD through activation of glutamate receptors, 
stimulation of glutamate receptors results in excitotoxicity that, under conditions of reduced 
energy availability or increased oxidative stress, leads to Ca2+ influx into postsynaptic regions of 
dendrites.  This, in turn, can trigger apoptosis.  Aβ facilitates endocytosis of NMDA receptors and 
AMPA.  Aβ also binds to the receptors of p75 neurotrophin (p75NTr) and brain-derived 
neurotrophic factor (BDNF) also known as tyrosine kinase B receptor (trkBr), exacerbating a 
situation in which levels of BDNF and nerve growth factor (NGF) are already suppressed.  Aβ 
impairs nicotinic acetylcholine receptor (nAChr) signaling and acetylcholine (Ach) release from 
the presynaptic terminal.  Thus, ACh levels are markedly reduced in AD.  Levels of nAChR are 
diminished in the AD brain, in part by Aβ-induced internalization.  pCaMKII, phosphorylated 
Ca2+ calmodulin-dependent protein kinase 2; pCREB phosphorylated cyclic AMP response-
element-binding protein; VGCC voltage-gated Ca2+ channel.   
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A large body of evidence indicates that the accumulation of intracellular Aβ 
induces important expression of ER stress markers.  Immunohistochemical studies 
showed that neurons in postmortem brain samples of AD patients present staining of 
phosphorylated (activated) unfolded protein response (UPR) kinases, such as double 
stranded ribonucleic acid-activated protein kinase-like ER kinase (PERK, also known as 
EIF2AK3) and inositol-requiring kinase 1 (IRE1, also known as ERN1) (Hoozemans et 
al., 2009).  These proteins were clearly upregulated in hippocampal neurons in AD, 
particularly in neurons containing granulovacuolar degeneration.  Interestingly, pPERK-
positive neurons also presented abundant staining for GSK-3β.  This is a relevant 
observation since it points out that ER stress may trigger the expression of GSK-3β, a 
well-known tau kinase, and in that way enhance NFT formation (Resende et al., 2008). 
 
1.1.4.2.1 Endoplasmic reticulum stress 
The ER fulfills multiple cellular functions (reviewed in Xu et al., 2005).  The 
lumen of the ER is an exceptional compartment, holding the highest concentration of Ca
2+
 
within the cell, due to active transport of Ca
2+
 ions by Ca
2+
 ATPases (Fig. 1.7).  The 
lumen is an oxidative environment, important for generation of disulfide bonds and 
proper folding of proteins destined for secretion or display on the cell surface.  Because of 
its role in protein folding and transport, the ER is also rich in Ca
2+
-dependent molecular 
chaperones, such as 78-kDa glucose-regulated protein (GRP78), also known as Bip 
(GRP78/Bip), 94-kDa glucose-regulated protein (GRP94), and calreticulin, which 
stabilize protein folding intermediates (reviewed in Orrenius et al., 2003).  Importantly, 
Ca
2+ 
is a vital second messenger associated with the most fundamental molecular 
pathways within the cell.  Thus, its intracellular free levels are tightly regulated by the ER 
to avoid cell death induced by intracellular Ca
2+
 dysregulation. 
GRP94 has been extensively linked to cellular Ca
2+
 homoeostasis (Macer and 
Koch, 1988).  One of the major characteristics that GRP94 shares with other ER stress 
proteins is that its expression is induced trough a transcriptional feedback loop (Little et 
al., 1994), when cells are challenged with Ca
2+
 ionophores (Drummond et al., 1987).  
GRP94 binds Ca
2+
 and is one of approximately six luminal proteins that serve as the 
major Ca
2+
 buffers of the ER (Cala and Jones, 1994; Macer and Koch, 1988; Nigam et al., 
1994).  Purified GRP94 is predicted to bind 28 mol of Ca
2+
/mol of protein by one 
estimate (Macer and Koch, 1988) and 16-20 mol/mol by another, with a few high-affinity 
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(Kd 1-5 μM) binding sites and other lower-affinity sites (Kd ∼ 600 μM).  Furthermore, 
GRP94 affects the biosynthesis of several secreted and membrane-bound proteins, such as 
immunoglobulins (Melnick et al., 1994) or Toll-like receptors (Randow and Seed, 2001), 
and acts as a peptide-binding protein (Blachere et al., 1997; Srivastava and Udono, 1994).  
Its peopensity to bind several different peptides has been used to enhance immune 
responses.  When injected into mice, GRP94-bound peptides are transferred on to major 
histocompatability complex (MHC) class I proteins that then activate peptide-specific T-
cells (Berwin et al., 2002; Li et al., 2005; Suto and Srivastava, 1995). 
 
 
Orrenius, 2003 
Figure 1.7. The regulation of intracellular Ca
2+
 compartmentalization.  Cellular Ca2+ influx 
into the cytosol through the plasma membrane is a tightly control process, both temporally and 
spatially, that occurs largely by receptor-operated (for example, glutamate receptors), voltage-
sensitive and store-operated channels.  Once inside the cell, Ca2+ can either interact with Ca2+-
binding proteins or become sequestered into the ER or mitochondria.  At rest, cytosolic Ca2+ 
levels are maintained at relatively low levels, relative to the extracellular space and the 
intracellular stores by the presence of Ca2+-binding buffering proteins, via the extrusion of 
cytosolic Ca2+ across the plasma membrane through Ca2+ ATPase (PMCA) pumps and 
exchangers, and also due to sequestration into intracellular stores.  Then, after activation 
(electrical, synaptic or receptor (R) mediated), they rise rapidly to the low micromolar range.  The 
ER is the largest Ca2+ intracellular store via the pumping of cytosolic calcium of 
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sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps.  Inside the ER Ca2+ is maintained 
elevated by Ca2+-binding buffering proteins (calreticulin, calsequestrin, GRP94). Calcium release 
from the ER occurs through inositol triphosphate receptors (InsP3Rs or IP3Rs) and ryanodine 
receptors (RyRs).  Release through InsP3Rs requires the activation of G proteins (G) on the cell 
surface that induce phospholipase C (PLCγ) to cleave phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2) into diacylglycerol (DAG) and Ins(1,4,5)P3, although it might be possible to 
activate release without Ins(1,4,5)P3.  Alternatively, release can also occur through tyrosine-
kinase-coupled receptors.  Mitochondria pump cytosolic Ca2+ electrophoretically via a uniport 
transporter and can release it again through three different pathways: reversal of the uniporter, 
Na+/H+-dependent Ca2+ exchange, or as a result of permeability transition pore (mPTP) opening.  
The mPTP can also flicker to release small amounts of Ca2+.  Ca2+ efflux from cells is regulated 
primarily by the PMCA, which binds calmodulin and has a high affinity for Ca2+.  Ca2+ efflux 
might also be mediated by the Na+/ Ca2+-exchanger (NCX).   
 
Disturbances in ER function or loss of integrity lead to ER stress, which may be 
caused by accumulation of unfolded proteins or changes in Ca
2+
 homeostasis within the 
ER (Lindholm et al., 2006).  Most neurodegenerative disorders, including AD are 
associated with aggregation of misfolded proteins (Rao et al., 2004).  When viable 
proteins acquire pathological conformations, physiological functions in the cell are 
affected, which often culminates in cell death.  Pathogenic pathways involve membrane 
permeabilization, through either a channel mechanism or by hydrophobic interaction of 
prefibrillary oligomers with cellular targets (Jellinger, 2009).  
To eliminate misfolded proteins, cells can activate a large number of intracellular 
proteases and chaperones, which integrate the cellular protein quality-control system of 
the ER.  The two principal routes of intracellular protein catabolism are the ubiquitin-
proteasome system (UPS), and the autophagy-lysosome pathway or autophagy.  Both 
pathways were described as having a dual role in nervous system homeostasis, including 
both protection and degeneration (Jellinger, 2009).  
When protein misfolding occurs, the ER triggers a signaling pathway known as 
UPR (Fig. 1.8).  Initially cytoprotective, the UPR will trigger a typical apoptotic cascade 
if the cellular insult is not efficiently removed, representing a last resort of multicellular 
organisms to dispense of dysfunctional cells.  The UPR is essential for the non-lysosomal 
degradation and clearance of altered proteins that have the potential to induce cellular 
damage (Kim et al., 2008).  It is characterized by the coordinated activation of multiple 
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ER-resident sensors, including PERK, IRE1, and activating transcription factor 6 (ATF-
6).  Once activated, these proteins trigger signaling events, such as increased expression 
of ER chaperones, inhibition of protein entry into the ER, blockage of mRNA translation, 
and acceleration of altered protein export from the ER to the cytosol for ubiquitination 
and proteasome-mediated degradation (reviewed in Schroder and Kaufman, 2005).  
Normally, the N-termini of these transmembrane ER proteins are held by ER chaperone 
GRP78/Bip, preventing their aggregation.  But when misfolded proteins accumulate, 
GRP78/Bip is released, allowing aggregation of these transmembrane signaling proteins, 
and launching the UPR (Xu et al., 2005).  
Disturbances in Ca
2+
 regulation can also induce the UPR and perturb cellular 
events that control cell fate (Fig. 1.8).  B-cell leukemia/lymphoma 2 (Bcl-2) family 
proteins represent the strongest link between ER Ca
2+
 regulation and the cell death 
machinery, as several Bcl-2 proteins reside in the ER membrane and modulate ER Ca
2+
 
homeostasis.  In fact, Bcl-2 and B-cell leukemia/lymphoma extra long (Bcl-xL) decrease 
basal Ca
2+
 concentrations in the ER (Foyouzi-Youssefi et al., 2000), whereas Bcl-2-
associated X protein (Bax) has an opposite effect (Foyouzi-Youssefi et al., 2000).  
Several studies have demonstrated an association of ER stress and disturbed Ca
2+
 
homeostasis in AD pathogenesis (LaFerla, 2002).  The involvement of ER stress in AD 
has been confirmed by detection of hyperactivated PERK-eukaryotic translation initiation 
factor 2α (eIF2α) pathway (Unterberger et al., 2006).  In addition, PS1 and PS2 proteins, 
members of the multiprotein γ-secretase complex that mediates the intramembranous 
cleavage of APP, are abundantly expressed in neurons and localized in the ER membrane, 
further suggesting a link between AD and ER stress (Lindholm et al., 2006).  Mutant PS1-
expressing cells show altered Ca
2+
 homeostasis, increased Aβ production (Levitan et al., 
2001), and enhanced sensitivity to ER stress-induced apoptosis (Lindholm et al., 2006).  
Similarly, PS1 mutant transgenic mice display abnormalities in ER Ca
2+
 regulation and 
increased neuronal vulnerability toward cell death and excitotoxic injury.  It has also been 
demonstrated that mutant PS1 binds to and inhibits the UPR protein IRE1, suppressing 
the activation of the UPR (Katayama et al., 1999).  IRE1 activates downstream signals, 
including the transcription of the ER chaperone GRP78/Bip (Katayama et al., 2004).  
Recent studies revealed increased levels of GRP78/Bip and PERK in AD brains, further 
confirming the occurrence of ER stress in AD (Hoozemans et al., 2009; Hoozemans et al., 
2005).  Finally, ER stress can directly activate caspase-12.  Primary cortical neurons from 
caspase-12 knockout mice showed reduced susceptibility toward ER stress.  Neurons 
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were resistant to Aβ-induced cell death (Nakagawa et al., 2000), suggesting that ER stress 
and activation of caspase-12 may contribute to neuronal death in AD.  
 
Kim et al., 2008 
Figure 1.8.  UPR events and connection to the cell death machinery.  UPR signaling pathways 
induced by ER stress are represented, and some connections to the cell death machinery are also 
shown.  In non-stressed cells (not shown), the ER chaperone GRP78/Bip binds to the luminal 
domains of the ER-stress sensors IRE1α, PERK and ATF-6, maintaining these proteins in an 
inactive state. Upon accumulation of misfolded proteins in the ER, GRP78/Bip preferentially 
binds to unfolded or misfolded proteins, thus driving the equilibrium of GRP78/Bip binding away 
from IRE1α, PERK and ATF6, triggering the ER stress (shown).  These three proteins are the 
initiators of the three main signaling cascades of the UPR.  The release of GRP78/Bip allows 
IRE1α to dimerize, activating its protein kinase activity (through autophosphorylation) and 
intrinsic ribonuclease activity.  A IRE1α dimer binds tumor necrosis factor receptor-associated 
factor 2 (TRAF2), activating apoptosis signal-regulating kinase 1 (ASK1) and downstream 
kinases that activate p38 MAPK and JNK.  IRE1α signaling is positively regulated by binding of 
the multidomain pro-apoptotic Bax and Bak.  The interaction of Bax/Bak with IRE1α is required 
for the recruitment of TRAF2 and ASK1 leading to the activation of the mitogen-activated protein 
kinase (MAPKs) JNK and p38, through specific mitogen activated protein kinase kinase (MKK).  
The intrinsic ribonuclease activity of IRE1α then removes a 26-base intron from X-box-binding 
protein 1 (XBP1) mRNA.  The spliced XBP1 mRNA encodes a potent transcription factor that 
translocates to the nucleus, activating the expression of genes involved in restoring protein folding 
or degrading unfolded proteins.  The release of GRP78/Bip also results in the activation of PERK, 
through PERK homodimerization and trans-autophosphorylation.  Activated PERK then 
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phosphorylates the eIF2α, reducing global mRNA translation.  At the same time, favoring the 
translation of selected mRNAs, such as ATF-4 mRNA, that are preferentially translated in the 
presence of phosphorylated eIF2α. ATF-4 activates the transcription of UPR target genes 
encoding factors involved in restoring ER homeostasis such as, amino-acid biosynthesis, the 
antioxidative-stress response and apoptosis, as well as autophagy genes.  In contrast to PERK and 
IRE1, release of BiP from ATF-6 induces its translocation to the Golgi complex where it is 
processed by the site-1 (S1P) and site-2 (S2P) generates an ATF-6α.  This fragment migrates to 
the nucleus, activating the transcription of genes mainly involved in ER-assisted degradation 
(ERAD) and ER homeostasis.  Upon severe ER stress, ATF-4, XBP1, and ATF-6 can upregulate 
the expression of the proapoptotic transcription factor C/EBP homologous protein (CHOP), which 
mediates apoptosis by the upregulation of proapoptotic BH3-only protein Bim, and by 
suppressing Bcl-2 expression.  CHOP activity is enhanced through phosphorylation by 
p38MAPK.  Phosphorylation by JNK in turn activates Bim, while inhibiting Bcl-2 functions.  The 
autophagy protein Beclin is inhibited by direct binding to Bcl-2.   
 
1.1.4.2.2 JNK stress sensor 
The JNK signaling pathway has been identified as a key event in AD-
associated apoptosis.  The IRE1α/tumor necrosis factor receptor-associated factor 2 
(TRAF2)/apoptosis signal-regulating kinase 1 (ASK1) pathway activates stress kinases 
(Kim et al., 2008; Salminen et al., 2009; Urano et al., 2000), which have deep functional 
effects on neuronal homeostasis (Bogoyevitch and Kobe, 2006; Dhanasekaran and Reddy, 
2008; Sekine et al., 2006).  ER stress activates ASK1, which subsequently triggers JNK 
and p38 mitogen-activated protein kinase (MAPK) signaling (Fig. 1.8).  However, it is 
not fully understood whether ER stress is the only inducer of ASK1.  For example,  Aβ 
induces neuronal apoptosis through reactive oxygen species (ROS)-mediated ASK1 
activation rather than via ER stress (Kadowaki et al., 2005).  However, ER stress can 
activate ROS production via Ca
2+
 mitochondrial signaling.  The ASK1-mediated JNK 
pathway plays a key part in AD pathogenesis (Okazawa and Estus, 2002).  This stress 
signaling kinase can regulate APP processing (Colombo et al., 2009) and control the 
phosphorylation state of APP at the Thr668 site, which is important for both APP 
cleavage and degradation in physiological conditions.  Inhibition of JNK-mediated 
phosphorylation of APP causes it to follow the proteasome degradation pathway 
(Colombo et al., 2007). It may also induce accumulation of intracellular Aβ (Colombo et 
al., 2009; Shoji et al., 2000), phosphorylate tau protein and trigger aggregation of NFTs 
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(Reynolds et al., 1997; Vogel et al., 2009).  Furthermore, JNK mediates the activation of 
several molecules, including caspase-2 (Troy et al., 2000), p53 (She et al., 2002), and 
Bcl-2 family members (Sorenson, 2004) and potentiate inflammatory responses via AP-1 
activation (Manning and Davis, 2003). 
A histopathological analysis of AD brains showed accumulation of activated 
pJNK in granules within hippocampal pyramidal cells (Lagalwar et al., 2007).  These 
granules normally co-localize with granulovacuolar degeneration bodies (GVD) 
(Lagalwar et al., 2007), which also contain GSK-3β (Leroy et al., 2002), a recognized 
PERK target kinase.  GVD are large cytoplasmic vacuoles (Lagalwar et al., 2007) that 
result from autophagic vacuoles usually seen in AD (Nixon, 2007).  Interestingly, it has 
been shown that excessive ER stress can induce autophagic uptake of accumulated 
material from the overloaded ER (Yorimitsu and Klionsky, 2007).  Both activated pJNK 
and pGSK-3β are present in pre-tangle accumulations of tau protein (Ishizawa et al., 
2003; Zhu et al., 2001b), which are different structures from GVDs.  Furthermore, recent 
data demonstrated that JNK can induce caspase cleavage of tau protein, but also that 
GSK-3β activation is required for tau aggregation (Sahara et al., 2008).  In addition, c-
Jun, an immediate-early proapoptotic protein of the JNK pathway was found to be 
colocalized with fragmented DNA in neurons (Anderson et al., 1996).  Enhanced 
expression of transcriptional factors c-Jun and c-Fos, increased levels of c-Jun mRNA, 
and phosphorylation of c-Jun on its N-terminal transactivation domain have all been 
observed in neuronal apoptosis (Sastry and Rao, 2000).  Finally, Aβ itself may induce 
activation of JNK and c-Jun (Morishima et al., 2001).  Consistently, Aβ-induced cell 
death is attenuated in cortical neurons from JNK3-null mice, while JNK3 mediates cell 
death through the activation of c-Jun and enhanced expression of apoptosis antigen-1 
ligand (FasL) (Morishima et al., 2001). 
 
1.2 Cell death mechanisms 
Programmed cell death (PCD) plays a key role in the development of the 
nervous system.  However, deregulation of cell death programs are involved in 
developmental and neoplastic disorders of the nervous system, and increasing evidence 
suggests that such deregulation may also occur in neurodegenerative diseases.  In fact, 
many neurological disturbances are characterized by gradual loss of specific groups of 
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neurons, resulting in disorders of movement and cognitive function, such as AD (Vila and 
Przedborski, 2003). 
Cell death represents a highly heterogeneous process with distinct morphological 
features, which results from activation of diverse, although partially overlapping, 
biochemical cascades.  Dying cells are engaged in a cascade of reversible molecular 
events, until a first irreversible process takes place.  Often known as the “point of no-
return”, this limiting molecular event is still an undeciphered enigma.  It has been 
proposed that a cell should be considered dead when any of the following molecular or 
morphological criteria is met: (1) loss of cell plasma membrane integrity, as defined by 
the incorporation of vital dyes in vitro (e.g., propidium iodide); (2) cell fragmentation into 
discrete bodies; and/or (3) engulfment of cellular corpse, or its fragments by adjacent 
cells in vivo (Kroemer et al., 2009).  The precise characterization of the molecular 
machinery of cell death is expected to have repercussions on the development of 
innovative therapeutic strategies.  
Although PCD has often been equated with apoptosis, nonapoptotic forms of cell 
death also exist.  In fact, at least three different forms of PCD are distinguishable, 
including type I, also known as nuclear or apoptotic, type II or autophagic, and type III or 
cytoplasmic.  These are activated at particular times of nervous system development, but 
may also occur after various insults, such as DNA damage or accumulation of damaged 
proteins.  Apoptosis is the best characterized type of PCD, where cells typically round up, 
form blebs, and undergo chromatin condensation, nuclear fragmentation, and formation 
of apoptotic bodies (Galluzzi et al., 2009).  These morphological changes are largely the 
result of the activation of cysteine proteases, termed caspases.   
In comparison with apoptosis, little is known about other nonapoptotic forms of 
PCD.  Autophagy is the process by which intact organelles and/or large portions of the 
cytoplasm are engulfed within double-membraned autophagic vacuoles for degradation.  
The massive accumulation of autophagic vacuoles may represent either an alternative 
pathway of cell death, or an ultimate attempt of cells to survive by adapting to stress.  In 
fact, autophagic cell death is crucial during development in Drosophila melanogaster 
(Mohseni et al., 2009), and knockout of essential autophagy genes has been shown to 
protect cultured mammalian cells from cell death (Maiuri et al., 2007).  Nevertheless, 
both pharmacologic and genetic inhibition of autophagy does not prevent cell death 
(Galluzzi et al., 2008).  Type III PCD, or cytoplasmic cell death, is a necrosis-like form of 
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PCD that may involve swelling of the ER and mitochondria, but lacks typical apoptotic 
features, such as apoptotic bodies and nuclear fragmentation (Bredesen et al., 2006).  
 
1.2.1 Death receptor and mitochondrial pathways of apoptosis 
Caspase activation by the death receptor of extrinsic pathway of apoptosis 
involves the binding of extracellular death ligands, such as FasL or tumour necrosis 
factor-α (TNFα) to transmembrane death receptors (Fig. 1.9).  Engagement of death 
receptors with their cognate ligands provokes the recruitment of adaptor proteins, such as 
the Fas-associated death domain protein (FADD), which in turn recruit and aggregate 
several molecules of caspase-8, thereby promoting its autoprocessing and activation.  
Active caspase-8 then proteolytically processes and activates caspase-3 and -7, provoking 
further caspase activation events that culminate in substrate proteolysis and cell death.  In 
some situations, extrinsic death signals can cross-talk with the intrinsic pathway through 
caspase-8-mediated proteolysis of the Bcl-2 homology domain 3 (BH3)-only protein Bid 
(BH3-interacting domain death agonist).  Truncated Bid (tBid) can promote 
mitochondrial cytochrome c release and assembly of the apoptosome, comprising seven 
molecules of apoptotic protease-activating factor-1 (APAF1) and the same number of 
caspase-9 homodimers (reviewed in Kroemer et al., 2007). 
In the mitochondrial or intrinsic pathway of apoptosis, diverse stimuli that 
provoke cell stress or damage typically activate one or more members of the BH3-only 
protein family (Fig. 1.9).  BH3-only proteins act as pathway-specific sensors for various 
stimuli and are regulated in distinct ways.  BH3-only protein activation above a crucial 
threshold overcomes the inhibitory effect of the anti-apoptotic Bcl-2 family members and 
promotes the assembly of Bcl-2 agonist killer 1 (Bak)-Bax oligomers within 
mitochondrial outer membranes.  These oligomers permit the efflux of intermembrane 
space proteins, such as cytochrome c, into the cytosol.  On release from mitochondria, 
cytochrome c can seed apoptosome assembly.  Active caspase-9 then propagates a 
proteolytic cascade of further caspase activation events (reviewed in Kroemer et al., 
2007). 
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Benn and Woolf, 2004 
Figure 1.9.  Pathways of apoptosis.  The extrinsic apoptotic pathway involves specific death 
ligands, TNFα or FasL, that are recognized by death receptors TNFR1 (TNF receptor 1) and Fas, 
located in the cell surface.  TNFR1 stimulation recruits proteins to form a complex, which signals 
to survival pathways (blue arrows) or the JNK- and caspase-2-induced death pathways (black 
arrows).  Fas stimulation induces FADD-mediated activation of procaspase-8 or DAXX (death-
associated protein)-mediated activation of JNK.  JNK transforms Bid in jBid, promoting its 
translocation to the mitochondria and release of SMAC/DIABLO (second-mitochondrial derived 
activator of caspases).  The intrinsic apoptotic pathway is triggered at the mitochondria by several 
stimulus.  (a),  Membrane permeabilization occurs through BH3-only proteins that sequester and 
inhibit the repression of Bax by Bcl-2, promoting Bax translocation to mitochondria and the 
release of cytochrome c, SMAC/DIABLO, AIF (apoptosis-inducing factor) and HTRA2/OMI 
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(high temperature requirement serine protease 2).  (b), Cytochrome c binds to APAF1 (apoptosis 
protease activating factor-1) to recruit and activate caspase-9, that together form the apoptosome, 
which activates the downstream executioner caspases-3 and -7. SMAC/DIABLO sequesters and 
inhibits IAP (inhibitor of apoptosis) proteins.  AIF causes DNA degradation through PARP1 
(poly(ADP-ribose) polymerase-1).  ER stress mediated apoptosis occurs through caspase-12 and 
caspase-3 activation.  AIP1, ASK1-interacting protein 1; AKT/PKB, protein kinase B; AP1, 
activator protein-1; BAD, Bcl-2-associated death protein; Bak, Bcl-2 agonist killer 1; Bid (BH3-
interacting domain death agonist) tBid (truncated Bid); Bim, Bcl-2-interacting mediator of cell 
death; BMF, Bcl-2 modifying factor; Bok, Bcl-2-related ovarian killer protein; FADD,FAS-
associated death domain; FLICE, FADD-like interleukin-1β; HRK, 5/harakiri; IκB, inhibitory 
subunit of NF-κB; IKK, IκB kinase; NF-κB, nuclear factor-κB; NIK, NF-κB-inducing kinase; 
NOXA, phorbol-12-myristate-13 acetate-induced protein (PMAIP1); PDK1/2, 3- phospho-inoside 
dependent kinase 1/2; PI3K, phosphatidyl inositol 3-kinase; PUMA, p53-upregulated modulator 
of apoptosis; RAIDD, RIP-associated ICH-1 homologous protein with a death domain; UV, 
ultraviolet light; XIAP, X-chromosome linked inhibitor of apoptosis protein; TRADD, TNF-
receptor death domain. 
 
1.2.2 Role of apoptosis in Alzheimer’s disease 
The study of apoptosis in neurodegenerative diseases remains a challenging task.  
For years, the question on whether apoptosis plays a key role as the major form of cell 
death in neurodegenerative diseases has been largely discussed, especially because 
synaptic loss and electrophysiological abnormalities typically precede cell loss.  In 
addition, given the slow progression of most neurodegenerative diseases, in contrast with 
the rapid progression of a cell through apoptosis, only a few cells exhibiting apoptotic 
features are found in postmortem human brain tissue.  Therefore, the synchronous 
detection of a substantial number of apoptotic neurons at any given time point is, indeed, 
unlikely.  In turn, apoptotic processes may be terminated or not yet begun by the time the 
tissue is available for examination.  In fact, the collected tissue is usually representative of 
the end-stage disease, being removed much later than it would be ideal to treat patients 
and prevent neuronal cell death.  Finally, the criteria used to classify the type of cell death 
as apoptosis is often based solely on morphological assessment and biochemical assays, 
which may also account for other forms of PCD.  For example, the terminal transferase 
dUTP nick-end labeling (TUNEL) assay is usually used as a marker of apoptosis in 
human brain tissue. However, TUNEL can also label necrotic cells, which is why more 
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than one assay should be considered when determining the type of cell death 
experimentally (Galluzzi et al., 2009).  Despite these limitations, there is now a consensus 
for a major role of apoptosis in human neuronal cell death and neurodegenerative 
processes.  Studies on the pathological mechanisms underlying neuronal apoptosis in 
hereditary forms of neurodegenerative diseases have provided important clues, by linking 
neuronal apoptosis with oxidative stress and mitochondrial dysfunction.  Nevertheless, 
the most prominent facts underlying the role of apoptosis in neurodegenerative diseases 
came from studies using either in vitro cell culture systems or in vivo models of disease.  
Although with inherent limitations, as these models tend to examine the effect of only one 
toxin or genetic defect, usually involving acute exposure to neurological insults, they 
have greatly increased our fundamental knowledge.  This knowledge may now be used 
for the development of new drugs that interfere with the apoptotic cascade in human 
neurodegenerative diseases (Vila and Przedborski, 2003).  
Regardless of the various genetic and environmental factors that may lead to the 
manifestation of AD, several features of the neurodegenerative process are common to 
different experimental models, including increased levels of oxidative stress, metabolic 
compromise, perturbed Ca
2+
 regulation, ER stress, mitochondrial dysfunction, DNA 
damage, activation of apoptotic biochemical cascades, autophagy and abnormalities in 
protein processing and degradation (Culmsee and Landshamer, 2006).  Interestingly, both 
synaptic loss and neuritic dystrophy are affected early in AD, with no apparent cell loss.  
Although these events precede extensive neuronal loss, it is unknown whether the 
corresponding neuronal cell bodies are truly healthy.  Conversely, it is also unclear 
whether early dendritic and axonal defects kill the corresponding neurons, or whether 
dendritic, axonal and neuronal deaths are each direct consequences of extracellular A.  
Nevertheless, the pathogenic cascade of AD finally results in neuronal cell and synapse 
loss.  
Discussion of the nature of neuronal loss in AD remains controversial.  Although 
autophagy has been suggested to play a central role in AD neurodegeneration (Ling and 
Salvaterra, 2009), it is still not clear whether it does play a causative role or, inversely, a 
protective role, or if it is a consequence of the disease process itself (Hung et al., 2009).  
In contrast, the detection of cleaved caspases and the accumulation of their cleaved 
substrates in post-mortem AD brain tissue, represent a small part of the whole frame 
supporting the hypothesis that apoptosis plays a key role in AD (Ribe et al., 2008).  In 
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addition, biochemical and morphological hallmarks of apoptosis have been associated 
with neuropathological features found in AD brain tissue, including NFTs and amyloid 
plaques.  This further underlies the role of neuronal apoptosis in the progression of the 
disease (Culmsee and Landshamer, 2006).  
Finally, there is increasing evidence for a pivotal role of ER stress in AD-
associated cell death.  During ER stress, perturbed Ca
2+
 homeostasis or altered protein 
processing leads to the accumulation of unfolded protein in the ER, which activates the 
UPR.  In turn, the UPR activates transcription factor C/EBP homologous protein (CHOP), 
which may induce apoptosis.  In fact, CHOP has been suggested as the link between ER 
and mitochondria during apoptotic cell death induced by the A peptide (Costa et al., 
2010). 
 
1.2.2.1 Function of caspases 
Substantial evidence demonstrates that multiple caspases are detected in brains 
of patients with AD.  In fact, caspases-1, -2, -3, -5, -6, -7, -8 and -9 have all been found to 
be transcriptionally increased in AD, compared with controls (Pompl et al., 2003). 
Caspase-2 was initially described as a neuronally expressed caspase that was 
downregulated during brain development (Kumar et al., 1992).  Nevertheless, one 
paradigm that is supported in both cell culture work as well as primary neurons from 
wild-type and caspase-2 null animals is Aβ-induced neuronal death.  In this paradigm, the 
death pathway is conserved in central and peripheral neurons and in PC12 neuronal cell 
line (Troy et al., 2000).  Removal of caspase-2 acutely or chronically confers resistance to 
Aβ.  It is likely that Aβ-mediated death of neurons does not require other caspases 
because caspase-2 deficient neurons are resistant to Aβ and, although caspase-3 becomes 
activated in response to Aβ, it is neither necessary nor sufficient for death (Troy et al., 
2000).  As a therapeutic target, caspase-2 has certain advantages.  In the nervous system, 
the expression of caspase-2 is neuron-specific; thus, inhibition or ablation of caspase-2 in 
the nervous system would only affect neurons.  All the evidence suggests that caspase-2 
is activated rapidly and is upstream or independent of mitochondria, which makes it an 
attractive target for ablation without disturbing mitochondrial function (Troy and Ribe, 
2008).    
Active caspase-3 has been detected in neurons of AD brains, with a high degree 
of colocalization with NFTs and senile plaques (Su et al., 2001).  It has recently been 
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shown that caspase-3 is increased and preferentially located in the postsynaptic density 
fractions in AD, suggesting an important role for caspase-3 in synapse degeneration 
during disease progression (Louneva et al., 2008).  In fact, in parallel with its role in 
apoptosis, caspase-3 may be also important in AD pathogenesis by cleaving tau in its C-
terminal region; in AD brains, caspase-3-cleaved tau colocalizes with both intracellular 
A and activated caspase-3, mainly in tangle bearing neurons.  Finally, different caspases, 
including caspase-3, have also been shown to cleave APP, generating A-containing 
peptides (Gervais et al., 1999; LeBlanc et al., 1999), while amyloid plaques are enriched 
in caspase-cleaved APP (Gervais et al., 1999).  This suggests that A plaque formation 
and toxicity is likely amplified in a caspase-dependent manner.  Nevertheless, by cleaving 
APP and presenilins, caspase-3 may give rise to C31, which induces cell death through a 
caspase-independent process and triggers selective increase of A42 in vitro 
(Dumanchin-Njock et al., 2001). 
Caspase-9 activity has been specifically implicated in the pathology of AD.  It 
was demonstrated that neurons and dystrophic neuritis within plaque regions of AD 
hippocampal brain sections, display strong activation of caspase-9.  Importantly, these 
studies suggest that caspase-9 activation precedes NFT formation (Rohn et al., 2002).  
Caspase-9 was also shown to directly cleave APP, originating the strong pro-apoptotic 
peptide C31 (Lu et al., 2000).  Finally, it appears that caspase-9 may induce apoptosis in 
AD brains independently of caspase-3 or Apaf-1.  This would represent an alternative 
circuit to the classical intrinsic pathway of apoptosis in AD (Madden and Cotter, 2008).  
Cells from caspase-12 gene deleted mice showed reduced susceptibility towards 
ER stress (Nakagawa et al., 2000).  Particularly, cultured cortical neurons were resistant 
to death caused by the Aβ (Nakagawa et al., 2000).  This indicates that ER stress and 
activation of caspase-12 may contribute to neuronal death in AD.  However, as the 
presence of caspase-12 is less likely in human neurons, related molecules with similar 
functions may be present.  Human caspase-4 shows similar characteristics to mouse 
caspase-12 and is localized to the ER and to the mitochondria.  Caspase-4 is increased in 
AD brains, suggesting that this caspase may play a role in ER stress-induced cell death 
(Hitomi et al., 2004). 
Altogether, caspases play an active role at distinct levels of A-induced 
neurotoxicity and AD. Apart from representing a terminal event in apoptosis associated 
with AD, activation of caspases appears to constitute also a proximal event that promotes 
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the pathology underlying the disease.  Nevertheless, caspase-independent pathways of 
apoptosis may be relevant to certain neurodegenerative diseases.  Such pathways are 
mediated through the mitochondrial release of apoptosis-inducing factor (AIF) and/or 
EndoG. AIF is normally confined to the mitochondrial intermembrane space, but 
translocates to the cytosol and to the nucleus after apoptotic insults.  In particular, AIF 
has been associated with neuronal death in AD (Adamczyk et al., 2005).  
 
1.2.2.2 Involvement of Bcl-2 family members 
Apart from caspases, several other molecules involved in the apoptotic cascade 
have also been linked to AD. It has been shown, for instance, that Bcl-2 family members 
Bax and Bcl-2 co-localize in the frontal cortex of AD patients (Lu et al., 2005).  In 
hippocampal tissue, apoptotic proteins c-Fos, c-Jun, and Bak were shown to be increased 
(Sajan et al., 2007).  In vitro, A induces expression of pro-apoptotic Bcl-2 proteins, 
including Bax, and down regulation of anti-apoptotic members such as Bcl-2, Bcl-xL and 
Bcl-w (Yao et al., 2005).  Increased Bax expression has also been associated with senile 
plaques in AD hippocampal brain tissue and neurons with tau-positive NFTs (MacGibbon 
et al., 1997).  Consistently, A fails to induce apoptosis in Bax-deficient neurons 
(Selznick et al., 2000), whereas overexpression of Bcl-xL and Bcl-2 attenuates A-
induced apoptosis (Song et al., 2004; Tan et al., 1999).  A also induces Bcl-2-interacting 
mediator of cell death (Bim) in cultured hippocampal and cortical neurons.  Moreover, 
Bim was found to be up-regulated in entorhinal cortical neurons of postmortem AD 
human brains (Biswas et al., 2007b). 
A successful therapeutic intervention would seem to entail an anti-apoptotic gain 
of function and/or a pro-apoptotic loss of function to promote mitochondrial function 
stabilization (Letai, 2005).  Therefore Bax and BH3-only proteins inhibitors can represent 
potential targets for therapeutic intervention in AD and other neurodegenerative 
disorders.  However, while several small molecule inhibitors of anti-apoptotic members 
of the Bcl-2 family have been reported (Jana and Paliwal, 2007), only a few inhibitors of 
pro-apoptotic members are described.  Bombrun et al described molecules that inhibit 
cytochrome c release from mitochondria and suggested that this action was mediated by 
inhibition of Bax channel-forming activity (Bax channel blockers) (Bombrun et al., 
2003).  Hetz et al later described and evaluated two novel Bax channel inhibitors Bci1 
and Bci2 (Hetz et al., 2005).  It was demonstrated that these compounds prevent 
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activation of mitochondria-induced apoptosis, augmenting protection against ischemia-
induced tissue damage. Becattini et al (Becattini et al., 2004), using NMR-based 
strategies, designed a series of compounds that bind and suppress the BH3-only protein 
Bid.  
 
1.2.3 Role of organelle dysfunction in Alzheimer’s disease 
When apoptosis was first characterized, cytoplasmic organelles were described 
as morphologically intact (Kerr et al., 1972).  However, it is now well established that 
most organelles of the dying cell manifest subtle biochemical alterations, in particular, 
partial proteolysis and membrane permeabilization, which may contribute to the apoptotic 
phenotype.  Importantly, each organelle can sense stressful and pathogenic alterations that 
initiate local or global responses, leading to either adaptation, or cell death if a critical 
damage threshold is reached (Fig. 1.10). 
 
 
 
Figure 1.10.  Schematic overview of organelle dysfunction and cell death mechanisms.  The 
death ligand interacts with the respective death receptor at the plasma membrane, recruiting 
adaptor proteins such as FADD, and activating caspases-8.  The initiator caspase then cleaves 
effector caspases-3, which activates key downstream targets and executes apoptosis.  This process 
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is mitochondrial independent and can be inhibited through diverse mechanisms, including the 
activation of inhibitors of apoptosis (IAPs).  Excessive glutamate and other death signals activate 
intracellular cascades involving increased levels of ROS, Ca2+, and p53.  For example, DNA 
damage insults engage the p53 apoptotic pathway and this increases DNA fragmentation. Death 
stimuli target mitochondria either directly or through transduction by translocation of Bax and 
Bad to the mitochondrial membrane.  Mitochondria then release cytochrome c and other 
apoptogenic factors into the cytosol.  Cytochrome c induces oligomerization of Apaf-1, recruiting 
and activating procaspase-9. Activated caspase-9 then cleaves and activates effector caspase-3. 
The opening of the permeability transition pore (PTP) occurs in the apoptotic cascade during 
Ca2+-dependent cell death, disrupting the mitochondrial structure and releasing apoptogenic 
factors. In addition, the ER senses local stress through chaperones, Ca2+-binding proteins and Ca2+ 
release channels, which might transmit Ca2+ responses to mitochondria. ER stress-induced cell 
death is also mediated by the UPR via the proteasome. Similarly, cell death may result from 
compromised chaperone-mediated autophagy, a mechanism in equilibrium with the ER. Further, 
the GC constitutes a privileged site for the generation of the pro-apoptotic mediator ganglioside 
GD3 and facilitates local caspase-2 activation. Finally, axonal transport is critical in sensing and 
enhancing cell damage. In this regard, hyperphosphorylated tau impairs axonal transport and leads 
to cell death. GC, Golgi complex.  From Viana et al., 2010. 
 
1.2.3.1 Mitochondria 
Mitochondrial function is compromised in brain cells of AD patients. 
Impairment of tricarboxylic acid (TCA) cycle enzymes of mitochondria was found to 
correlate with the clinical state of AD (Bubber et al., 2005).  Recently, it was 
demonstrated that A induces apoptosis in primary hippocampal neurons which derive, at 
least in part, from mitochondria dysfunction, as assessed by depolarized membrane 
potential, decreased cytochrome c oxidase activity and ATP levels, and cytochrome c 
release (Yang et al., 2009).  These results indicate that A induces neuronal death by 
activating an apoptotic pathway involving impaired mitochondria function and cellular 
homeostasis.  A is also involved in the disruption of Ca2+ homeostasis, through ER-
mediated stress, thereby inducing mitochondrial dysfunction (Pereira et al., 2004).  
Furthermore, A-mediated mitochondrial dysfunction also enhances generation of ROS.  
In addition to membrane lipid or protein damage, ROS can mediate DNA damage, which 
activates fatal apoptotic signaling through the tumor suppressor p53 and poly(ADP-
ribose) polymerase (PARP) (Culmsee and Landshamer, 2006).   
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Based on the above, it is clear that therapeutic strategies that modulate 
mitochondrial-dependent cell death pathways may provide a key tool to protect neurons. 
An increasing number of growth factors activate cell survival in neuronal cells.  By 
activating counter receptors, growth factors stimulate cellular intrinsic pathways, which 
lead to the upregulation of cytoprotective proteins (Bogaerts et al., 2008).  In addition, 
mitochondrial membrane permeabilization can be inhibited by the knockout of 
cyclophilin D, a mitochondrial matrix protein, or by the use of cyclosporin A or other 
pharmacological inhibitors of cyclophilin D (Nakagawa et al., 2005).  Overexpression of 
anti-apoptotic members of the Bcl-2 family has a major neuroprotective effect (Mehta et 
al., 2007), and the use of peptidomimetics designed to act like Bcl-2 antiapoptotic 
proteins should also be evaluated.  Antioxidants and small compounds, such as lipoic 
acid, cystamine, vitamin E, and carnitine have shown neuroprotective effects in 
neurodegenerative conditions (Lee et al., 2009).  FK 506, a calcineurin inhibitor, and 
Dimebon, an antihistamine drug, are neuroprotective mainly by inducing mitochondria 
stabilization (Lee et al., 2009).  Nicotinamide, resveratrol, and sirtuins modulate the 
tricarboxylic acid cycle in mitochondria and provide neuroprotective effects in 
neurodegenerative conditions (Lee et al., 2009).  Rosiglitazone, known as a peroxisome 
proliferator activated receptor-gamma agonist and an anti-diabetic drug in the 
thiazolidinedione class of drugs, was neuroprotective in a subset of patients with AD 
(Watson et al., 2005).  
These studies suggest that targeting mitochondria, especially the mitochondrial 
membrane permeabilization, to block the release of pro-apoptotic proteins and stabilize 
energy metabolism may provide optimal neuroprotection.  
 
1.2.3.2 Golgi complex 
The involvement of the Golgi complex (GC) in PCD and neurodegenerative 
diseases has recently been the focus of intense research (Fan et al., 2008).  The GC 
undergoes irreversible fragmentation during apoptosis, in part as a result of caspase-
mediated cleavage of several GC-associated proteins.  In fact, it has been demonstrated 
that GC cisterns are smaller in apoptotic PC12 cells (Sesso et al., 1999).  In addition, Fas 
receptor mediated and staurosporine-induced apoptosis triggered caspase mediated 
cleavage of several GC proteins, including p115 and golgin-160 (Mukherjee et al., 2007; 
Mancini et al., 2000).  Moreover, GM130, an integral membrane protein, was rapidly 
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diminished during Fas-mediated apoptosis associated with GC fragmentation (Walker et 
al., 2004).  
Worthy of note is the demonstration that GC fragmentation occurs in an early, 
preclinical stage of neurodegeneration (Karecla and Kreis, 1992; Mourelatos et al., 1996).  
As a consequence, neuronal GC integrity has been suggested as a reliable index of initial 
degeneration (Stieber et al., 1996).  
Although some evidence suggests that GC fragmentation is involved in the 
apoptotic process, other results argue that GC fragmentation is not a consequence of 
apoptosis (Diaz-Corrales et al., 2004; Gomes et al., 2008).  Nevertheless, given its central 
location and essential role in membrane trafficking, the GC is ideally positioned to sense 
and integrate information regarding the status of the cell.  For example, the structure of 
the GC might be particularly conducive to sense small changes in lipid composition of the 
bilayer (Mancini et al., 2000).  In fact, the GC may represent a novel apoptotic signaling 
organelle.  Interestingly, several signaling proteins implicated in apoptotic pathways are 
enriched at GC membranes, including TNF-R1, Fas, phosphatidyl inositol 3-kinase 
(PI3K), beclin, GD3 synthase (α-2,8- sialytransferase), and BRUCE, a novel ubiquitin-
conjugating enzyme that contains a baculovirus inhibitor of apoptosis (BIR) motif.  GC 
membranes are also likely to be the site of ceramide signaling, which has been implicated 
in the induction of apoptosis by conversion of ceramide to ganglioside GD3 (De Maria et 
al., 1997; Rippo et al., 2000).  Finally, substantial evidence indicates that the GC might 
participate as a functional Ca
2+
 storage as it contains all Ca
2+
/manganese-ATPases 
(SPCAs), and is regarded as a inositol 1,4,5- trisphosphate (IP3)-sensitive intracellular 
Ca
2+
 store.  The GC accommodates IP3Rs and neuronal Ca
2+
 sensor, and possesses Ca
2+
 
binding proteins Cab45 and CALNUC in its lumen.  This organelle takes up Ca
2+
 using 
both sarco(endo)-plasmic-reticulum Ca
2+
-ATPases (SERCA) and secretory pathway 
SPCAs.  Thus, the integrity of the GC is required for normal Ca
2+
 homeostasis and 
signaling (reviewed in Fan et al., 2008).  It is expected that continuous attention to the GC 
function should provide a more detailed and accurate understanding of disease 
mechanisms and potential drug targets during neurodegeneration.  
 
1.2.3.3 Endoplasmic reticulum 
Several studies demonstrated ER stress and disturbed Ca
2+
 homeostasis in AD 
pathogenesis (LaFerla, 2002).  The involvement of ER stress in AD has been confirmed 
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by detection of hyperactivated PERK-eIF2α pathway (Unterberger et al., 2006).  In 
addition, PS1 and PS2 proteins, members of the multiprotein α-secretase complex that 
mediates the intramembranous cleavage of APP, are abundantly expressed in neurons and 
localized in the ER membrane, further suggesting a link between AD and ER stress 
(Lindholm et al., 2006).  Mutant PS1-expressing cells show altered Ca
2+
 homeostasis 
(Leissring et al., 2000), increased Aβ production (Levitan et al., 2001), and enhanced 
sensitivity to ER stress-induced apoptosis (Lindholm et al., 2006),  (Terro et al., 2002).  
Similarly, PS1 mutant transgenic mice display abnormalities in ER Ca
2+
 regulation and 
increased neuronal vulnerability toward cell death and excitotoxic injury.  It has also been 
demonstrated that mutant PS1 binds to and inhibits the UPR protein IRE1, suppressing 
the activation of the UPR (Katayama et al., 1999).  IRE1 activates downstream signals, 
including the transcription of the GRP78/Bip (Katayama et al., 2004).  Recent studies 
revealed increased levels of GRP78/Bip and PERK in AD brains, further confirming the 
occurrence of ER stress in AD (Hoozemans et al., 2005),  (Hoozemans et al., 2009).  
Finally, ER stress can directly activate caspase-12.  Furthermore, primary cortical neurons 
from caspase-12 knockout mice showed reduced susceptibility towards ER stress.  On the 
other hand, neurons were resistant to Aβ-induced cell death (Nakagawa et al., 2000), 
suggesting that ER stress and activation of caspase-12 may contribute to neuronal death 
in AD. 
Targets for drug discovery in the context of ER stress in neurodegeneration are 
still under validation.  A screen for compounds that block tunicamycin-induced death of a 
neuronal cell line resulted in the discovery of salubrinal, a compound that prevents 
dephosphorylation of eIF2α.  This results in increased eIF2α phosphorylation and 
inactivation, thereby generating stronger PERK responses (Boyce et al., 2005).  
Salubrinal was reported to protect neuronal cells from death triggered by various ER 
stress inducers (Reijonen et al., 2008; Smith et al., 2005).  However, this inhibitor of 
eIF2α activity also impairs long-term memory in a mouse model (Costa-Mattioli et al., 
2007), suggesting that the approach would not be acceptable as a direction for chronic 
therapies.  
It has been described that chemical inhibitors of ASK1 might provide 
cytoprotection in neurodegenerative disorders (Kawaguchi et al., 2008).  As JNK is 
activated downstream of ASK1, and JNK is known to activate Bid while inhibiting Bcl-2, 
it would be interesting to explore whether chemical inhibitors of JNK may have 
cytoprotective activity in such context (Salh, 2007).  
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An additional potential strategy for ameliorating ER stress induced by inclusion 
bodies is to stimulate autophagy, efficiently clearing insoluble protein aggregates from 
cells.  Chemical screens for enhancers of autophagy have been reported, which have 
identified compounds that improve clearance of protein inclusions from cultured cells ,  
(Zhang et al., 2007),  (Sarkar et al., 2007) .  Among the compounds purported to increase 
autophagy, without signs of cellular toxicity, are several drugs already approved by the 
US Food and Drug Administration.  These include antipsychotics (such as fluspirilene, 
trifluoperazine, pimozide) and Ca
2+
-channel modulators (such as nicardipine, niguldipine, 
amiodarone), acting through mechanisms that are distinct from that of rapamycin (a 
mammalian target of rapamycin (mToR) inhibitor) (Zhang et al., 2007).  A different 
strategy proposed for removing insoluble protein inclusions is to increase chaperone 
activity in cells, especially cytosolic hsp70.  It would be interesting to explore the efficacy 
of chemical chaperones that serve as ligands to stabilize protein structure and promote 
protein folding, analogous to what has been described for compounds such as 
SR121463A (1-[4-(Ntertbutyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-
spiro-[4-(2-morpholinoethoxy)cyclohexane] indol-2-one, fumarate) (Serradeil-Le Gal et 
al., 1996), and others (Burrows et al., 2000; Tamarappoo and Verkman, 1998).  Thus, 
previous studies are encouraging and suggest that targeting the cellular protein quality 
control system of the ER is an attractive strategy that warrants further exploitation for the 
treatment of neurodegenerative conditions associated with accumulation of damaged 
molecules within the cell.  
 
1.2.4 Inhibition of neuronal apoptosis by bile acids 
The therapeutic role of the endogenous bile acid ursodeoxycholic acid (UDCA) 
has been firmily established in the treatment of liver diseases (Lazaridis et al., 2001; 
Paumgartner and Beuers, 2002).  Interestingly, after conjugation with taurine, 
tauroursodeoxycholic acid (TUDCA) administrated in high doses can be delivered to 
other tissues, including the brain (Rodrigues et al., 2003a).  In vitro, TUDCA inhibits 
apoptosis induced by several stimuli in diverse cell types, such as in neuronal cells (Fig. 
1.11) (Rodrigues et al., 2000b; Solá et al., 2003).  Furthermore, the protective role of 
TUDCA has been extended to several mouse models of neurological disorders, including 
Hungtington‟s disease (Keene et al., 2002; Keene et al., 2001; Rodrigues et al., 2000b), 
Parkinson‟s disease (Duan et al., 2002; Ved et al., 2005), and acute ischemic (Rodrigues 
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et al., 2002) and hemorrhagic stroke (Rodrigues et al., 2003a).  Interestingly, pretreatment 
with TUDCA also significantly reduced glutamate-induced apoptosis of rat cortical 
neurons (Castro et al., 2004). 
Prompted by these results, the anti-apoptotic role of TUDCA has been 
investigated in experimental models of AD.  Initial studies using primary rat neurons and 
astrocytes incubated with Aβ showed increased levels of apoptosis, which was prevented 
by TUDCA and UDCA (Rodrigues et al., 2000a).  The anti-apoptotic effects of TUDCA 
were further confirmed in PC12 neuronal cells incubated with Aβ (Ramalho et al., 2004).  
Similar results were seen in in vitro models of familial AD that consist of mouse 
neuroblastoma cells expressing APP with the Swedish mutation or double-mutated human 
APP and PS1 (Ramalho et al., 2006), as well as in primary cortical neurons incubated 
with fibrillar Aβ42.  Of note, in vitro cellular models of AD have limitations to their use 
and the results should be interpreted with caution. 
Because of their potential role in Aβ-induced toxicity, mitochondria were 
isolated and co-incubated with TUDCA to assess its protective effect against apoptosis.  
In fact, UDCA and, more efficiently, TUDCA inhibited Aβ-induced mitochondrial 
membrane permeabilization and consequent cytochrome c release in isolated neuronal 
mitochondria (Rodrigues et al., 2000a).  Moreover, using electron paramagnetic 
resonance spectroscopy analysis, it was demonstrated that TUDCA prevented Aβ-driven 
modifications in mitochondrial membrane redox status, lipid polarity and protein order 
(Rodrigues et al., 2001).  The effects of TUDCA on the Aβ-affected mitochondria were 
further confirmed by the observation of decreased Bax translocation in the presence of 
this bile acid (Solá et al., 2003). 
Consistent with results obtained in non-neurological models, it was also shown 
that TUDCA might interfere with upstream targets of mitochondria, including cell cycle 
related proteins (Fig. 1.11).  In fact, TUDCA incubations resulted in inhibition of E2F-1 
induction, p53 stabilization and Bax expression in PC12 neuronal cells (Ramalho et al., 
2004).  Further, TUDCA protected PC12 cells against p53- and Bax-dependent apoptosis 
induced by E2F-1 and p53 overexpression, respectively. The role of p53 in mediating the 
effects of TUDCA was further confirmed using an in vitro model of familial AD 
(Ramalho et al., 2006).  In neuroblastoma cells, TUDCA modulated p53 activity and Bcl-
2 family changes.  Moreover, overexpression of p53 was sufficient to induce apoptosis, 
which was in turn reduced by TUDCA.  It is still not clear, however, how TUDCA 
interferes with p53 expression and activation.  Importantly, TUDCA interacts with a 
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specific region of the mineralocorticoid receptor (MR) ligand-binding domain and 
dissociates it from hsp90 in neuronal cells incubated with Aβ (Solá et al., 2006).  As a 
consequence, TUDCA translocates into the nucleus with MR, modulating its 
transactivation and inhibiting Aβ-induced apoptosis.  The elucidation of the molecular 
targets affected by the TUDCA-mediated regulation of MR, which might include p53, 
would be important to fully understand the anti-apoptotic action of the bile acid in 
neuronal acids.  In fact, it was demonstrated recently that UDCA reduces p53 
transcriptional activity and its ability to bind DNA in hepatocytes (Amaral et al., 2007).  
Thus, it is tempting to speculate that a similar effect would occur in neurons exposed to 
Aβ. 
 
 
 
Figure 1.11.  Proposed mechanisms of UDCA and TUDCA inhibition of apoptosis.UDCA 
negatively modulates the mitochondrial pathway by inhibiting Bax translocation, ROS formation, 
cytochrome c release, and caspase-3 activation.  UDCA can also interfere with the death receptor 
pathway, inhibiting caspase-3 activation.  Moreover, TUDCA inhibits apoptosis associated with 
ER stress, by modulating intracellular Ca2+ levels, and inhibiting calpain and caspase-12 
activation.  Importantly, UDCA interacts with NSR, leading to NSR/hsp90 dissociation and 
nuclear translocation of the UDCA/NSR complex.  Once in the nucleus, UDCA modulates the 
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E2F-1/p53/Bax pathway, thus preventing apoptosis.  Finally, UDCA downregulates cyclin D1 and 
Apaf-1, further inhibiting the mitochondrial apoptotic cascade.  Cyt c, cytochrome c; hsp90, heat 
shock protein 90; NSR, nuclear steroid receptor.  From Amaral et al., 2009. 
 
Notably, TUDCA prevented caspase-2 activation in neuroblastoma cells.  A 
recent study suggests that Aβ-induced cell death also required the activation of caspase-2 
(Troy et al., 2000).  Caspase-2 triggers apoptosis through activation of the mitochondrial 
pathway and it has also been described as a target of the JNK pathway. Further 
investigations are warranted to elucidate the mechanism(s) by which TUDCA interferes 
with this signaling pathway.  Finally, recent data also showed that TUDCA modulates 
Aβ-induced apoptosis, in part, by activating a PI3K signaling pathway, underscoring the 
pleiotropic effect of the bile acid (Solá et al., 2003).  In fact, incubation with wortmannin, 
an inhibitor of the PI3K pathway, significantly reduced the ability of TUDCA to 
modulate p53-induced apoptosis (Ramalho et al., 2006). 
TUDCA also mitigates the toxic downstream effects of Aβ.  In primary rat 
cortical neurons incubated with fibrillar Aβ42, TUDCA inhibited the levels of apoptosis 
and caspase-3 activation and abrogated the caspase-3-cleavage of tau into a toxic species 
(Ramalho et al., 2008).  Thus, by interfering with apoptotic pathways, both at the 
mitochondrial and transcriptional levels, TUDCA not only increased the survival of 
neurons but also prevented downstream abnormal conformations of tau.  This might have 
beneficial consequences in slowing cognitive decline. 
In the last decade, we assisted to a major advance in understanding the role of 
anti-apoptotic bile acids as neuroprotective agents.  The association of the ubiquitous 
anti-apoptotic properties of certain hydrophilic bile acids with their safety profile, renders 
this group of molecules as a potential therapeutic alternative in neurodegenerative 
disorders.  However, the exact cellular mechanism(s) of anti-apoptotic bile acid effects 
are not clearly understood.  Thus, further exploitation of molecular pathways by which 
these molecules modulate cell death is warranted to consolidate our understanding 
therapeutic potential of specific bile acids. 
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Objectives 
 
The studies presented in this thesis were driven by the ambition to further 
understand cell death mechanisms in AD, with the hopes to contribute to rational 
therapeutic strategies.  Supported by the knowledge that apoptosis plays a role in 
neurodegeneration associated with AD, we designed three major objectives.  First, our 
goal was to determine the physical properties of Aβ peptide toxic assemblies and 
elucidate the cellular mechanism(s) of toxicity.  Second, we aimed at investigating stress 
signaling events triggered by soluble Aβ at the ER level and specifically characterizing 
the JNK stress pathway.  Finally, we intended to further explore alternative pathways of 
neuroprotection by TUDCA. 
The specific questions addressed in this thesis are: 
1. Are pro-apoptotic properties of Aβ peptides associated with their distinct 
mechanisms of aggregation/fibrillization?  
2. Does soluble Aβ trigger early stress signaling cascades involving the ER? 
3. What is the role of JNK as early stress sensor of Aβ toxicity that is activated 
by the ER?  
 
Ultimately, the overarching goal of the research presented in this thesis is to 
expand the understanding of the pathological mechanisms of AD.  The conjugation of this 
information with existing anti-apoptotic tools, such as the use of TUDCA, will likely 
provide valuable insights to develop novel, more effective therapeutic strategies for AD.   
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2.1 Abstract 
The vasculotropic E22Q mutant of the amyloid β (Aβ) peptide is associated with 
hereditary cerebral hemorrhage with amyloidosis Dutch type.  The cellular mechanism(s) 
of toxicity and nature of AβE22Q toxic assemblies are not completely understood.  
Comparative assessment of structural parameters and cell death mechanisms elicited in 
primary human cerebral endothelial cells by AβE22Q, and wild-type Aβ revealed that 
only AβE22Q triggered the Bax mitochondrial pathway of apoptosis.  AβE22Q neither 
matched the fast oligomerization kinetics of Aβ42 nor reached its predominant β-sheet 
structure, achieving a modest degree of oligomerization with a secondary structure that 
remained a mixture of β- and random-conformations.  The endogenous molecule 
tauroursodeoxycholic acid (TUDCA) was a strong modulator of AβE22Q-triggered 
apoptosis but did not significantly change secondary structures and fibrillogenic 
propensities of Aβ peptides.  These data dissociate the pro-apoptotic properties of Aβ 
peptides from their distinct mechanisms of aggregation/fibrillization in vitro, providing 
new perspectives for modulation of amyloid toxicity. 
 
Keywords: Apoptosis; cerebral amyloid angiopathy; E22Q mutant Aβ peptide; 
mitochondria; TUDCA 
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2.2 Introduction 
Cerebral amyloid angiopathy (CAA), a common feature of Alzheimer‟s disease 
(AD), is an age-associated condition characterized by the deposition of amyloid peptides 
in cortical and leptomeningeal vessels causing capillary disruption and endothelium 
dysfunction, and playing a significant role in intracerebral hemorrhage (Coria and Rubio, 
1996; Rensink et al., 2003; Vinters, 1987).  Different proteins are associated with CAA 
(reviewed in Revesz et al., 2003; Yamada, 2000).  The most common is amyloid β (Aβ), 
which is the main component of the deposits seen in normal aging and sporadic 
Alzheimer‟s disease (AD) that originates by processing of the amyloid precursor protein 
(APP) (reviewed in Ghiso and Frangione, 2002).   
Of the several mutations identified in the APP gene, substitutions at residues 
flanking the Aβ region affect the rate of enzymatic APP processing and the production of 
Aβ42, resulting in an early-onset AD phenotype (Selkoe, 1999).  On the contrary, 
mutations within the Aβ sequence, particularly at residues 21-23, generate Aβ variants 
Dutch, Iowa, Flemish, Artic, and Italian (Grabowski et al., 2001; Hendriks et al., 1992; 
Levy et al., 1990; Miravalle et al., 2000) that preferentially associate with CAA, 
hemorrhagic strokes and/or dementia.  One of the most aggressive clinical phenotypes 
described in familial AD is associated with a glutamine to glutamic acid substitution at 
residue 22 (E22Q), found in a disorder known as hereditary cerebral hemorrhage with 
amyloidosis Dutch type (HCHWA-D) (Levy et al., 1990).  The disease is characterized by 
recurrent strokes and vascular dementia in the absence of neurofibrillar pathology, with 
fatal cerebral bleeding resulting from the massive amyloid deposition in leptomeningeal 
vessels and cortical arteries and arterioles (reviewed in Zhang-Nunes et al., 2006).  
Parenchymal mature plaques characteristic of AD are rare in this kindred, while diffuse 
preamyloid deposits are relatively frequent and show a remarkable relationship with age.  
They are more abundant in younger patients, suggesting that these lesions may develop 
into the less profuse mature fibrillar counterparts (Maat-Schieman et al., 2005; Maat-
Schieman et al., 2000; Natte et al., 2001).  
In general, Aβ mutants have been demonstrated to exert stronger toxicity than 
the wild-type counterparts in both neuronal (Murakami et al., 2003) and cerebrovascular 
cells (Davis and Van Nostrand, 1996; Eisenhauer et al., 2000; Miravalle et al., 2000; Van 
Nostrand et al., 2001), albeit striking differences exist among the variants themselves.  
Differences in toxicity likely correlate with distinct structural properties conferred by the 
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amino acid substitutions, which typically translate into enhanced fibrillogenic properties 
(Nilsberth et al., 2001; Wisniewski et al., 1991).  These, in turn, influence the onset and 
aggressiveness of the respective clinical phenotypes (reviewed in Ghiso and Frangione, 
2002).   
One of the most studied mutants is the aggressive intra-Aβ genetic variant E22Q.  
Following intraventricular injection in rats, this variant dramatically disrupts synaptic 
plasticity.  Together with the Arctic (E22G) mutant, it is 100-fold more potent than wild-
type Aβ40 at inhibiting long-term potentiation (Klyubin et al., 2004).  The Dutch Aβ 
peptide has also been shown to exert potent effects on vessel wall cells, exhibiting anti-
angiogenic properties (Paris et al., 2005) and inducing apoptosis in cerebral endothelial 
and smooth muscle cells, under conditions in which wild-type Aβ had no effects (Davis 
and Van Nostrand, 1996; Eisenhauer et al., 2000; Miravalle et al., 2000; Van Nostrand et 
al., 2001).  Nevertheless, the cellular mechanism(s) by which Aβ mutants induce toxicity 
remains poorly understood and requires further investigation. 
Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid known to play 
a key role in modulating the apoptotic threshold in various cells types by interfering with 
classical mitochondrial pathways of cell death (Rodrigues et al., 1998).  Its antiapoptotic 
effects have been demonstrated in several pathological conditions, including different 
neurological disorders (Colak et al., 2008; Duan et al., 2002; Keene et al., 2002; Macedo 
et al., 2008; Rodrigues et al., 2003a).  TUDCA modulates Aβ-induced cell death by 
inhibiting the mitochondrial pathway of apoptosis and enhancing survival signaling in rat 
cortical neurons (Solá et al., 2003).  Moreover, it can interfere with targets upstream of 
mitochondria, including cell cycle-related proteins E2F-1 and p53 (Ramalho et al., 2004), 
through functional modulation of nuclear steroid receptors (Solá et al., 2006).  These data 
strongly suggest that TUDCA may also be beneficial in reducing other manifestations of 
brain amyloid toxicity, such as CAA. 
Many studies have been devoted to elucidate the mechanisms of Aβ 
neurotoxicity.  However, there is limited information available regarding the effect(s) of 
amyloid peptides on endothelial vessel wall cells that are in immediate contact with the 
vascular amyloid deposits in CAA.  In this study, we compared aggregation/fibrillization 
properties, secondary structure, and cell death pathways of the Dutch variant and wild-
type Aβ40 and Aβ42, both in the presence and absence of TUDCA.  Our data dissociate 
the apoptotic properties of Aβ peptides in human cerebral endothelial cells and their 
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distinct mechanisms of aggregation in vitro, while providing new perspectives for 
modulation of amyloid-induced apoptosis. 
 
2.3 Materials and methods 
2.3.1 Peptide synthesis 
Synthetic wild-type Aβ40 and Aβ42 peptides as well as Aβ40 peptide containing 
the E22Q substitution were synthesized by James I. Elliott at Yale University using N-
tert-butyloxycarbonyl chemistry and then purified by reverse phase-high performance 
liquid chromatography on a Vydac C4 column (Western Analytical, Murrieta, CA) 
(Ghiso et al., 2004; Miravalle et al., 2000).  Molecular masses were corroborated by 
matrix-assisted
 
laser desorption ionization time-of-flight (MALDI-TOF) mass
 
spectrometry, and concentration assessed by amino acid
 
analysis.  All peptides were 
supplied as single components eluted from the reverse phase columns with experimental 
molecular masses of 4329.41 Da for Aβ40 (theoretical mass, 4329.86 Da), 4514.24 Da 
for Aβ42 (theoretical mass, 4514.10 Da), and 4328.80 Da for Aβ40E22Q (theoretical 
mass, 4328.87 Da).  
 
2.3.2 Peptide aggregation 
Synthetic Aβ homologues were dissolved to 1 mM in hexafluoro-isopropanol 
(HFIP; Sigma Chemical Co., St. Louis, MO), a pre-treatment that breaks down -sheet 
structures and disrupts hydrophobic forces leading to monodisperse A preparations 
(Dahlgren et al., 2002).  Following lyophilization to remove HFIP, peptides were 
subsequently solubilized in deionized water and added of an equal volume of a 2x-
concentrated phosphate buffered saline (PBS), pH 7.4, to a final concentration of 1 mg/ml 
in 1 x PBS.  Peptides, in the presence or absence of 100 µM TUDCA (Sigma), were 
either incubated at 37
o
C for up to 48 h for the aggregation studies or diluted into culture 
media at the required concentration for the toxicity experiments.  For the aggregation 
studies, structural properties were assessed by Western blot analysis, circular dichroism 
(CD) spectroscopy, and Thioflavin T binding. 
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2.3.3 Peptide structural analysis 
For the Western blot analysis, 200 ng aliquots of each peptide either freshly 
solubilized or after 24 and 48 h of agregation, in the presence or absence of TUDCA, 
were separated on 16.5% Tris-Tricine SDS-PAGE.  After electrophoresis, proteins were 
electrotransferred to nitrocellulose membranes (Hybond-ECL; GE Healthcare Life 
Sciences, Piscataway, NJ) using 10 mM 3-cyclohexylamino-1-propanesulfonic acid 
(Sigma) buffer, pH 11.0, containing 10% (v/v) methanol, at 400 mA for 2 h.  After 
blocking in 5% nonfat milk in PBS containing 0.1% Tween 20, the membranes were 
immunoreacted with a combination of mouse monoclonal anti-Aβ antibodies 4G8 
(epitope: residues Aβ18-22) and 6E10 (epitope: residues Aβ3-8), both from Covance 
(Princeton, NJ), at a 1/3000 dilution each, followed by incubation with horseradish 
peroxidase (HRP)-labeled F(ab‟)2 anti-mouse IgG (1/5000; GE Healthcare Life 
Sciences).  Fluorograms were developed with SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Rockford, IL) and exposed to Hyperfilm ECL (GE 
Healthcare Life Sciences). 
The secondary structure of Aβ peptides was estimated by CD spectroscopy as 
previously described (Ghiso et al., 2004; Miravalle et al., 2000).  Spectra in the far-UV 
light (190–260 nm; band width: 1 nm; intervals: 1 nm; scan rate: 60 nm/min) yielded by 
the different peptides at each time point of aggregation were recorded at 24°C with a 
Jasco J-720 spectropolarimeter (Jasco Corp., Tokyo, Japan), using a 0.2 mm-path quartz 
cell and a peptide concentration of 1 mg/ml.  For each sample, 15 consecutive spectra 
were obtained, averaged and baseline-subtracted.  Results were expressed in terms of 
mean residue ellipticity (degree-cm
2
 dmol
_1
) (Kelly et al., 2005). 
Thioflavin T binding was assessed essentially as previously described (LeVine, 
1999; Walsh et al., 1999).  Six µl aliquots of each of the peptide aggregation time-point 
samples were added of 10 µl of 0.1 mM Thioflavin T (Sigma) and 50 mM Tris-HCl 
buffer, pH 8.5 to a final volume of 200 µl.  Fluorescence was recorded after 300 s in a 
LS-50B luminescence spectrometer (Perkin Elmer, Waltham, MA) with excitation and 
emission wavelengths of 435 nm (slit width = 10 nm) and 490 nm (slit width = 10 nm), 
respectively.  Each sample was analyzed in duplicate. 
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2.3.4 Culture of human brain microvascular endothelial cells 
Primary human cerebral endothelial cells (HCEC; Cell Systems, Kirkland, WA) 
were grown in CS-C Complete Medium on dishes coated with Attachment Factor (Cell 
Systems), at 37ºC in a 5% CO2 atmosphere.  For cell death assays and 
immunocytochemistry, cells were plated at a density of 4x10
4 
cells/ml.  For 
immunoblotting, cells were plated at a density of 1x10
5 
cells/ml.  In all cases, cells were 
allowed to rest for 1 day prior to treatment with the Aβ peptides. 
 
2.3.5 Induction of apoptosis 
HFIP pre-treated Aβ peptides were dissolved to 500 µM in PBS, as indicated 
above, and subsequently added of warm F12K Nutrient Mixture (Invitrogen/Gibco, 
Carlsbad, CA) supplemented with 1% fetal bovine serum (FBS; Invitrogen/Gibco) to a 50 
µM final concentration.  These freshly prepared peptide solutions were incubated with 
HCEC, cultured as described above, for 12 or 24 h.  In co-incubation experiments, 100 
µM TUDCA was added to the cell cultures 12 h prior to the addition of Aβ peptides.  As 
negative controls, cells were separately incubated either in the absence of amyloid 
peptides, or with TUDCA alone.  In all cases, attached cells were either fixed for Hoechst 
staining and immunocytochemistry analysis, or processed for viability assays.  For 
Western blot analysis, attached and floating cells were combined prior to the preparation 
of cytosolic and mitochondrial protein fractions and subsequent protein extraction. 
 
2.3.6 Measurement of cell death 
Cell viability was measured by trypan blue exclusion and by the lactate 
dehydrogenase (LDH) viability
 
assay (Sigma) according to the manufacturer's 
instructions.  Apoptotic nuclei were detected by Hoechst labeling after cell fixation with 
4% formaldehyde in PBS, for 10 min at room temperature.  Following incubation with 
Hoechst dye 33258 (Sigma) at 5 g/mL in PBS for 5 min, and PBS washes, slides were 
mounted with PBS:glycerol (3:1, v/v) and fluorescence visualized with an Axioskop 
fluorescence microscope (Carl Zeiss GmbH, Hamburg, Germany).  Fluorescent nuclei 
were scored and categorized according to the condensation and staining characteristics of 
chromatin.  Normal nuclei showed non-condensed chromatin dispersed over the entire 
nucleus.  Apoptotic nuclei were identified by condensed and fragmented chromatin 
contiguous to the nuclear membrane, as well as nuclear fragmentation and presence of 
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apoptotic bodies.  Three random microscopic fields per sample of approximately 250 
nuclei were counted and mean values expressed as the percentage of apoptotic nuclei. 
 
2.3.7 Immunocytochemistry 
After 24 h of exposure to the respective amyloid peptides, both in the presence 
and absence of TUDCA, HCEC were either directly processed for mitochondria labeling 
in live cells or fixed in 4% formaldehyde in PBS as above for the immunocytochemical 
evaluation of cytochrome c and Bax.  Staining of mitochondria in Aβ-challenged cells 
was performed by incubation for 30 min with 100 nM Red-Fluorescent MitoTracker 
Probe (Invitrogen/Molecular Probes, Eugene, OR) to allow for the selective incorporation 
of the dye and subsequent staining of the organelles.  Immunofluorescence signals were 
evaluated using fluorescence microscopy as above.  Bax mitochondrial immuno-
colocalization was performed with the Tyramide Signal Amplification Kit 
(Invitrogen/Molecular Probes), according to the manufacturer´s instructions.  Briefly, 
cells were fixed with 4% formaldehyde as above, washed with PBS, and incubated with 
1% blocking reagent, 0.1% Triton X-100 for 1 h, at room temperature.  Incubation with 
mouse monoclonal anti-Bax antibody (Santa Cruz Biotechnology, Santa Cruz, CA) (1:50 
in blocking solution; overnight, 4ºC) was followed by HRP-conjugated goat anti-mouse 
IgG (Bio-Rad Laboratories, Hercules, CA) (1:200; 1 h, room temperature).  Cells were 
subsequently incubated with Alexa Fluor 350-labeled tyramide (1:100 in amplification 
buffer/0.0015% H2O2; 10 min, room temperature), washed with PBS, and mounted in 
PBS: glycerol (3:1, v/v).  Fluorescence was visualized as above. 
For cytochrome c immunostaining, after Aβ challenge and fixation, HCEC were 
incubated for 1 h with PBS containing 0.3% Triton X-100 (PBST) and 20 mg/ml bovine 
serum albumin (BSA).  This was followed by 2 h incubation with monoclonal antibody 
anti-cytochrome c (BD Biosciences, Franklin Lakes, NJ; 1:200 in PBST containing 5 
mg/ml BSA) and 1 h reaction with Alexa Fluor 488 conjugated anti-mouse secondary 
antibody (Invitrogen; 1:200 in PBST with 5 mg/ml BSA).  Slides were mounted with 
Dapi-containing Mounting Medium (Vectashield, Burlingame, CA) and images acquired 
in a Nikon Eclipse E-800 Deconvolution Microscope, using Image-Pro Plus software 
(Media Cybernetics, Silver Springs, MD) and Autodeblur (AutoQuant Imaging, Inc., 
Watervliet, NY) for deconvolution.  Specificity of immune detection was assessed by 
omission of the primary antibody. 
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2.3.8 Bax translocation and cytochrome c release 
Sub-cellular distribution of Bax and cytochrome c in amyloid-challenged HCEC 
was determined using mitochondrial and cytosolic protein extracts.  Briefly, cells were 
collected by centrifugation at 600g for 5 min at 4°C.  The pellets were washed once in 
ice-cold PBS and resuspended with 3 volumes of isolation buffer (20 mM HEPES/KOH, 
pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) 
supplemented with Complete protease inhibitor cocktail tablets (Roche Diagnostics 
GmbH, Mannheim, Germany), in 250 mM sucrose.  After chilling on ice for 15 min, cells 
were disrupted by 40 strokes of a glass homogenizer, and homogenates were centrifuged 
twice at 2500g for 10 min at 4°C to remove unbroken cells and nuclei.  The supernatants 
were further centrifuged at 12000g for 30 min at 4°C, and the pellets containing the 
mitochondrial fraction resuspended in isolation buffer and frozen at -80°C.  For cytosolic 
proteins, the 12000g supernatants were collected, filtered sequentially through 0.2 μm and 
0.1 μm Ultrafree MC filters (Millipore, Bedford, MA) to remove other cellular organelles, 
and frozen at -80°C.  Protein concentrations of the subcellular fractions were determined 
using the Bio-Rad protein assay kit according to the manufacturer‟s specifications.  For 
Western blot detection of cytochrome c and Bax, typically 10 μg of mitochondrial and 50 
μg of cytosolic proteins were separated on 15% SDS-PAGE and transferred onto 
nitrocellulose membranes.  After sequentially blocking with 15% H2O2 and 5% non-fat 
milk (1 h, room temperature), membranes were separately incubated overnight at 4°C 
with mouse monoclonal anti-Bax (Santa Cruz Biotechnology) and anti-cytochrome c 
(PharMingen, San Diego, CA) diluted 1:500, and 1:2000, respectively.  Finally, 
immunoblots were incubated with HRP-conjugated secondary antibodies (Bio-Rad 
Laboratories; 1:5000, 3 h, room temperature) and processed for chemiluminescence 
detection using the SuperSignal Chemiluminescent Substrate (Thermo Scientific).  
Mitochondrial contamination of the cytosolic protein extracts was assessed with 
cytochrome c oxidase II (Cox II; Santa Cruz Biotechnology; 1:200).  Cox II and -actin 
(Sigma; 1:25000) were used as loading controls for mitochondrial and cytosolic fractions, 
respectively. 
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2.3.9 Statistical analysis 
Statistical analysis was performed using GraphPad InStat version 3.00 (Graph-
Pad Software) for the analysis of variance and Bonferroni‟s multiple comparison tests.  
Values of p < 0.05 were considered significant. 
 
2.4 Results 
2.4.1 TUDCA does not affect Aβ peptide aggregation and secondary structure 
It has been postulated that Aβ toxicity correlates with peptide aggregation 
propensity.  Based on our previous findings demonstrating an inhibitory role of TUDCA 
on Aβ neurotoxicity, we studied its effect on the aggregation/fibrillization properties of 
the Dutch variant comparing with wild-type Aβ40 and Aβ42.  As indicated in Figure 
2.1A, wild-type Aβ40 remained mostly monomeric up to 48 h of incubation, with the 
appearance of only faint dimeric bands on Western blot analysis at this time point.  In 
contrast, as expected, Aβ42 showed high tendency to aggregate.  Dimers and even faint 
tetrameric species were observed immediately after solubilization, whereas high 
molecular mass aggregates were readily visible at 24 h and accentuated at 48 h.  AβE22Q 
showed an intermediate behavior with the formation of SDS-resistant oligomeric 
assemblies clearly noticeable at 48 h incubation but of lower molecular masses than those 
of Aβ42.  Notably, in all cases, co-incubation with TUDCA resulted in no significant 
changes in the aggregation properties of the different peptides. 
The effect of TUDCA on the fibrillogenic propensity of the peptides was 
assessed by Thioflavin T binding.  Co-incubation with TUDCA did not modify the 
inherent properties of each peptide (Fig. 2.1B).  In fact, Aβ42 continued to express the 
highest fluorescence values, while Aβ40 levels remained negligible even at 48 h.  
AβE22Q showed an intermediate behavior, in agreement with the aggregation pattern 
shown in Fig. 2.1A.  Secondary structure analysis by CD spectroscopy illustrated both the 
different structural characteristics of the peptides and the lack of effect of TUDCA (Fig. 
2.1C).  The initial Aβ40 structure showed a minimum at 198 nm, characteristic of 
unordered conformations.  Within 48 h of incubation, the peptide acquired a β-sheet-rich 
structure showing the typical minimum at 218 nm in the CD scan.  Aβ42 showed a 
predominantly β-sheet conformation even immediately after solubilization.  AβE22Q 
exhibited an intermediate structural configuration, in agreement with the data illustrated 
in Fig. 2.1A and B, with a mixture of random and β-sheet components when freshly 
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solubilized and an increase in the β-sheet component at 48 h.  However, AβE22Q did not 
achieve the predominant β-sheet conformation of the Aβ42 in the time frame of the 
experiments. Corroborating the Western blot and Thioflavin T data, co-incubation with 
TUDCA did not induce conformational changes in the secondary structures of any of the 
Aβ peptides studied. 
 
 
Figure 2.1.  Structural studies of wild-type and Dutch-variant Aβ peptides.  HFIP-treated 
peptides at 1 mg/ml in PBS were aggregated at 37oC for up to 48 h.  Peptide 
aggregation/fibrillization propensity as well as secondary structure were analyzed both in the 
presence or absence of 100 µM TUDCA.  (A) Oligomerization of wild-type and Dutch-variant 
peptides assessed by Western blot probed with a combination of monoclonal anti-Aβ antibodies 
4G8 and 6E10 after separation on 16.5% Tris-Tricine SDS-PAGE.  (B) Fibrillization of wild-type 
and Dutch-variant peptides estimated by fluorescence evaluation (Excitation/Emission 
wavelengths 435 nm/490 nm, respectively) after Thioflavin T binding.  Solid lines, Aβ peptides 
alone; broken lines, Aβ peptides in the presence of TUDCA.  (C) Secondary structure of wild-
type and Dutch-variant peptides assessed through the respective spectra in the far-UV light (190-
260 nm) in a Jasco J-720 spectropolarimeter via a 0.2 mm-path quartz cell, at 24 (top) and 48 h 
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(bottom) of aggregation.  Blue, Aβ peptides alone; red, Aβ peptides in the presence of TUDCA; 
green, TUDCA alone. 
 
The effect of TUDCA on the fibrillogenic propensity of the peptides was 
assessed by Thioflavin T binding.  Co-incubation with TUDCA did not modify the 
inherent properties of each peptide (Fig. 2.1B).  In fact, Aβ42 continued to express the 
highest fluorescence values, while Aβ40 levels remained negligible even at 48 h.  
AβE22Q showed an intermediate behavior, in agreement with the aggregation pattern 
shown in Fig. 2.1A.  Secondary structure analysis by CD spectroscopy illustrated both the 
different structural characteristics of the peptides and the lack of effect of TUDCA (Fig. 
2.1C).  The initial Aβ40 structure showed a minimum at 198 nm, characteristic of 
unordered conformations.  Within 48 h of incubation, the peptide acquired a β-sheet-rich 
structure showing the typical minimum at 218 nm in the CD scan.  Aβ42 showed a 
predominantly β-sheet conformation even immediately after solubilization.  AβE22Q 
exhibited an intermediate structural configuration, in agreement with the data illustrated 
in Fig. 2.1A and B, with a mixture of random and β-sheet components when freshly 
solubilized and an increase in the β-sheet component at 48 h.  However, AβE22Q did not 
achieve the predominant β-sheet conformation of the Aβ42 in the time frame of the 
experiments. Corroborating the Western blot and Thioflavin T data, co-incubation with 
TUDCA did not induce conformational changes in the secondary structures of any of the 
Aβ peptides studied.  
 
2.4.2 TUDCA inhibits AβE22Q-induced apoptosis in brain microvascular 
endothelial cells 
Morphologic evaluation of apoptosis induced by Aβ peptides in HCEC was 
performed by fluorescence microscopy following Hoechst staining (Fig. 2.2A).  The 
results showed that nuclear fragmentation was differentially triggered by Aβ peptides, 
starting at 12 h of treatment, with a maximum at 24 h, under the conditions tested.  
Interestingly, the A22Q variant was very aggressive in HCEC, increasing apoptosis by 
almost 3-fold compared to controls (p < 0.001), in contrast to wild-type Aβ40 and Aβ42 
which had almost no effect (Fig. 2.2B).  Consistent with its vasculotropic properties, 
A22Q did not significantly increase cell death in primary rat cortical neurons 
(unpublished observations).  TUDCA was highly effective at modulating A22Q-
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induced toxicity, significantly inhibiting peptide-induced nuclear fragmentation to levels 
comparable to controls (p < 0.05).  Trypan blue dye exclusion and LDH levels (data not 
shown) were in accordance with the morphological results.  Detailed characterization of 
the structural assemblies of A22Q indicated that the induction of apoptosis correlated 
with the presence of peptide oligomers of low molecular mass and intermediate 
Thioflavin-binding capacity (Fig. 2.1).  Notably, pre-treatment with TUDCA, did not 
induce significant changes either in the peptide structure or in the 
aggregation/fibrillization propensity.   
 
 
 
Figure 2.2.  AβE22Q-induced apoptosis in HCEC is inhibited by TUDCA.  Cells were 
incubated either with vehicle (control), 50 μM of wild-type or Dutch-variant Aβ peptides, ± 100 
μM TUDCA for 24 h.  In co-incubation experiments, cells were pre-treated with TUDCA for 12 h 
and the bile acid was left in the culture medium with Aβ peptides.  (A) Fluorescence microscopy 
of Hoechst staining shows condensed or fragmented nuclei indicative of apoptosis in control cells 
(a), and in cells exposed to TUDCA (b), Aβ40 (c), and Aβ42 (d).  Nuclear condensation or 
fragmentation was markedly increased in cells incubated with AβE22Q (e), but less evident in 
cells exposed to AβE22Q plus TUDCA (f).  (B) Histogram shows the percentage of apoptotic 
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cells (mean ± SEM) identified by condensed and fragmented chromatin contiguous to the nuclear 
membrane, as well as nuclear fragmentation and presence of apoptotic bodies, following Hoechst 
staining and fluorescence microscopy.  †p < 0.001 from control; *p < 0.05 from AβE22Q. 
 
2.4.3 TUDCA prevents AβE22Q-induced mitochondrial Bax translocation and 
cytochrome c release 
To further investigate the cell death pathways differentially triggered by Aβ 
peptides in HCEC, we sought to determine the specific involvement of the mitochondrial 
pathway of apoptosis.  Our results showed that the AE22Q mutant was very effective at 
triggering cytochrome c translocation from mitochondria to the cytosol when compared to 
Aβ40 and Aβ42 (Fig. 2.3), which exhibited almost negligible effects.  This is consistent 
with the lack of ability of the wild-type peptides to induce major apoptotic changes in 
HCEC.  Data on Bax translocation from the cytosol to mitochondria, assessed by Western 
blot, were in agreement with cytochrome c changes (Fig. 2.3).   
 
 
 
Figure 2.3.  AβE22Q-induced Bax translocation and cytochrome c release in HCEC.  Cells 
were incubated either with vehicle (control), or 50 μM wild-type or Dutch-variant Aβ peptides for 
24 h.  Mitochondrial and cytosolic protein fractions were extracted for Western blot analysis.  
Representative immunoblots of Bax and cytochrome c cellular distribution are shown.  
Cytochrome c oxidase II (Cox II) and -actin were used as loading controls for mitochondrial and 
cytosolic fractions, respectively.  Cyt c, cytochrome c. 
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The role of TUDCA in preventing AE22Q-induced, mitochondria-dependent 
cell death was assessed by immunofluorescence microscopy.  We confirmed that 
incubation of HCEC with the AE22Q mutant resulted in cytochrome c release from 
mitochondria as illustrated by the strong cytoplasmic staining, which was mostly 
abolished by TUDCA (Fig. 2.4).   
 
 
 
Figure 2.4.  TUDCA inhibits AβE22Q-induced cytochrome c release in HCEC.  Cells were 
incubated either with vehicle (control), 50 μM of wild-type or Dutch-variant Aβ peptides, ± 100 
μM TUDCA for 24 h.  In co-incubation experiments, cells were pre-treated with TUDCA for 12 h 
and the bile acid was left in the culture medium with Aβ peptides.  Fluorescence microscopy 
shows mitochondrial localization of cytochrome c in control cells (a) and in cells exposed to 
TUDCA (b), Aβ40 (c), and Aβ42 (d).  Strong cytoplasmic staining was evident in cells incubated 
with AβE22Q (e).  Notably, co-incubation with TUDCA mostly abolished the effect induced by 
the Dutch-variant peptide (f). 
 
In addition, our results demonstrated that TUDCA significantly reduced co-
localization of Bax with mitochondrial markers after incubation of HCEC with AE22Q 
(Fig. 2.5A).  In fact, TUDCA reduced mitochondrial co-localization of Bax to control 
values (Fig. 2.5B; p < 0.05). 
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Figure 2.5.  TUDCA inhibits AβE22Q-induced cytochrome c release in HCEC.  Cells were 
incubated either with vehicle (control), 50 μM of wild-type or Dutch-variant Aβ peptides, ± 100 
μM TUDCA for 24 h.  In co-incubation experiments, cells were pre-treated with TUDCA for 12 h 
and the bile acid was left in the culture medium with Aβ peptides.  Fluorescence microscopy 
shows mitochondrial localization of cytochrome c in control cells (a) and in cells exposed to 
TUDCA (b), Aβ40 (c), and Aβ42 (d).  Strong cytoplasmic staining was evident in cells incubated 
with AβE22Q (e).  Notably, co-incubation with TUDCA mostly abolished the effect induced by 
the Dutch-variant peptide (f). 
 
2.5 Discussion 
Extensive CAA is the neuropathological hallmark of familial AD cases linked to 
intra-Aβ mutations.  These Aβ genetic variants show potent vasculotropic properties and 
result in a predominant deposition of Aβ peptides ending at position 40 (Castano et al., 
1996; Kumar-Singh et al., 2002; Shin et al., 2003).  These are also the species that target 
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the vasculature in sporadic AD, in contrast with the primary association of Aβ42 with the 
parenchymal deposits (Miller et al., 1993; Mori et al., 1992).  
Aggregation/fibrillization of Aβ plays a critical role in neurodegeneration.  It is 
now considered that the transition from soluble monomeric species circulating under 
normal conditions to the oligomeric, protofibrillar and end-point fibrillar assemblies 
contribute significantly to disease pathogenesis.  In particular, intermediate oligomeric 
and protofibrillar forms seem to display the most potent effects in neuronal cells inducing 
synaptic disruption and neurotoxicity (reviewed in Caughey and Lansbury, 2003; Walsh 
and Selkoe, 2007).  In contrast, the abundance of mature amyloid plaques correlates 
poorly with AD severity (Lue et al., 1999; McLean et al., 1999).  Mutants with 
accelerated formation of intermediate species and increased stability of these structures, 
such as the Arctic (E22G) variant, elicit an earlier and stronger effect on neuronal cells 
compared with wild-type peptides (Nilsberth et al., 2001; Whalen et al., 2005).  In 
contrast, the effect of Aβ genetic variants on cerebral vessel wall cells, specifically on 
endothelial cells has not been so well characterized.  The E22Q peptide has been shown 
to selectively exert deleterious effects on these cells, significantly increasing apoptotic 
responses in comparison to the wild-type Aβ40 (Eisenhauer et al., 2000; Miravalle et al., 
2000).  Nevertheless, the nature of the amyloid assemblies inducing toxicity remains 
uncertain.  In the present study, we characterized in detail the conformational properties 
of the E22Q peptide triggering apoptotic responses in HCEC and demonstrated its 
intermediate fibrillogenic/aggregation properties and content of -sheet conformation 
compared with wild-type A40 and A42.  In one extreme, Aβ40 exhibited virtual lack of 
oligomerization; in the other, Aβ42 showed high molecular mass assemblies with strong 
fibrillar components.  The absence of apoptosis resulting from endothelial challenge with 
both wild-type peptides suggests that the intermediate conformation of the E22Q 
oligomeric assemblies accounts for the potent, specific apoptotic effect of this genetic 
variant. 
The limited high-order oligomerization/fibrillization observed in AβE22Q 
correlates well with the findings from nuclear magnetic resonance spectroscopy and 
molecular dynamics simulation studies, which highlighted the effect of the mutation in 
fibril stabilization (Ma and Nussinov, 2006; Zheng et al., 2007). These studies indicated 
that the wild-type Aβ peptide, although mostly unstructured in solution, bears some 
regions exhibiting structural order and protease resistance.  A fragment stretching from 
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amino acids 21 through 30 adopts a stable bend structure which appears to nucleate 
monomer folding (Lazo et al., 2005).  The turn is stabilized by hydrophobic interactions 
between Val24 and Lys28 and by long-range electrostatic interactions between Lys28 and 
either Glu22 or Asp23.  The computational studies predicted that the E22Q mutation 
would translate into destabilization of the turn and enhanced oligomerization propensity 
(Grant et al., 2007; Krone et al., 2008), consistent with our findings.  Also, a contributing 
factor to the nucleation propensity of the Dutch variant may be constituted by the 
depletion of the Glu22-Lys28 salt-bridge as a consequence of the Glu for Gln substitution 
(Krone et al., 2008). 
The major form of apoptosis in mammalian cells proceeds through the 
mitochondrial pathway, which involves mitochondrial outer membrane permeabilization 
and modulation by the Bcl-2 family of proteins.  While some members of this family, 
typically located in the mitochondrial membrane, are potent inhibitors of apoptosis, 
others, including Bax, are pro-apoptotic and predominantly cytosolic (reviewed in Youle 
and Strasser, 2008).  Upon commitment to apoptosis, and after mitochondrial 
translocation, Bax undergoes conformational changes, oligomerizes and forms pores in 
the outer mitochondrial membrane, allowing the release of proteins, including 
apoptogenic cytochrome c, to the cytoplasm.  These events facilitate downstream stages 
of the cell death cascades, leading to DNA fragmentation and formation of apoptotic 
bodies.  Our data clearly demonstrates that AβE22Q is a strong inducer of the Bax pro-
apoptotic mitochondrial pathway in HCEC and highlights its role in various downstream 
events.  In fact, E22Q increased mitochondrial Bax and, consequently, cytosolic 
cytochrome c.  As expected, both events were accompanied by downstream nuclear 
fragmentation.  Although apoptosis indicators have not been investigated in HCHWA-D 
cases, it is noteworthy that studies in AD patients have demonstrated alterations in the 
expression of apoptosis-related genes, such as Bax (Mattson, 2000; Sajan et al., 2007), 
suggesting that this process also takes place in vivo.  
TUDCA is an endogenous bile acid that modulates the apoptotic threshold by 
interfering with classical mitochondrial pathways of cell death (Rodrigues et al., 1998).  It 
has been previously shown that TUDCA is neuroprotective in pharmacological and 
transgenic mouse models of Huntington‟s disease (Keene et al., 2002; Keene et al., 2001), 
reduces lesion volumes in rat models of ischemic and hemorrhagic stroke (Rodrigues et 
al., 2003a; Rodrigues et al., 2002), improves survival and function of nigral transplants in 
a rat model of Parkinson‟s disease (Duan et al., 2002), and partially rescues from 
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mitochondrial dysfunction a Parkinson‟s disease model in C. elegans (Ved et al., 2005).  
Additionally, TUDCA modulates Aβ-induced neuronal death by inhibiting the 
mitochondrial machinery and enhancing survival signaling (Solá et al., 2003), most likely 
through functional modulation of nuclear steroid receptors (Solá et al., 2006).  In 
particular, TUDCA was shown to mitigate primary neurons mitochondrial insufficiency 
and toxicity by inhibiting Bax translocation from cytosol to mitochondria (Rodrigues et 
al., 2000b) and subsequent downstream events ending in caspase activation, substrate 
cleavage and ultimately cell death.  In this study, we show that TUDCA additionally 
protects brain microvascular endothelial cells from the apoptotic insult triggered by the 
potent vasculotropic E22Q peptide through suppression of Bax translocation, cytochrome 
c release, and subsequent cell death.  Notably, despite its potent anti-apoptotic role, 
TUDCA pre-treatment did not significantly alter the aggregation properties, fibrillogenic 
capacity, or secondary structure of the Aβ peptides in our experimental in vitro paradigm.  
Future experiments should clarify if TUDCA has any differential effect in the peptide 
fibrillization occurring in cell culture conditions. 
The present data highlight a dichotomy between aggregation/fibrillization 
patterns and apoptotic properties of Aβ peptides in HCEC.  Whether these observations 
downplay the role of high molecular mass structural assemblies in the induction of 
apoptosis, or simply indicate that TUDCA directly affects upstream pathways remains to 
be elucidated.  It is conceivable that TUDCA may bind to the monomers/small oligomers 
of the Aβ peptides affecting their capability to insert into lipid bilayers and form channels 
(Jang et al., 2008; Jang et al., 2007).  Alternatively, as a cholesterol-derived molecule, 
TUDCA may insert into cellular membranes (Guldutuna et al., 1993; Rodrigues et al., 
2003b), thus preventing the subsequent insertion of Aβ.  Certainly, further studies are 
needed to identify the exact targets of TUDCA; nevertheless, this work provides new 
perspectives for the modulation of amyloid-induced toxicity in CAA, presenting new 
targets for therapeutic interventions. 
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3.1 Abstract 
Amyloid β (Aβ) peptide-induced neurotoxicity is typically associated with cell 
death through mechanisms not entirely understood.  Here, we investigated stress signaling 
events triggered by soluble Aβ in differentiated rat neuronal-like PC12 cells.  
Morphologic evaluation of apoptosis confirmed that Aβ induced nuclear fragmentation 
that was prevented by pre-treatment with the antiapoptotic bile acid tauroursodeoxycholic 
acid (TUDCA).  In addition, Aβ exposure triggered an early signaling response by the 
endoplasmic reticulum (ER) and caspase-12-mediated apoptosis, which was independent 
of the ER-stress pathway.  Furthermore, ER stress markers, including GRP94, ATF-6α, 
CHOP and eIF2α were strongly downregulated by Aβ, independent of protein 
degradation, and partially restored by TUDCA.  Calpain inhibition prevented caspase-12 
activation and reduced levels of ATF-6α.  Importantly, Aβ-induced GRP94 
downregulation was related to protein secretion and partially rescued through inhibition 
of the secretory pathway by geldanamycin and brefeldin.  In conclusion, we showed that 
the ER is a proximal stress sensor for soluble Aβ-induced toxicity, resulting in caspase-12 
activation and cell death in PC12 neuronal cells.  Moreover, GRP94 secretion was 
associated with Aβ-induced apoptotic signaling.  These data provide new information 
linking apoptotic properties of Aβ peptide to distinct subcellular mechanisms of toxicity.  
Further characterization of this signaling pathway is likely to provide new perspectives 
for modulation of amyloid-induced apoptosis. 
 
Keywords: Amyloid β; Apoptosis; Endoplasmic reticulum; Caspase-12; ATF-6α; 
GRP94; Tauroursodeoxycholic acid 
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3.2 Introduction 
Alzheimer‟s Alzheimer‟s disease (AD) is associated with the accumulation of 
pathogenic amyloid β (Aβ) assemblies in brain resulting in progressive dismantling of 
synapses and loss of neurons in selected areas.  It is recognized that increased production, 
oligomerization and aggregation of βpeptides are crucial factors in the onset of AD. 
Toxic Aβ40 and Aβ42 are processed from the amyloid-βprecursor protein (APP) via 
cleavage by β- and γ-secretase complexes (LaFerla et al., 2007; Thinakaran and Koo, 
2008). APP is a transmembrane protein, which is folded and modified in endoplasmic 
reticulum (ER), and then transported through the Golgi complex to the outer membrane. 
Currently, it is not clear which cellular compartment processes APP to toxic Aβpeptides 
(LaFerla et al., 2007). 
ER serves two major functions in the cell, including proper folding of newly 
synthesized proteins destined for secretion, cell surface or intracellular organelles, and as 
a reservoir of Ca
2+
.  The ER is highly sensitive to alterations in Ca
2+
 homeostasis and 
perturbations in its environment that result in ER stress.  The ER responds by triggering 
specific signaling pathways including the unfolded protein response (UPR), the ER-
overload response (EOR), and the ER-associated degradation (ERAD).  These pathways 
are collectively known as the ER stress response, which is also associated with increased 
expression of genes that expand the folding capacity of the ER, preventing new protein 
synthesis, and accelerating degradation of misfolded proteins.  The UPR is characterized 
by the coordinated activation of multiple proteins that can be divided into three groups, 
consisting of ER stress-induced cell death sensors, modulators and effectors.  The ER 
membrane residing proteins inositol-requiring enzyme 1 (IRE1), activating transcription 
factor 6 (ATF-6), and double-stranded RNA-activated protein kinase like ER kinase 
(PERK) serve as proximal ER stress sensors, which are maintained in an inactive state by 
binding to the chaperone 78-kDa glucose-regulated protein, also known as 
immunoglobulin heavy chain binding protein or Bip (GRP78/Bip).  GRP78/Bip is a distal 
sensor and functions as a master regulator of the UPR.  During ER stress, the release of 
GRP78/Bip results in inhibition of translation (PERK), and upregulation of molecular 
chaperones (ATF-6) and ERAD activity (IRE1) (Bernales et al., 2006; Romisch, 2005).  
ER stress-induced cell death modulators include members of the Bcl-2 family (Bcl-2, 
Bcl-xL, Bak and Bik) (Nutt et al., 2002; Thomenius et al., 2003) and CHOP (Zinszner et 
al., 1998), among others. 
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Finally, several molecules that are either present on the ER surface or in the 
soluble compartment have been implicated as effectors that cause death in response to 
prolonged ER stress.  Caspase-12 is an initiator caspase which is specifically involved in 
apoptosis (Rao et al., 2001); and its activation may occur through ER stress-induced 
calpain or caspase-7 cleavage of procaspase-12 (Nakagawa and Yuan, 2000; Rao et al., 
2001).  ER stress-activated IRE1 may also aggregate procaspase-12 at the ER membrane 
surface through the cytosolic adaptor tumor necrosis factor associated receptor factor 2 
(TRAF2) proteins, resulting in cleavage and activation of caspase-12 (Yoneda et al., 
2001).  Most notably, caspase-12, together with caspase-9, serves as a mediator of an 
intrinsic apoptosis pathway that is independent of mitochondria (Morishima et al., 2002). 
The ER is a repository of antiapoptotic GRP94, a member of the heat shock 
protein 90 (hsp90) family (Koch et al., 1986; Lee, 1992; Mazzarella and Green, 1987; 
Tanaka et al., 1990).  GRP94 is a hydrophobic, ATP-, peptide- (Booth and Koch, 1989; 
Tanaka et al., 1990), and calcium-binding protein that contains several helix-loop-helix 
structural domains (Csermely et al., 1998).  Its antiapoptotic properties (Lee et al., 2008; 
Little and Lee, 1995; McCormick et al., 1997) are not fully understood.  It has also been 
described to act as a vaccine in prophylactic and therapeutic models of cancer 
immunotherapy (Basu et al., 2000; Tamura et al., 1997).  More recently, GRP94 was 
shown to be released from cells undergoing necrotic cell death as a consequence of lethal 
viral infection, suggesting a potential physiological role for chaperone proteins in the 
regulation of immunological responses to pathological cell death (Basu et al., 2000; 
Berwin et al., 2001).  Inhibitors of hsp90 and GRP94, such as geldanamycin (GA) have 
been investigated in the treatment of cancer.  GA inhibits hsp90 and GRP94 by binding 
competitively to its N-terminal ATP-binding site, which results in misfolding and 
degradation of hsp90 substrates through the ubiquitin-proteasome pathway.  While GA-
mediated enhanced degradation of certain hsp90 proteins is now well established, 
(reviewed in Pratt, 1998; Sepp-Lorenzino et al., 1995), few studies have reported GA-
mediated inhibition of intracellular trafficking (Barzilay et al., 2004). 
In this study, we show that Aβ-induced toxicity activates caspase-12, which is 
known to mediate ER-specific apoptosis in PC12 neuronal cells.  Unexpectedly, we also 
demonstrated that ER stress-induced cell death sensors and modulators are clearly 
downregulated.  ATF-6α is proteolytically cleaved by calpain I, and GRP94 is secreted to 
the extracellular medium, in association with Aβ-induced toxicity. 
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3.3 Materials and methods 
3.3.1 Cell culture and culture conditions 
PC12 cells were grown in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, 
USA) supplemented with 10% heat-inactivated horse serum (Sigma-Aldrich), 5% fetal 
bovine serum (Invitrogen Corp., Carlsband, CA, USA) and 1% penicillin/streptomycin 
(Invitrogen), and maintained at 37°C in a humidified atmosphere of 5% CO2.  Cells were 
plated and differentiated in the presence of nerve growth factor (NGF) (Promega Corp., 
Madison, WI), as previously described (Park et al., 1998).  Cell density was maintained at 
1 x 10
5
 cells/cm
2
 for morphological assessment of apoptosis and viability assays, or 4 x 
10
5
 cells/cm
2
 for transfection assays and protein extraction. 
To induce apoptosis, cells were exposed to 25 µM of Aβ (25-35) peptide active 
fragment (Bachem AG, Bubendorf, Switzerland) for 1, 2, 8 and 24 h.  This concentration 
was found to be ideal in maximizing the cellular response of Aβ with minimum 
exacerbated toxic effects in neuronal-like PC12 cells (data not shown).  Brefeldin and 
thapsigargin (Sigma-Aldrich) were used at 18 and 3 µM, respectively, as positive controls 
for ER-specific apoptosis.  To test the effect of antiapoptotic TUDCA, cells were 
incubated in medium supplemented with 100 µM TUDCA (Sigma-Aldrich), or no 
addition (control), for 12 h, and then exposed to 25 µM of Aβ (25-35) for 1, 2, 8 and 24 h.  
Cells were fixed for microscopic assessment of apoptosis or processed for cell viability 
assays.  In addition, total proteins were extracted for immunoblotting. 
In parallel experiments, cells were pretreated for 30 min before Aβ incubation 
with SP600125, the c-Jun N-terminal kinase (JNK) inhibitor (Calbiochem, Darmstadt, 
Germany), at either 10 µM for 24 h, or 50 µM SP600125 for 3 h.  Similarly, cells were 
pretreated with 10 µM calpain inhibitor I (Roche Applied Science, Mannheim, Germany) 
for 24 h or 50 µM calpain inhibitor I for 3 h.  Proteasome and caspase inhibition during 
apoptosis was achieved by pretreating cells with either 10 µM MG-132 and z-VAD.fmk 
(Calbiochem) for 24 h, or 50 µM MG-132 and z-VAD.fmk for 3 h.  To determine the 
effect of Ca
2+
 deregulation, cells were pretreated with 50 µM ZnCl2, 100 nM 
xestospongin C, 20 µM nifedipine, 10 µM dantrolene and 0.05 to 5 µM cyclosporin A 
(Sigma-Aldrich) for 3 h.  Finally, cells were pretreated with 0.05 to 5 µM GA and 9 µM 
brefeldin (Sigma-Aldrich) for 3 h to inhibit protein secretion. 
 
Aβ-induced GRP94 secretion 
75 
3.3.2 Measurement of cell death  
Cell viability was measured by trypan blue exclusion.  Apoptotic nuclei were 
detected by Hoechst labeling after cell fixation with 4% formaldehyde in phosphate 
buffer saline (PBS), for 10 min at room temperature.  Following incubation with Hoechst 
dye 33258 (Sigma-Aldrich) at 5 g/mL in PBS for 5 min, and PBS washes, slides were 
mounted with PBS:glycerol (3:1, v/v) and fluorescence visualized with an Axioskop 
fluorescence microscope (Carl Zeiss GmbH, Hamburg, Germany).  Fluorescent nuclei 
were scored and categorized according to the condensation and staining characteristics of 
chromatin.  Normal nuclei showed non-condensed chromatin dispersed over the entire 
nucleus.  Apoptotic nuclei were independently identified by condensed and fragmented 
chromatin contiguous to the nuclear membrane, as well as nuclear fragmentation and 
presence of apoptotic bodies.  Three random microscopic fields per sample of ~ 250 
nuclei were counted and mean values expressed as the percentage of apoptotic nuclei. 
 
3.3.3 Immunoblotting 
Steady-state levels of caspase-12, ATF-6α, KDEL, CHOP and eIF2α were 
determined by Western blot analysis.  Briefly, 80 µg of total and nuclear proteins were 
separated by 12% sodium dodecyl-polyacrylamide gel electrophoresis.  After 
electrophoretic transfer onto nitrocellulose membranes, immunoblots were incubated with 
15% H2O2 for 15 min at room temperature.  Following a block with 5% milk solution, 
membranes were incubated overnight at 4°C with primary mouse monoclonal antibody 
reactive to KDEL (10C3) (Abcam, Cambridge Science Park, Cambridge, UK), primary 
rabbit polyclonal antibodies reactive to ATF-6α (H-280), GADD153 (R-20) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), Anti-eIF2α [pS52] (Invitrogen).  Finally, 
secondary goat anti-mouse or anti-rabbit IgG antibody conjugated with horseradish 
peroxidase (Bio-Rad Laboratories, Hercules, CA, USA) was added for 3 h at room 
temperature.  The membranes were processed for protein detection using the SuperSignal 
substrate (Pierce Biotechnology, Rockford, IL, USA).  β-Actin (AC-15) (Sigma-Aldrich) 
was used as loading control for total proteins.  Protein concentrations were determined 
using the Bio-Rad protein assay kit (Bio-Rad) according to the manufacturer‟s 
specifications. 
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3.3.4 RNA isolation and RT-PCR 
Transcript expression of GRP94 was determined by RT-PCR.  Total RNA was 
extracted from rat PC12 cells using the TRIZOL reagent (Invitrogen).  For RT-PCR, 5 g 
of total RNA was reverse transcribed using oligo(dT) (Integrated DNA Technologies Inc., 
Coralville, IA) and SuperScript II reverse transcriptase (Invitrogen).  Specific 
oligonucleotide primer pairs were incubated with cDNA template for PCR amplification 
using the Expand High Fidelity
PLUS
 PCR System (Roche Applied Science, Mannheim, 
Germany).  The following sequences were used as primers: GRP94 sense 50-
TACTATGCCAGTCAGAAGAAAACG-30; GRP94 antisense 50-CATCCTTT 
CTATCCTGTCTCCATA-30; β-actin sense 50-CGTCTTCCCCTCCATCGTG-30; and β 
-actin antisense 50-CCAGTTGGTTACAATGCCGTG-30.  The product of the β-actin 
RNA was used as control. 
 
3.3.5 Heat shock protein GRP94 ELISA assay 
The rat hsp90 glycoprotein 96 (hsp90 gp96) ELISA Kit (Cusabio Biotech 
Co.,Newark, USA) was used to measure GRP94 levels, according to the manufacturer‟s 
protocol.  Supernatant samples were applied to plates containing biotinylated antibody for 
GRP94 (1:100).  After 1 h incubation at 37
o
C, plates were washed and incubated with 
HRP-avidin (1:100) for an additional 1 h, after which the chemiluminescence substrate 
solution was added and incubated for 10-30 min.  The reaction was stopped and the 
optical density was measured after 30 min using a microplate reader set to 450 nm. 
 
3.3.6 Statistical analysis 
The relative intensities of protein bands were analyzed using the Quantity One 
Version 4.6 densitometric analysis program (Bio-Rad) and normalized to the respective 
loading controls.  Statistical analysis was performed using GraphPad InStat Version 3.00 
(GraphPad Software, San Diego, CA) for the analysis of variance and Bonferroni‟s 
multiple comparison tests.  Values of p < 0.05 were considered significant. 
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3.4 Results 
3.4.1 Aβ-induced apoptosis is mediated by caspase-12 activation and modulated 
by TUDCA in PC12 neuronal-like cells 
Soluble Aβ (25-35) fragment induces apoptosis in PC12 neuronal-like cells, 
which is abrogated by TUDCA pre-treatment (Ramalho et al., 2004; Viana et al.,2010).  
ER is a potential intracellular target of Aβ protein (Nakagawa et al., 2000), and TUDCA 
exerts protection from apoptosis, in part, by preventing caspase-12 activation (Xie et al., 
2002).  In this study, neuronal PC12 cells pre-exposed to NGF for 8 days were treated 
with either Aβ (25-35), or ER-specific apoptotic stimuli brefeldin and thapsigargin, with 
or without TUDCA, and assessed for cell death and caspase-12 fragmentation.  We 
confirmed that Aβ (25-35)-induced apoptosis after 24 h was reduced to almost control 
levels in cells pre-treated with TUDCA (p < 0.05) (Fig. 3.1A).  General cell death as 
assessed by trypan blue dye exclusion was in accordance with the morphological data 
(Fig. 3.1B).  Similar results were obtained in PC12 cells exposed to 10 M Aβ40 (data 
not shown).  TUDCA was also effective at modulating brefeldin- and thapsigargin-
induced apoptosis (Fig. 3.1A). 
After Aβ (25-35) exposure, caspase-12 processing peaked at 24 h, and pre-
treatment with TUDCA markedly reduced Aβ-induced effects by ~ 70% (p < 0.05) (Fig. 
3.2).  The activation of caspase-12 by calpains in apoptosis has been previously 
documented (Nakagawa and Yuan, 2000).  Moreover, the JNK pathway is activated in 
response to ER stress by IRE1 (Nishitoh et al., 1998; Urano et al., 2000), which may 
activate caspase-12 through TRAF2, the same cytosolic adaptor of JNK at the ER 
membrane surface (Yoneda et al., 2001).  To test if calpains or JNK plays a role in 
mediating neuronal cell death induced by Aβ, we incubated PC12 cells in the presence or 
absence of calpain inhibitor I or SP600125 JNK inhibitor for 24 h.  After 24 h of 
incubation with Aβ, calpain inhibition, but not JNK inhibition, prevented caspase-12 
fragmentation by almost 50% (p < 0.05), suggesting that calpains are involved in Aβ-
induced caspase-12 activation. 
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Figure 3.1.  TUDCA inhibits cell death induced by Aβ, brefeldin and thapsigargin in PC12 
neuronal cells.  Cells were incubated with either 25 µM soluble Aβ (25-35), 9 and 18 µM 
brefeldin, 1.5 and 3 µM thapsigargin, or no addition (control), ± 100 µM TUDCA for 24 h.  In co-
incubation experiments, TUDCA was added 12 h prior to incubation with Aβ, brefeldin or 
thapsigargin. (A) Total and trypan blue stained cells were counted and cell viability calculated as 
the number of surviving cells per total number of cells.  (B) Cells were fixed and stained with 
Hoechst for microscopic assessment of apoptosis, and the percentage of apoptotic cells was 
determined.  Cells exposed to Aβ, brefeldin or thapsigargin alone showed more nuclear 
fragmentation compared with cells pre-treated with TUDCA.  The results are expressed as mean ± 
SEM for at least three different experiments.  *p < 0.01 from control; †p < 0.05 from Aβ, 
brefeldin or thapsigargin alone. 
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Figure 3.2. TUDCA modulates Aβ-induced caspase-12 processing in PC12 neuronal cells.  
Cells were incubated with 25 µM Aβ, or no addition (control), ± 100 µM TUDCA, 10 µM 
SP600125 and 10 µM calpain inhibitor I for 24 h.  In co-incubation experiments, TUDCA was 
added 12 h prior to incubation with Aβ. SP600125 and calpain inhibitor I were added 30 min prior 
to incubation with Aβ.  Total proteins were extracted for western blot analysis as described in 
Materials and Methods.  Representative immunoblot of procaspase-12 and cleaved caspase-12 in 
cells exposed to Aβ, ± TUDCA, SP600125 or calpain inhibitor I (top), and active caspase-12 
levels (bottom).  The results are normalized to endogenous β-actin protein levels and expressed as 
mean ± SEM arbitrary units of at least four different experiments.  *p < 0.05 from control; †p < 
0.05 from Aβ alone. 
 
3.4.2 Aβ-induced, caspase-12-mediated cell death is independent of ER stress  
Caspase-12 Caspase-12 can be activated under specific ER stress stimuli 
(Nakagawa et al., 2000).  In addition, Aβ causes ER stress (Lee do et al., 2010) and 
proteosomal dysfunction (Shringarpure et al., 2000).  To determine whether ER stress 
plays a role in Aβ-induced apoptosis mediated by caspase-12 in PC12 neuronal cells, we 
evaluated several ER stress markers by immunoblotting (Fig. 3.3).  ER stress makers 
were upregulated or activated after either brefeldin or thapsigargin incubation, but not 
after Aβ exposure for 24 h.  Interestingly, ATF-6α, eIF2α, CHOP and GRP94 were 
markedly downregulated after Aβ incubation.  This effect was partially inhibited by 
TUDCA (Fig. 3.3).  Thus, ER is strongly involved in Aβ-induced apoptosis, although 
with no evidence of ER stress activation. 
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Figure 3.3. Aβ-induced apoptosis in PC12 neuronal cells is independent of ER stress.  Cells 
were incubated with 25 µM Aβ, or no addition (control), ± 100 µM TUDCA for 2 h. Positive 
controls for ER stress were brefeldin 18 µM and thapsigargin 3 µM for 2 h.  In co-incubation 
experiments, TUDCA was added 12 h prior to incubation with Aβ, brefeldin or thapsigargin.  
Total proteins were extracted for western blot analysis as described in Materials and Methods.  
Representative immunoblots of ER stress markers ATF-6α, eIF2α, CHOP, GRP94 and 
GRP78/Bip.  β-Actin was used as loading control. 
 
3.4.3 ATF-6α and GRP94 downregulation is independent of protein degradation  
Cells containing a mutated presenilin-1 (PS1) gene showed significantly 
inhibited induction of GRP78 mRNA expression when stimulated for ER stress 
(Katayama et al., 1999).  More importantly, GRP78 and GRP94 are decreased in brains of 
sporadic AD patients (Katayama et al., 1999).  The reduction of GRP94 protein levels 
may be explained by selective proteolytic cleavage by calpains activated during 
etoposide-induced apoptosis (Reddy et al., 1999).  In this study, basal levels of GRP94 
and ATF-6α mRNA expression were not altered in PC12 cells when exposed to Aβ for 2 
and 24 h (data not shown).  We tested if GRP94 and ATF-6α cleavage was mediated by 
proteases, such as caspases and calpains, or by the proteasome, since calpain inhibitors 
might also interfere with the proteasome activity.  Our results showed that general 
caspase inhibitor z-VAD-fmk and JNK inhibitor SP600125 did not prevent cleavage of 
GRP94 and ATF-6α, after 24 h of Aβ incubation (Fig. 3.4A).  Nevertheless, both calpain 
and proteasome inhibition were partially protective (Fig. 3.4A). Proteasome activity 
remained unchanged and autophagy was not activated by Aβ incubation under the 
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conditions tested (data not shown).  Thus, typical mechanisms for protein degradation, 
such as the proteasome and autophagy were not triggered by Aβ incubation in PC12 
neuronal-like cells. 
 
 
 
Figure 3.4. Aβ-induced downregulation of ATF-6α and GRP94 in PC12 neuronal cells is 
independent of degradation mechanisms.  Cells were incubated with 25 µM Aβ, or no addition 
(control), ± 10 µM of SP600125, calpain inhibitor I, MG132, and z-VAD.fmk for 24 h.  For 
shorter incubations with Aβ, 50 µM of each inhibitor was used for 2 h.  In co-incubation 
experiments, the inhibitors were added 30 minutes prior to incubation with Aβ.  Total proteins 
were extracted for western blot analysis as described in Materials and Methods.  (A) 
Representative immunoblot of ATF-6α and GRP94 in cells exposed to Aβ, ± 10 µM of SP600125, 
calpain inhibitor I, MG132, and z-VAD.fmk for 24 h.  (B) Representative immunoblot of ATF-6α 
and GRP94 in cells exposed to Aβ, ± 50 µM of SP600125, calpain inhibitor I, MG132, and z-
VAD.fmk for 2 h.  β-Actin was used as loading control. 
 
Since caspase-12 activation coincided with the early reduction of GRP94 at 2 h 
of Aβ incubation, we tested if GRP94 and ATF-6α cleavage was selectively mediated by 
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calpains or the proteasome, and not a consequence of general protein degradation.  Cells 
were pretreated with 50 µM of each inhibitor fro 30 min (Reddy, et al. 1999), followed by 
2 h of Aβ incubation.  In contrast to MG-132, pretreatment with calpain inhibitor I 
prevented ATF-6α cleavage (Fig. 3.4B).  However, GRP94 downregulation was not 
blocked by any of the inhibitors.  These results suggested that ATF-6α is selectively 
cleaved by calpains during Aβ-induced apoptosis, whereas GRP94 is not cleaved by 
proteases during apoptosis. 
 
3.4.4 GRP94 downregulation is independent of Ca2+ deregulation  
GRP94 has been linked directly to cellular Ca
2+
 homeostasis (Biswas et al., 
2007a).  GRP94 binds Ca
2+ 
and is one of approximately six luminal proteins that serve as 
the major buffers of the ER (Cala and Jones, 1994; Macer and Koch, 1988; Nigam et al., 
1994).  A key mechanism by which Aβ is believed to alter cellular Ca2+ homeostasis 
involves disruption of plasma membrane Ca
2+ permeability.  At the extracellular level, Aβ 
exerts actions on endogenous plasmalemmal ion channels, such as L-type channels (Fox 
et al., 1987), and  pore formation (Arispe et al., 1993).  Furthermore, Aβ oligomers 
induce massive calcium entry into mitochondria, which opens the mitochondrial 
permeability transition pore (mPTP) (Sanz-Blasco et al., 2008), and Aβ targets the mPTP 
resulting in damage amplification (Du et al., 2008).  We used Ca
2+
 blockers to determine 
whether GRP94 reduction was due to unregulated flux of extracellular Ca
2+
 induced by 
Aβ exposure.  ZnCl2, which blocks pore formation was unable to prevent GRP94 
downregulation (Fig. 3.5A).  Combinations of ZnCl2 with calpain inhibitor I and TUDCA 
were also ineffective, as was pretreatment with nifedipine that blocks L-type channels. 
Next, we inhibited the release of Ca
2+
 from the ER using xestospongin C and 
dantrolene, which block inositol triphosphate receptors (IP3Rs) and ryanodine receptors 
(RyRs), respectively.  Under the established conditions, only xestospongin C was able to 
partially prevent the reduction of GRP94 (Fig. 3.5B).  Finally, cyclosporine A, a strong 
inhibitor of calcium-induced mPTP opening, did not prevent the reduction of GRP94 
protein levels (Fig. 3.5C).  Thus, Ca
2+
 deregulation induced by Aβ incubation is not the 
main molecular mechanism of GRP94 downregulation. 
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Figure 3.5. Aβ-induced downregulation of GRP94 in PC12 neuronal cells is independent of 
Ca
2
 deregulation.  Cells were incubated with 25 µM Aβ, or no addition (control), ± 50 µM ZnCl2, 
100 nM xestospongin C, 20 µM nifedipine, 10 µM dantrolene, and 0.05 or 5 µM cyclosporin A 
for 2 h.  In co-incubation experiments, the inhibitors were added 30 min prior to incubation with 
Aβ.  Total proteins were extracted for western blot analysis as described in Materials and Methods.  
(A) Representative immunoblot of GRP94 in cells exposed to Aβ, ± 50 µM of ZnCl2.  
Combinations of ZnCl2 with 50 µM calpain inhibitor I or 100 µM TUDCA for 2 h are also shown.  
Thapsigargin 3 µM was used as positive control.  (B) Representative immunoblot of GRP94 in 
cells exposed to Aβ, ± 100 nM xestospongin C, 20 µM nifedipine and 10 µM dantrolene.  (C) 
Representative immunoblot of GRP94 in cells exposed to Aβ, ± 0.5 or 5 µM of cyclosporine A.  
Thapsigargin 3 µM and brefeldin 18 µM were used as positive controls; and β-actin as a loading 
control. 
 
3.4.5 Protein secretion inhibitors block GRP94 downregulation 
GA is an antibiotic that specifically inhibits hsp90 and GRP94 (Chavany et al., 
1996; Pratt, 1998).  Inhibition of hsp90 mainly leads to targeted degradation of client 
proteins via the ubiquitin proteasome pathway (Smith et al., 1995; Whitesell et al., 1994), 
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while the best understood response to inhibition of GRP94 is the transcriptional 
upregulation of ER chaperones (Lawson et al., 1998).  In addition, GA also mediates 
inhibition of intracellular trafficking of hsp90 substrates (Barzilay et al., 2004).  To 
determine the effect of GA on Aβ-induced GRP94 downregulation, we preincubated cells 
with different concentrations of GA for 30 min prior to exposure to Aβ for 2 h (Fig. 3.6). 
 
 
 
Figure 3.6. Aβ-induced downregulation of GRP94 in PC12 neuronal cells is blocked by 
protein secretion inhibitors.  Cells were incubated with 25 µM Aβ, or no addition (control), ± 
0.05 to 5 µM GA for 2 h.  In co-incubation experiments, the inhibitors were added 30 min prior to 
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incubation with Aβ.  Total proteins and total RNA were extracted for western blot and RT-PCR 
analysis, respectively, as described in Materials and Methods.  (A) Representative immunoblot of 
GRP94 in cells exposed to Aβ, ± 0.5 and 5 µM GA.  Thapsigargin 3 µM and brefeldin 18 µM 
were used as positive controls.  (B) Representative RT-PCR of GRP94 in cells exposed to Aβ, ± 
0.05 to 5 µM of GA.  (C) Representative immunoblot of GRP94 in cells exposed to Aβ, ± 9 µM 
brefeldin.  Combinations of 0.5 µM GA with 100 µg/ml cyclohexemide for 2 h are also 
represented.  β-Actin was used as loading control.  (D) Secreted protein levels of GRP94.  
Supernatant anti-GRP94 of cells pretreated with 0.5 µM GA and 9 µM brefeldin, and challenged 
with Aβ for 2 h was quantified using an ELISA assay.  The results are expressed as mean ± SEM 
for at least three different experiments. *p < 0.05 from control; †p < 0.05 from Aβ alone. 
 
We found that GA pretreatment prevented GRP94 downregulation in a 
concentration-dependent manner (Fig. 3.6A), without significantly altering GRP94 
mRNA expression (Fig. 3.6B).  In addition, GA effect was not dependent on de novo 
protein synthesis as determined in experiments using cyclohexamide (Fig. 3.6C).  
However, a non-apoptotic concentration of brefeldin that inhibits protein secretion was 
also able to prevent GRP94 dowregulation (Fig. 3.6C).  Finally, an ELISA assay for 
GRP94 in the supernatant of cells challenged with Aβ established that GRP94 levels were 
increased in the extracellular medium of cells incubated with Aβ, independently of a 
necrotic mechanism (Fig. 3.6D).  Retention of GRP94 within the cell by GA and 
brefeldin was associated with levels of apoptosis of ~ 5%, similar to those seen in control 
cells.  Thus, Aβ induces early stimulation of GRP94 secretion, an effect that was 
mitigated by inhibition of the secretory pathway. 
 
3.5 Discussion 
The role of Aβ in the pathogenesis and progression of AD-associated 
neurodegeneration has not been firmly established and even remains controversial.  The 
present study shows that Aβ-induced toxicity activates caspase-12 that mediates ER-
specific apoptosis in PC12 neuronal cells, which in turn is modulated by antiapoptotic 
TUDCA.  Notably, we demonstrated that ER stress-induced cell death sensors and 
modulators are downregulated, and propose that ATF-6α is proteolytically cleaved by 
calpains, and GRP94 is secreted to the extracellular milieu during Aβ-induced apoptosis. 
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There is a growing list of mediators that link ER stress to the apoptotic 
machinery.  Caspase-12 was proposed to function as the apical caspase responsible for 
initiating an apoptotic cascade in response to ER stress and Aβ (Nakagawa et al., 2000).  
In the present study, we showed that Aβ-induced apoptosis in PC12 neuronal-like cells 
requires caspase-12 activation that peaked after 24 h of Aβ incubation, and which was 
inhibited by antiapoptotic TUDCA.  Both the JNK pathway (Tan et al., 2006) and 
calpains (Nakagawa and Yuan, 2000) have been shown to activate caspase-12.  Our 
results confirmed that calpain inhibition partially abrogated caspase-12 activation.  This 
fact suggests a role for intracellular Ca
2+
, given that calpains are activated by Ca
2+
 (Croall 
and DeMartino, 1991) and Aβ-incubation results in intracellular Ca2+ overload 
(Kuchibhotla et al., 2008). 
ER is very sensitive to changes in Ca
2+
 homeostasis, leading to ER stress and 
caspase-12 activation (Nakagawa et al., 2000; Orrenius et al., 2003).  In the present study, 
we investigated if caspase-12 activation after Aβ-incubation resulted from ER stress.  We 
found that ER stress markers such as GRP94, ATF-6α, eIF2α and CHOP were 
downregulated in PC12 cells exposed to Aβ peptide.  This effect was extremely 
pronounced for GRP94 levels, which became undetectable after only 2 h of incubation 
with Aβ. 
ER-resident molecular chaperones, such as GRP78 and GRP94 are 
downregulated in brains of AD patients and in PS1 mutant cells (Katayama et al., 1999).  
Moreover, it has been demonstrated that in etoposide-induced apoptosis, the reduction of 
GRP94 levels is due to calpain cleavage (Reddy et al., 1999).  Here, we demonstrated that 
under Aβ-induced apoptosis, GRP94 downregulation was calpain-independent.  In 
contrast, ATF-6α downregulation was prevented by calpain inhibition.  This fact, 
suggested that ATF-6α is either a substrate for calpain cleavage, or that calpain regulates 
proteases that normally cleave and activate ATF-6α.  During the ER stress response, 
ATF-6α is cleaved with release of its cytoplasmic bZIP domain from the membrane, and 
translocation to the nucleus (Haze et al., 1999). 
GRP94 is a passive high-capacity reservoir for Ca
2+
, whose activity is regulated 
by Ca
2+
.  Furthermore, despite the redundancy of Ca
2+
-binding proteins in the ER, the 
ability of GRP94 to bind Ca
2+
 is uniquely important in the cellular context, as cells 
become hypersensitive to perturbations in Ca
2+ 
homeostasis in the absence of GRP94.  
Here, we demonstrated that deregulation of Ca
2+ homeostasis induced by Aβ-incubation 
was not related with downregulation of GRP94.  In fact, Aβ can induce intracellular Ca2+ 
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overload by several mechanisms (reviewed in Demuro et al., 2010).  In the present study, 
we used nifedipine and ZnCl2 at the plasma membrane level to inhibit L-type Ca
2+ 
channel and zinc pore formation, respectively.  Xestospongin C and dantrolene were used 
at the ER level to inhibit Insp3Rs and RyRs receptors, respectively.  Moreover, 
cyclosporine A inhibits Ca
2+ 
regulation between ER-mitochondria through the mPTP pore 
formation.  Despite the fact that GRP94 binds Ca
2+ 
and serves as the major Ca
2+ 
buffer in 
the ER (Cala and Jones, 1994; Macer and Koch, 1988; Nigam et al., 1994), our results 
suggested that GRP94 downregulation is not strictly related to Ca
2+ 
deregulation.  
Nevertheless, inhibition of Ca
2+ 
deregulation slightly prevented the reduction of GRP94 
levels. 
GRP94 has been identified in the extracellular space as a consequence of acute 
stress in lethal viral infection and necrotic cell death (Basu et al., 2000; Berwin et al., 
2001).  Indeed, stress proteins such as heat shock proteins, glucose regulated proteins and 
calreticulin are released from cells in a variety of circumstances, thus interacting with 
adjacent cells or in some cases entering the bloodstream (reviewed in Calderwood et al., 
2007).  Furthermore, GA inhibits GRP94 and hsp90 (Neckers, 2002), and activates a heat 
shock response, possibly through increased expression of molecular chaperones (McLean 
et al., 2004; Sittler et al., 2001).  Nonetheless, only a few reports have suggested that GA 
may mediate the inhibition of intracellular protein trafficking (Barzilay et al., 2004).  In 
the present study, we demonstrated that GRP94 downregulation is blocked in cells 
pretreated with GA in a dose-dependent manner.  This occurred in a degradation-
independent fashion, since neither the proteasome nor autophagy mechanisms were 
activated under the conditions tested.  Further, mRNA levels of GRP94 were not 
upregulated in the presence of GA, and synthesis of de novo proteins did not appear to be 
involved.  Next, we tested if the capacity of GA to inhibit intracellular protein trafficking 
was the mechanism responsible to block GRP94 downregulation.  Brefeldin, a known 
inhibitor of the secretion pathway, blocked GRP94 downregulation.  Finally, we further 
confirmed that GRP94 was secreted to the extracellular medium in the presence of Aβ-
peptide.  To our knowledge, this is the first report demonstrating that Aβ exposure in 
PC12 neuronal-like cells induces GRP94 secretion.  Once secreted, stress proteins may 
either increase stress resistance, after binding to stress sensitive recipient cells, such as 
neurons, signal tissue destruction and danger to inflammatory cells, or aid in 
immunosurveillance, by transporting intracellular peptides to distant immune cells 
(Calderwood et al., 2007). 
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In conclusion, this study provides convincing data that Aβ-induced toxicity 
triggered an early signaling response by the ER, independent of the ER-stress pathway.  
ER-stress markers were downregulated, including GRP94 that was secreted to the 
extracellular milieu in Aβ-induced apoptosis.  Additional studies are warranted to 
determine the specific role of GRP94 protein on Aβ-induced toxicity.  Notably, this 
signaling pathway was observed in an apoptotic context, rather than necrotic, which 
opens a new window for the development of novel therapeutic strategies in AD. 
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4.1 Abstract 
Amyloid β peptide (Aβ)-induced neurotoxicity is typically associated with 
apoptosis.  In previous studies, we have shown that tauroursodeoxycholic acid (TUDCA), 
an endogenous anti-apoptotic bile acid, modulates Aβ-induced apoptosis.  Here, we 
investigated stress signaling events triggered by soluble Aβ and further explored 
alternative pathways of neuroprotection by TUDCA in differentiated rat neuronal-like 
PC12 cells.  Morphologic evaluation of apoptosis confirmed that Aβ-induced nuclear 
fragmentation was prevented by TUDCA.  In addition, Aβ exposure resulted in activation 
of the early stress c-Jun N-terminal kinase (JNK) pathway, JNK nuclear translocation, 
and caspase-2 activation.  Knock-down experiments of JNK established caspase-2 as a 
specific downstream target of JNK in Aβ-induced apoptosis.  Furthermore, active 
caspase-2 cleaved golgin-160 and was localized to the Golgi complex.  Importantly, 
TUDCA abrogated Aβ-induced JNK/caspase-2 signaling.  In conclusion, we show that 
JNK is the proximal stress sensor for soluble Aβ-induced toxicity, which translocates to 
the nucleus, activates caspase-2, and is strongly modulated by TUDCA in PC12 neuronal 
cells.  Active caspase-2 cleaves golgin-160, suggesting caspase-2-dependent transduction 
of Aβ apoptotic signaling through the Golgi complex.  These data provide new 
information linking apoptotic properties of Aβ peptide to distinct subcellular mechanisms 
of toxicity.  Further characterization of this signaling pathway and exact targets of 
modulation are likely to provide new perspectives for modulation of amyloid-induced 
apoptosis by TUDCA. 
 
Keywords: Amyloid β; Apoptosis; c-Jun N-terminal kinase; Caspase-2; Golgi complex; 
Tauroursodeoxycholic acid 
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4.2 Introduction 
Alzheimer‟s disease (AD) is the most common human age-related, sporadic 
neurodegenerative disorder, and characterized by a global cognitive decline.  The 
neuropathological hallmarks of AD include synaptic loss and/or dysfunction, diminished 
neuronal metabolism, senile plaques, neurofibrillary tangles (NFT), and loss of multiple 
neurotransmitter systems (Selkoe, 2001).  Brain regions involved in learning and memory 
processes are reduced in size in AD patients, resulting from degeneration of synapses and 
death of neurons.  Although the mechanisms involved in neuronal dysfunction and death 
are still not completely understood, there is growing evidence to suggest that apoptosis 
may play a key role (Loo et al., 1993; Su et al., 1997) . 
The c-Jun N-terminal kinase (JNK) pathway is a central stress signaling pathway 
implicated in neuronal plasticity, regeneration and death (Herdegen et al., 1997).  Several 
lines of evidence suggest a potential involvement of the JNK pathway in AD 
pathogenesis.  Post-mortem brain sections from AD patients revealed altered subcellular 
distribution and activation of JNK (Pei et al., 2001; Zhu et al., 2001b).  Expression of c-
Jun, a JNK preferential transcriptional target, was also increased in AD brains (Anderson 
et al., 1994; Anderson et al., 1996).  In addition, JNK staining was localized in neurons 
with intracellular accumulation of amyloid β (Aβ), and those surrounding amyloid 
plaques in transgenic mice overexpressing a mutant form of presenilin-1 (Shoji et al., 
2000).  Further, JNK phosphorylates tau, the major constituent of NFT, at sites identified 
in paired helical filaments (Reynolds et al., 1997).  Finally, JNK is activated by Aβ, 
mediating both Aβ toxicity and its adverse effect on hippocampal long term potentiation 
(Bozyczko-Coyne et al., 2001; Minogue et al., 2003; Morishima et al., 2001; Troy et al., 
2001; Wei et al., 2002).  Of note, neurons from c-Jun-null mice are resistant to Aβ 
toxicity (Kihiko et al., 1999). 
Caspase-2 is the most evolutionarily conserved caspase, suggesting that it might 
play a crucial role during programmed cell death.  It shares sequence homology with 
initiator caspases, but its cleavage specificity is closer to that of effector caspases 
(Vakifahmetoglu-Norberg and Zhivotovsky).  The limited knowledge that exists 
regarding  its mechanism of activation and the lack of specific substrates has hampered 
further studies of this unique caspase (Bouchier-Hayes et al., 2009).  Although caspase-2 
can be activated in a JNK-independent mechanism (Marques et al., 2003), the association 
between caspase-2 activation and JNK in response to Aβ-induced neuronal death has been 
documented in cell culture studies, including those with primary neurons from caspase-2 
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null animals (Troy et al., 2000).  In addition, acute or chronic removal of caspase-2 has 
been shown to confer resistance to Aβ. 
The role of apoptosis in Aβ-induced toxicity suggests that its modulation may 
slow the neurodegenerative process.  The endogenous hydrophilic bile acid 
ursodeoxycholic acid (UDCA) and its taurine-conjugate tauroursodeoxycholic acid 
(TUDCA) increase the apoptotic threshold in several cell types (Rodrigues et al., 1998).  
In fact, we have demonstrated that TUDCA interrupts classic apoptotic pathways by 
inhibiting mitochondrial membrane depolarization and channel formation (Rodrigues et 
al., 1999; Rodrigues et al., 2003b; Rodrigues et al., 2000b).  TUDCA is also a potent 
suppressor of Aβ-induced changes of lipid/protein fluidity and oxidative status in the 
membranes of isolated mitochondria (Rodrigues et al., 2001).  Finally, we have shown 
that TUDCA inhibits Aβ-induced apoptosis in vitro (Ramalho et al., 2004; Solá et al., 
2003), and that TUDCA is neuroprotective in pharmacologic and transgenic mouse model 
of Huntington‟s disease (Keene et al., 2002; Keene et al., 2001), and in rat models of 
ischemic and hemorrhagic stroke (Rodrigues et al., 2003a; Rodrigues et al., 2002).  
UDCA is FDA-approved for the treatment of primary biliary cirrhosis and its therapeutic 
effects in liver diseases may result from the ability to modulate cell fate (Paumgartner and 
Beuers, 2004).  UDCA administration was also safe and tolerable in patients with 
amyotrophic lateral sclerosis, and penetrated into the central nervous system in a dose-
dependent manner (Parry et al.). 
In this study, we show that JNK is the proximal stress sensor for Aβ-induced 
toxicity, and that it translocates to the nucleus and activates caspase-2 in PC12 neuronal 
cells.  Caspase-2 then induces cleavage of golgin-160, suggesting a unique transduction 
mechanism of Aβ apoptotic signaling through the Golgi complex.  Importantly, TUDCA 
was efficient in modulating the JNK/caspase-2 apoptotic pathway. 
 
4.3 Materials and methods 
4.3.1 Cell culture and induction of apoptosis 
PC12 cells were grown in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, 
USA) supplemented with 10% heat-inactivated horse serum (Sigma-Aldrich), 5% fetal 
bovine serum (Invitrogen Corp., Carlsband, CA, USA) and 1% penicillin/streptomycin 
(Invitrogen), and maintained at 37°C in a humidified atmosphere of 5% CO2.  Cells were 
plated and differentiated in the presence of nerve growth factor (NGF) (Promega Corp., 
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Madison, WI), as previously described (Park et al., 1998).  Cell density was either at 1 x 
10
5
 cells/cm
2
 for morphological assessment of apoptosis and viability assays, or 4 x 10
5
 
cells/cm
2
 for transfection assays and protein extraction.  PC12 neuronal cells were then 
incubated in medium supplemented with 100 µM TUDCA (Sigma-Aldrich), or no 
addition (control), for 12 h, and exposed to 25 µM of peptide active fragment Aβ (25–35) 
(Bachem AG, Bubendorf, Switzerland) for 1, 2, 8, and 24 h.  Cells were fixed for 
microscopic assessment of apoptosis or processed for cell viability assays.  In addition, 
total proteins were extracted for immunoblotting. 
 
4.3.2 Measurement of cell death 
Cell viability was measured by trypan blue exclusion and by the lactate 
dehydrogenase (LDH) viability
 
assay (Sigma-Aldrich), according to the manufacturer's 
instructions.  Apoptotic nuclei were detected by Hoechst labeling after cell fixation with 
4% formaldehyde in phosphate buffer saline (PBS), for 10 min at room temperature.  
Following incubation with Hoechst dye 33258 (Sigma-Aldrich) at 5 g/mL in PBS for 5 
min, and PBS washes, slides were mounted with PBS:glycerol (3:1, v/v) and fluorescence 
visualized with an Axioskop fluorescence microscope (Carl Zeiss GmbH, Hamburg, 
Germany).  Fluorescent nuclei were scored and categorized according to the condensation 
and staining characteristics of chromatin.  Normal nuclei showed non-condensed 
chromatin dispersed over the entire nucleus.  Apoptotic nuclei were independently 
identified by condensed and fragmented chromatin contiguous to the nuclear membrane, 
as well as nuclear fragmentation and presence of apoptotic bodies.  Three random 
microscopic fields per sample of ~ 250 nuclei were counted and mean values expressed as 
the percentage of apoptotic nuclei. 
 
4.3.3 Inhibition of JNK pathway  
The involvement of JNK pathway in Aβ-induced toxicity was confirmed by cell 
viability assays after inhibition of JNK and c-Jun activation.  PC12 cells were transfected 
at 80% density with either the binding domain of the JNK interacting protein-1 (JIP-1) 
(pCMV-Flag-JBD (JIP-1)) (Dickens et al., 1997), or dominant negative DN-c-Jun 
Flag169 plasmids (Ham et al., 1995), using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer‟s protocol.  At 24 h after transfection, PC12 cells were incubated with 
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25 µM A (25-35) for an additional 24 h.  Cell viability was then measured by trypan 
blue exclusion and confirmed by LDH viability
 
assays.  
 
4.3.4 Immunoblotting 
Steady-state levels of phosphorylated JNK (p-JNK) and c-Jun (p-c-Jun), total 
JNK and c-Jun, and caspase-2 proteins were determined by Western blot analysis.  
Briefly, 80 µg of total and nuclear proteins were separated by 12% sodium dodecyl-
polyacrylamide gel electrophoresis.  After electrophoretic transfer onto nitrocellulose 
membranes, immunoblots were incubated with 15% H2O2 for 15 min at room temperature.  
Following blocking with a 5% milk solution, membranes were incubated overnight at 4°C 
with primary mouse monoclonal antibodies reactive to p-JNK (G-7), primary rabbit 
polyclonal antibodies reactive to p-c-Jun (Ser 63/73), caspase-2 (H-19) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and primary rabbit monoclonal antibodies 
reactive to SAPK/JNK (56G8), c-Jun (60A8) (Cell Signaling Technology, Inc., Danvers, 
MA, USA).  Finally, secondary goat anti-mouse or anti-rabbit IgG antibody conjugated 
with horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA, USA) was added for 3 
h at room temperature.  The membranes were processed for protein detection using the 
SuperSignal substrate (Pierce Biotechnology, Rockford, IL, USA).  β-Actin (AC-15) 
(Sigma-Aldrich), GADPH (6C5) (Santa Cruz) and anti-acetyl-histone H3 (Upstate 
Biotechnology, Lake placid, NY, USA) were used as loading controls for total, cytosolic 
and nuclear proteins, respectively.  Protein concentrations were determined using the Bio-
Rad protein assay kit (Bio-Rad) according to the manufacturer‟s specifications. 
 
4.3.5 Immunocytochemistry 
Cellular localization of p-JNK, p-c-Jun and caspase-2 was determined by 
immunocytochemistry.  Cells were fixed for 30 min in 4% formaldehyde and blocked 
with 10% donkey serum, 1% FBS and 0.1% Triton X-100 for 1h, at room temperature.  
Cells were then incubated either with mouse monoclonal anti-p-JNK antibody, rabbit 
polyclonal anti-p-c-Jun antibody, or rabbit polyclonal anti-caspase-2 (all at 1:50 in 
blocking solution; Santa Cruz), overnight at 4ºC.  After rising, cells were incubated with 
Alexa Fluor 488 conjugated anti-mouse secondary antibody (1:200 in blocking solution; 
Invitrogen) or fluorescently labeled anti-rabbit CyTM5 (1:200 in blocking solution; 
Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) for 1 h at room 
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temperature.  Finally, cells were stained with 5 g/mL of Hoechst dye 33258 for 5 min, or 
co-incubated with mouse monoclonal anti-GM130 (1:200 in blocking solution; BD 
Biosciences, Franklin Lakes, NJ, USA), overnight at 4ºC.  Adequate controls were 
prepared by omitting the primary antibody or using preimmune IgG, which eliminated all 
labeling.  Subcellular localization of p-JNK, p-c-Jun and caspase-2 were visualized using 
an Axioskop fluorescence microscope. 
 
4.3.6 Short interference-mediated silencing of the jnk gene 
A pool of 2 specific short interference RNA (siRNA) nucleotides designed to 
knock down jnk gene expression in rats (Wang et al., 2007b) was purchased from 
Dharmacon (Waltham, MA, USA).  A control siRNA containing a scrambled sequence 
that does not lead to the specific degradation of any known cellular mRNA was used as 
control.  PC12 cells were transfected at 80% density with siRNA at the final 
concentration of 50 and 75 nm using Lipofectamine 2000.  JNK knockdown was 
determined at 24 h after transfection.  Floating and attached cells were harvested for 
preparation of total and nuclear protein extracts, which were then subjected to Western 
blot analysis.   
 
4.3.7 Expression of Golgin-160 cleavage products 
PC12 cells were transfected with either green fluorescent protein (GFP)-tagged 
wild-type golgin-160, or mutant golgin-160 (3DE) using Lipofectamine 2000.  Stable cell 
lines were selected with 0.4 mg/ml G418 (Invitrogen) and screened as described 
previously (Mancini et al., 2000).  Cells were plated and treated at ~ 90% confluency with 
10 mM sodium butyrate in normal growth medium for 12-15 h to increase expression of 
the GFP fusion protein.  Cells were exposed to either 25 µM Aβ (25-35), 10 µM 
staurosporine (positive control) or left untreated, then lysed and processed for 
immunoblotting of GFP (B-2) (Santa Cruz).  
 
4.3.8 Statistical analysis 
The relative intensities of protein bands were analyzed using the Quantity One 
Version 4.6 densitometric analysis program (Bio-Rad) and normalized to the respective 
loading controls.  Statistical analysis was performed using GraphPad InStat Version 3.00 
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(GraphPad Software, San Diego, CA) for the analysis of variance and Bonferroni‟s 
multiple comparison tests. Values of p < 0.05 were considered significant. 
 
4.4 Results 
4.4.1 Aβ-induced apoptosis is mediated by JNK activation and modulated by 
TUDCA in PC12 neuronal-like cells 
Soluble Aβ (25-35) fragment induces apoptosis in neuronal PC12 cells and 
TUDCA is a strong modulator of cell death (Ramalho et al., 2004).  Neuronal PC12 cells 
pre-exposed to NGF for 8 days were treated with Aβ, with or without TUDCA and 
assessed for cell death, and phosphorylation of JNK and c-Jun.  Aβ-induced apoptosis 
was reduced to control levels in cells pre-treated with TUDCA (p < 0.05) (Fig. 4.1).   
 
 
 
Figure 4.1.  TUDCA inhibits apoptosis induced by Aβ in PC12 neuronal cells.  Cells were 
incubated with 25 µM soluble Aβ (25-35), or no addition (control), ± 100 µM TUDCA for 24 h.  
In co-incubation experiments, TUDCA was added 12 h prior to incubation with Aβ.  Cells were 
fixed and stained for microscopic assessment of apoptosis as described in Materials and Methods.  
Fluorescence microscopy of Hoechst staining (top) and percent apoptosis in cells exposed to Aβ ± 
TUDCA (bottom).  Cells exposed to Aβ alone (a) showed more nuclear fragmentation compared 
with cells pre-treated with TUDCA (b).  The results are expressed as mean ± SEM for at least 
three different experiments.  *p < 0.01 from control and †p < 0.05 from Aβ alone.  Scale bar, 10 
µm. 
 
p-JNK increased over time in the absence of TUDCA, peaking at 2 h, while p-c-
Jun peaked at 24 h.  Total JNK and c-Jun remained constant (Fig. 4.2A).  Pre-treatment 
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with TUDCA markedly reduced Aβ-induced JNK and c-Jun phosphorylation (p < 0.05) 
(Fig. 4.2B).  The protective function of TUDCA was independent of Erk and 
phosphatidylinositol 3-kinase/Akt survival activation pathways (data not shown). 
 
 
 
Figure 4.2.  TUDCA modulates Aβ-induced p-JNK and p-c-Jun levels in PC12 neuronal 
cells.  Cells were incubated with 25 µM soluble Aβ (25-35), or no addition (control), ± 100 µM 
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TUDCA, for the indicated time points.  In co-incubation experiments, TUDCA was added 12 h 
prior to incubation with Aβ.  Total proteins were extracted for western blot analysis as described 
in Materials and Methods.  (A) Protein levels of p-JNK and p-c-Jun in cells incubated with Aβ for 
1, 2, 8 and 24 h.  (B) Protein levels of p-JNK and p-c-Jun in cells exposed to Aβ ± TUDCA for 2 
h and 24 h, respectively.  The results are normalized to endogenous total JNK and c-Jun 
production and expressed as mean ± SEM arbitrary units for at least four different experiments.  
(C) Percent cell death measured by trypan blue exclusion after transfection with the binding 
domain of JIP-1 and the dominant negative DN-c-Jun Flag169 plasmids.  *p < 0.01 and §p < 
0.05 from control; ‡p < 0.01 and †p < 0.05 from Aβ alone. 
 
To confirm that JNK activation is required for Aβ-induced cell death in vitro, we 
used two dominant interfering forms of the JNK signaling pathway, pCMV-Flag-JBD 
(JIP-1) (Dickens et al., 1997) and DN-c-Jun FlagΔ169 (Ham et al., 1995).  The binding 
domain fragment of scaffolding protein JIP-1 has been shown to bind JNK and reduce its 
ability to phosphorylate substrates such as c-Jun, thus inhibiting the JNK pathway.  In 
addition, DN-c-Jun Flag169 lacks the c-Jun transactivation domain.  When 
overexpressed, DN-c-Jun Flag169 competes with endogenous c-Jun for binding to DNA 
regulatory elements, thus inhibiting c-Jun-dependent transcription.  Aβ-dependent general 
cell death was essentially abolished in cells transfected with constructs encoding either 
pCMV-Flag-JBD (JIP-1) or DN-c-Jun FlagΔ169 (Fig. 4.2C).  To assess transfection 
efficiency, we have done as described in (Ramalho et al., Journal of Neurochemistry, 
2004). Briefly, cells were co-transfected with the luciferase construct, pCMV-Control 
vector (Promega Corp., Madison, WI, USA). Based on this reporter, transfection 
efficiencies were approximately 70% and did not differ between wild-type and dominant 
negative plasmids.  After 24 h of incubation with Aβ, cell death was 18% in cells 
expressing either pCMV-Flag-JBD (JIP-1) or DN-c-Jun FlagΔ169 constructs, and 30% in 
cells expressing the vector only (p < 0.01).  Thus, JNK appears to be an early stress 
sensor for Aβ-induced toxicity, which in turn is strongly modulated by TUDCA. 
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4.4.2 p-JNK localizes to the nucleus and mediates Aβ-induced caspase-2 
activation 
Under specific stress stimuli, JNK is an absolute requirement for neuronal cell 
death.  Importantly, confinement of JNK inhibition to the cytoplasm failed to protect 
neurons, whereas a nuclear-targeted inhibitor provided robust protection (Bjorkblom et 
al., 2008).  To determine whether p-JNK cellular distribution plays a critical  role in Aβ-
induced apoptosis of PC12 neuronal cells, we performed immunofluorescence studies.  
After 2 h of Aβ incubation, p-JNK was primarily localized to the nucleus, suggesting a 
nuclear signaling mechanism (Fig. 4.3A).  Importantly, TUDCA significantly reduced p-
JNK nuclear localization.  These results were corroborated by immunoblot analysis of 
nuclear protein extracts (Fig. 4.3B).  
 
 
 
Figure 4.3.  Aβ induces p-JNK translocation to the nucleus in PC12 neuronal cells.  Cells 
were incubated with 25 µM Aβ, or no addition (control), ± 100 µM TUDCA, for the indicated 
time points.  In co-incubation experiments, TUDCA was added 12 h prior to incubation with Aβ.  
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(A) Fluorescence microscopy shows immuno-co-localization of p-JNK (in red) with the nucleus 
(in blue) at 2 h of Aβ incubation.  Scale bar, 10 µm.  (B) Representative immunoblots of nuclear 
and cytosolic p-JNK.  The blots were normalized to nuclear and cytosolic endogenous protein 
levels with anti-acetyl-histone H3 and GADPH, respectively.   
 
In addition, p-JNK nuclear localization was associated with increased caspase-2 
intermediate active fragment at 30 kDa at 2 h of Aβ incubation, and a maximum at 24 h 
(p < 0.05) (Fig. 4.4).  Notably, pre-treatment with TUDCA reduced active caspase-2 to 
control levels (p < 0.05). 
 
 
 
Figure 4.4.  TUDCA modulates Aβ-induced active caspase-2 levels in PC12 neuronal cells.  
Cells were incubated with 25 µM Aβ, or no addition (control), ± 100 µM TUDCA, for the 
indicated time points.  In co-incubation experiments, TUDCA was added 12 h prior to incubation 
with Aβ.  Total proteins were extracted for western blot analysis as described in Materials and 
Methods.  Representative immunoblot of cleaved caspase-2 (top) and respective protein levels 
(bottom) in cells exposed to Aβ ± TUDCA for 1, 2, 8 and 24 h.  The results are normalized to 
endogenous β-Actin protein levels and expressed as mean ± SEM arbitrary units of at least four 
different experiments.  §p < 0.05 from control; †p < 0.05 from Aβ alone. 
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Next, we used siRNA to knock down JNK isoforms, and investigated whether 
caspase-2 is a specific downstream target of JNK.  The siRNAs designed against JNK 
isoforms were derived from the jnk1 and jnk2 respective conserved motif, and could 
recognize different sub-isoforms of the respective gene but not isoforms from the other 
gene (Wang et al., 2007b).  Caspase-2 activation was markedly reduced after silencing 
JNK with siRNA JNK 1/2 pool (Fig. 4.5).  Transfection of a scrambled siRNA control did 
not disturb the expression of JNK nor the housekeeping gene β-actin, confirming the 
specificity of JNK siRNAs.  Thus, caspase-2 appears to be a specific downstream target 
of the JNK pathway. 
 
 
 
Figure 4.5.  Silencing of JNK inhibits Aβ-induced caspase-2 activation in PC12 neuronal 
cells.  Cells were transfected either with control, scrambled siRNA or JNK siRNA pool at 50 and 
75 nM.  At 24 h after transfection, cells were challenged with 25 µM Aβ, or no addition (control) 
for 2 h.  Total proteins were extracted for immunoblot analysis as described in Materials and 
Methods.  Representative immunoblots of p-JNK and caspase-2.  The blots were normalized to β-
Actin endogenous protein levels. 
 
4.4.3 Aβ-induced caspase-2 activation mediates cell death via the Golgi complex  
Caspase-2 cleavage alone is not an accurate indication of either activity or 
activation state (Tu et al., 2006). Interestingly, the only caspase-2 specific substrate 
identified thus far is golgin-160, a peripheral Golgi membrane protein (Mancini et al., 
2000).  Although golgin-160 may be cleaved by other caspases, namely caspase-3 and 
caspase-7, it has been shown to possess a caspase-2 specific cleavage site at aspartate-59, 
which is not susceptible to other caspases.  To unequivocally demonstrate caspase-2 
activation, we generated PC12 cell lines stably expressing GFP-tagged wild-type golgin-
160, or mutant golgin-160 with all three caspase cleavage sites replaced with glutamates.  
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We confirmed that neither caspase-3, nor caspase-7, was activated under the experimental 
conditions used (data not shown), suggesting that the GFP-golgin-160 processing pattern 
was due to caspase-2 cleavage alone.  After induction of apoptosis by staurosporine or 
Aβ, the intact wild-type GFP-golgin-160 fusion protein was cleaved, generating a new 
fragment of 28 kDa (Fig. 4.6A).  However, this caspase-2 cleaved fragment was no longer 
detectable in cells expressing mutant GFP-golgin-160 fusion protein.  Importantly, 
immunocytochemistry analysis revealed that caspase-2 was localized to the Golgi process 
after 24 h of Aβ incubation (Fig. 4.6B); and this was reduced by pre-treatment with 
TUDCA.  In fact, fluorescence intensity of caspase-2 and Golgi co-localization was ~ 
30% diminished in the presence of TUDCA.  Thus, caspase-2 localizes to the Golgi and 
acts as an effector element of JNK-dependent Aβ-induced apoptosis, which in turn is 
effectively modulated by TUDCA. 
 
 
 
Figure 4.6.  Caspase-2 localizes to the Golgi complex and cleaves golgin-160 in Aβ-induced 
cell death in PC12 neuronal cells.  (A) Stable PC12 cells transfected with either wild-type 
golgin-160 or mutant golgin-160 were incubated with 25 µM Aβ, 1 µM staurosporine (positive 
control), or no addition (control) for 4 h.  Total proteins were extracted for western blot analysis 
as described in Materials and Methods.  A 28-kDa fragment was detected in wild-type golgin-160 
expressing cells treated with staurosporine or Aβ, but not in mutant golgin-160 expressing cells.  
Representative immunoblots of at least four different experiments are shown.  β-Actin protein was 
used as loading control.  (B) Fluorescence microscopy shows immuno-co-localization of caspase-
2 (in red) with the Golgi complex (in green) at 24 h of Aβ incubation.  Scale bar, 10 µm. 
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4.5 Discussion 
The role of Aβ in the pathogenesis and progression of AD-associated 
neurodegeneration has not been firmly established.  Aβ-induced toxicity is a multi-
factorial process thought to involve the generation of reactive oxygen species, alteration 
of intracellular calcium homeostasis, mitochondrial perturbation, and caspase activation 
(Selkoe, 2001).  Recent studies corroborated the involvement of apoptosis by showing 
that Aβ alters expression of the Bcl-2 family of apoptosis-related genes (Yao et al., 2005), 
and that survival signaling pathways are required for protection of Aβ-mediated neuronal 
apoptosis (Watson and Fan, 2005).  In addition, we have previously reported that anti-
apoptotic TUDCA prevents Aβ-induced apoptosis by inhibiting the mitochondrial 
pathway of cell death and regulating cell cycle-related proteins (Ramalho et al., 2006; 
Ramalho et al., 2004; Solá et al., 2003).  The present study demonstrates that Aβ-induced 
apoptosis is, at least partially dependent on JNK/caspase signaling.  Further, we show that 
JNK translocates to the nucleus and activates caspase-2, which in turn localizes to the 
Golgi complex and cleaves golgin-160 during toxic Aβ-induced apoptosis.  Importantly, 
TUDCA is an effective modulator of Aβ peptide-induced toxicity through inhibition of 
JNK nuclear localization and caspase-2 activation.  UDCA is FDA-approved for the 
treatment of primary biliary cirrhosis in humans.  In fact, the therapeutic effects of UDCA 
in liver diseases may result from its ability to inhibit apoptosis (Paumgartner and Beuers, 
2004). 
PC12 cells have been established as an efficient system for cell signaling studies 
(Vaudry et al., 2002).  In addition, PC12 cells respond to several stress stimuli via the 
JNK pathway, including Aβ-induced cell death (Troy et al., 2001), and is a logical choice 
for investigating the potential role of JNK in the context of neuronal apoptosis (Waetzig 
and Herdegen, 2003).  Previous studies have shown that activation of JNK signaling is 
closely linked to a variety of apoptotic stimuli; whereas inhibition of JNK provides 
protection against neuronal apoptosis in multiple paradigms, including Aβ-induced 
neurotoxicity (Bozyczko-Coyne et al., 2001; Morishima et al., 2001; Troy et al., 2001; 
Yao et al., 2005, 2007).  In addition, the activation of JNK has been reported in 
susceptible neurons of AD patients and has been correlated with AD pathogenesis (Zhu et 
al., 2001a).  JNK promotes apoptosis via both transcriptional and posttranslational 
regulation of Bcl-2 family members (Wang et al., 2007a; Yao et al., 2007)  c-Jun is also a 
major target of the JNK pathway as it contributes to the cellular stress response and is 
believed to mediate apoptosis neuronal cell death (Behrens et al., 1999) .  In fact, JNK 
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activation is accompanied by an increase in c-Jun Ser-63/73 phosphorylation (Coffey et 
al., 2002).  Although the constitutively high activity that is characteristic of neuronal JNK 
is largely cytoplasmic (Coffey et al., 2000), nuclear localization is critical for cell death 
(Bjorkblom et al., 2008).  Thus, the suppression of JNK-dependent apoptotic gene 
expression may be an effective therapeutic strategy for preventing apoptosis of neuronal 
cells.  
In the present study, we show that Aβ-induced apoptosis in PC12 neuronal-like 
cells requires early JNK activation, confirming this pathway as the proximal stress sensor 
for Aβ toxicity.  JNK activation peaked after 2 h of Aβ incubation, and was followed by 
c-Jun phosphorylation as well as cell death features.  Using two dominant interfering 
forms of the JNK signaling pathway, we further confirmed that JNK is required for Aβ-
induced apoptosis of PC12 neuronal cells.  Moreover, we showed that most early active 
JNK is confined to the cell nucleus.  Despite the myriad of physiological functions 
controlled by JNK in the cytoplasm, our results suggest that Aβ-induced cell death is, in 
part dependent on a nuclear site of JNK activity, consistent with previous observations 
under different conditions (Bjorkblom et al., 2008).  Notably, we demonstrated that 
TUDCA inhibited Aβ-induced JNK activation, changes in p-c-Jun levels, and JNK 
nuclear translocation.  It remains to be determined if JNK-mediated cell death is a strictly 
nuclear-specific process, or instead, p-JNK nuclear localization is a pan-cell death 
mechanism. 
Despite the extensive knowledge regarding JNK pathway activation, 
downstream cell signaling components remain unclear in Aβ-induced apoptosis.  
Caspase-2 has been described as a downstream target of JNK activation in different cell 
models (Murakami et al., 2007; Troy et al., 2001).  However, by using chemical 
inhibitors, which may lack specificity and block multiple events associated with Aβ-
induced apoptosis, these studies were unable to clarify the association (Bennett et al., 
2001; Bozyczko-Coyne et al., 2001).  Here we demonstrate that caspase-2 is a specific 
downstream target of Aβ-induced JNK activation.  In fact, after depleting cells of JNK by 
specific siRNA, Aβ incubations failed to activate both JNK and caspase-2.  As expected, 
TUDCA was also capable of inhibiting caspase-2 activation. 
The role of caspases in the pathogenesis and progression of AD has not been 
entirely established.  Nevertheless, previous studies have shown  that Aβ challenge and 
trophic factor withdrawal activate caspase-2 in neurons (Stefanis et al., 1998; Troy et al., 
2000).  More importantly, it has been described that protein levels of caspase-2 were 
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significantly increased in AD brains (Shimohama et al., 1999).  Here, we confirmed 
caspase-2 as a mediator of Aβ-induced apoptosis and provided mechanistic evidence for 
Aβ-induced caspase-2 activation through the JNK pathway.  Caspase-2 is an initiator 
caspase, but specific details of how, where, and when it is activated remain unclear.  
Furthermore, the mechanism(s) by which caspase-2 induces cell death is unknown.  
Unlike other initiator caspases, caspase-2 does not directly activate executioner caspases; 
and may act via mitochondrial outer membrane permeabilization to induce apoptosis 
(Guo et al., 2002).  Moreover, several stimuli of cell death that induce caspase-2-
dependent pathways do not require other caspases (Troy and Ribe, 2008).  Interestingly, 
caspase-2 deficient neurons are resistant to Aβ and, although caspase-3 becomes activated 
in response to Aβ, it is neither necessary nor sufficient for cell death (Troy et al., 2000). 
The results suggest that Aβ may require primarily caspase-2 to induce neuronal cell death. 
A major contributing factor to the paucity of knowledge on the physiological 
activation of caspase-2 is the inability to measure activation of initiator caspases.  
Caspase-2 undergoes autocatalytic processing when activated and is also cleaved by 
caspase-3 downstream of mitochondrial outer membrane permeabilization (Slee et al., 
1999).  However, this does not activate caspase-2 (Baliga et al., 2004), and thus 
monitoring cleavage alone is not sufficient to identify caspase-2 as the apical caspase 
(Bouchier-Hayes et al., 2009).  It is also critical to determine the downstream substrates 
of caspase-2 to fully understand its functions.  To date, no specific substrates of caspase-
2, other than procaspase-2 itself (Harvey et al., 1996) and golgin-160 (Mancini et al., 
2000) have been identified.  Golgin-160 is a peripheral Golgi membrane-associated 
autoantigen that is cleaved by caspase-2 in vitro during apoptosis (Mancini et al., 2000).  
In the nervous system, the expression of caspase-2 is neuron specific, which makes it an 
attractive target for therapeutic intervention.  In addition, caspase-2 is activated rapidly 
and is upstream or independent of mitochondria, which makes it an attractive target for 
inhibition, without disturbing mitochondrial function (Troy and Ribe, 2008). 
In the present study, we showed that Aβ-induced activated caspase-2 cleaves its 
substrate, the structural Golgi protein golgin-160.  After confirming that neither caspase-3 
nor -7 were activated, we examined the effects of stable expression of wild-type golgin-
160 and caspase-resistant mutant golgin-160.  Cells expressing mutant golgin-160 failed 
to present the characteristic caspase-2 cleavage fragment observed in wild-type golgin-
160 expressing cells.  Our results suggest that Aβ-induced apoptotic signals can be 
transduced at the Golgi complex.  In addition, we demonstrated that caspase-2 has a Golgi 
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complex subcellular distribution, which is effectively modulated by TUDCA.  The Golgi 
complex, with its central location and essential role in membrane traffic, is in an ideal 
position to sense and integrate information on the cell status.  Interestingly, several 
signaling proteins implicated in apoptotic pathways are enriched at Golgi membranes, 
including tumor necrosis factor receptor, Fas, an isoform of protein kinase C, and 
phophatidyl inositide 3-kinase.  Understanding the mechanisms of how proteins such as 
golgin-160 regulate Aβ-induced apoptotic signal transduction will be vital in elucidating 
the role of the Golgi complex in the apoptosis associated with AD. 
In conclusion, this study provides convincing data that Aβ-induced toxicity 
triggers the JNK early stress sensor pathway.  Our results also demonstrated that early 
active JNK is localized primarily to the nucleus, suggesting that this preferential 
subcellular distribution is critical for Aβ-induced neuronal death.  Moreover, our studies 
highlight the importance of caspase-2 and the JNK pathway(s) in the development of Aβ-
induced apoptosis.  Caspase-2 is localized in the Golgi complex, where it cleaves a 
structural Golgi protein.  Notably, TUDCA was able to inhibit JNK early activation and 
nuclear translocation, thus protecting cells from death.  Caspase-2 apoptotic features were 
also considerably inhibited in the presence of TUDCA.  These results clarify Aβ-induced 
subcellular toxicity mechanism and open new avenues in understanding anti-apoptotic 
TUDCA modulation. 
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In modern societies, people live longer than ever and this symbolizes the 
hallmark of human kind evolution.  Age-related diseases embody the opposite face, with 
neurodegenerative diseases representing one of the biggest challenges for modern 
medicine.  The fact that most people maintain a well-functioning nervous system and 
continue being productive through their long lives is truly encouraging. 
By mechanisms not fully understood, people who develop neurodegenerative 
diseases share common significant neuronal loss.  This highlights the importance of 
studying and understanding the cell death phenomenon.  It is now becoming accepted that 
cell death might be initiated through several organelles and specific stress sensors, which 
communicate cell death modulating signals.  Decoding this complex signaling network of 
inter-organellar cross-talk might represent the key for delaying or preventing 
neurodegenerative diseases.  New and effective therapeutic approaches are expected to 
emerge with the integration and understanding of these complex mechanisms. 
Detection of apoptosis in post mortem human tissue is complicated by many 
conceptual and technical factors.  First, the presumed daily rate of neuron loss in 
neurodegenerative disorders is low and disappearance of apoptotic cells is rapid (Vila and 
Przedborski, 2003).  The time period between the condensation of chromatin and the 
formation of apoptotic bodies lasts a few minutes (Bursch et al., 1990), and apoptotic 
bodies can be detected for only 4-5 hours (Arends et al., 1990).  Therefore, early 
morphological changes in apoptotic cells are not easily detected, and the chronological 
sequence of typical apoptotic morphological changes is controversial.  Second, post 
mortem specimens typically derive from advanced disease stages, when most of the 
neurons affected by the pathological process are already lost.  Third, most morphological 
post mortem studies rely on the TUNEL technique to document the presence of apoptotic 
cells.  However, we now know that TUNEL is not specific for apoptosis, especially in 
human post mortem tissue, in which factors such as hypoxia can produce TUNEL-
positive, non-apoptotic DNA damage (Kingsbury et al., 1998).  Aβ peptide induces 
apoptosis in primary neurons in vitro (Loo et al., 1993).  Further, pharmacological or 
molecular inhibition of particular members of the caspase family, such as caspases-2, -3, -
8 and -12, has been reported to offer partial or complete protection against Aβ-induced 
apoptotic cell death in vitro (Giovanni et al., 2000; Ivins et al., 1999; Nakagawa et al., 
2000; Troy et al., 2000).  Despite all of the above, scant evidence of caspase activation or 
apoptotic cell death has been gathered in animal models of AD and, therefore, in vivo 
confirmation for a potential beneficial effect of blocking apoptosis pathways in AD is still 
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uncertain.  Nevertheless, fragmentation of nuclear DNA has been detected in brains of 
patients with AD.  More conclusive biochemical evidence that apoptosis might occur in 
AD has been provided by the detection of activated caspases-3, -8 and -9 in hippocampus 
neurons of brains affected by AD (Rohn et al., 2001; Rohn et al., 2002; Selznick et al., 
1999; Stadelmann et al., 1999).   
Aβ is derived from γ-secretase-mediated processing of the APP, which can also 
be cleaved by caspases, such as caspase-3, at positions distinct from the classic secretase-
processing sites, in both cultured cells and brains affected by AD (Gervais et al., 1999).  
Caspase-mediated cleavage of APP releases not only Aβ, but also a carboxy-terminal 
peptide that is a potent inducer of apoptosis (Lu et al., 2000).  Similarly, caspase-3-
cleaved fragments of tau, a microtubule-associated protein that is the primary protein 
component of the filaments found in AD brains, have also been detected in post mortem 
samples (Rohn et al., 2002).  Nevertheless, neurons appear to compensate for the global 
neuronal loss in AD by expanding their connective interactions and functional capacities 
(Cotman and Anderson, 1988).  This may explain the fact that neurological deficits are 
only clinically detectable when ~ 50 to 70% of neurons are lost in a given population 
(Waldmeier and Tatton, 2004). 
From a translational viewpoint, research on apoptosis creates exciting 
opportunities.  The concept that cell death is not merely random and chaotic, but rather 
occurs in a programmed and regulated fashion was a stimulus to develop the work 
presented in this thesis.  In reality, identifying early signaling events in AD pathogenesis 
is crucial to unravel novel pharmacological targets, which may be amenable to 
therapeutic intervention before significant neuronal degeneration has occurred.  Soluble 
Aβ accumulation, altered phosphorylation of tau, and decreased synaptic density appear 
to occur early in the course of AD-like cytopathology in mouse models and perhaps also 
in patients with mild cognitive impairment, a frequent harbinger of AD.  In addition, 
acute application of soluble forms of human Aβ can rapidly, within minutes and, in some 
cases, reversibly alter synaptic transmission and mimetize the toxic effects observed in 
AD (Townsend et al., 2006).  Aggregation/fibrillization of Aβ plays a critical role in 
neurodegeneration.  In particular, intermediate oligomeric and protofibrillar forms seem 
to display the most potent effects in neuronal cells.  Mutant peptides with accelerated 
formation of intermediate species and increased stability of these structures affect mainly 
vascular cells.  The AE22Q variant peptide has been shown to selectively exert 
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deleterious effects on vascular cells, compared to the wild-type Aβ40 (Bossers et al., 
2009; Fadok et al., 1992).  Nevertheless, the nature of the amyloid assemblies and the 
mechanisms of toxicity remain uncertain.  Using human cerebral endothelial cells we 
studied the influence of the aggregation/fibrillization cascade on apoptosis-induced 
toxicity, and dissected the potential stress pathway.  We determined that AβE22Q 
presented an intermediate Aβ assembly between wild-type Aβ40 and Aβ42.  Aβ40 did not 
show any evidence of fibrillar components, which in turn were obvious for Aβ42.  In 
addition, we determined that neither wild-type Aβ40 nor Aβ42 triggered apoptosis in this 
cellular context.  On the other hand, AβE22Q strongly activated cell death in a selective 
way for human cerebral endothelial cells.  Furthermore, we demonstrated that the stress 
sensors activated by AβE22Q converged and transduced through the mitochondria.  
AβE22Q was a strong inducer of the Bax pro-apoptotic mitochondrial pathway in human 
cerebral endothelial cells, activating specific downstream events, such as cytochrome c 
release and nuclear fragmentation.  Importantly, we showed that TUDCA was effective at 
protecting from vasculotropic E22Q peptide, through suppression of Bax translocation to 
mitochondria.  Notably, despite its potent anti-apoptotic role, TUDCA did not interfere, at 
least directly, with the aggregation properties of Aβ peptide in vitro.  Future experiments 
should clarify whether TUDCA has any differential effect in peptide fibrillization in cell 
culture conditions and, ultimately, in vivo.  These results demonstrate that the 
aggregation/fibrillization cascade per se is not determinant of Aβ-induced apoptotic 
toxicity.  Rather, it is suggested that specific and selective conformational assemblies for 
each Aβ peptide are responsible for the toxic effects.  This is in accordance with data 
from other groups showing that the low-n oligomers, including dimers, trimers and 
tetramers were the most toxic species (Shankar et al., 2008; Townsend et al., 2006).  
Nevertheless, insoluble amyloid plaques may also play a pathogenic role, as their 
invariant accumulation may represent relatively inert reservoirs of small bioactive 
oligomers, which may readily disassemble in the presence of lipids (Martins et al., 2008).  
That plaque cores may release locally active Aβ species in vivo is suggested by a 
penumbra of synapse loss around cores in APP transgenic mice (Spires et al., 2005).  
Despite the fact that mitochondria play a central role in apoptotic cell death, 
recent studies have challenged this function and suggested that apoptosis can be induced 
by the ER stress pathway, independent of mitochondria (Lamarca and Scorrano, 2009).  
In line with this concept, it has been shown that AD does not result from some unusual 
toxic phenomenon but, rather, is caused by age-related declines seen in innumerable 
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metabolic pathways in all metazoans.  Specifically, plaque formation is thought to result 
from failure of the ER to catalyze the post-translational processing of Aβ (Erickson et al., 
2005).  Furthermore, there is an age-dependent decline in critical chaperones necessary 
for catalysis of this process in the ER (Erickson et al., 2006).  Corroborating this idea, 
ER-resident molecular chaperones such as GRP78 and GRP94 are donwregulated in 
brains of AD patients and in PS1 mutant cells (Katayama et al., 1999).  These 
observations provide an alternative explanation for the cognitive decline seen in the 
elderly.  The ER catalyzes the post-translational processing of the bulk of intrinsic plasma 
membrane proteins, including the newly synthesized synaptic proteins necessary for the 
initiation, consolidation, and retrieval of memory (Erickson et al., 2005).  If these proteins 
are not properly folded in the ER, rather than being inserted into the synaptic membrane, 
they are degraded, and the amino acids are recycled. 
One obstacle to understanding how Aβ induces toxicity is the ambiguity over 
which molecular species are responsible for the biological effect.  To overcome this 
concern, and minimize the differential effects of Aβ assemblies in the 
aggregation/fibrilization cascade, we have used one of the shortest and soluble forms of 
Aβ (25-35).  We investigated how ER senses the stress directly caused by Aβ toxic core.  
Our results showed that Aβ-induced toxicity resulted in activation of caspase-12, which 
mediates ER-specific apoptosis in PC12 neuronal cells.  Importantly, using the anti-
apoptotic compound TUDCA, or a calpain inhibitor, we were able to revert active 
caspase-12 to control levels.  Intriguingly, however, we observed that Aβ-induced 
toxicity triggered an early signaling response by the ER, independent of the ER-stress 
pathway.  In fact, ER stress markers such as GRP94, ATF-6α, eIF2α and CHOP/GADD 
153 were downregulated as early as 2 h after soluble Aβ incubation.  This was 
independent of transcription as well as degradation, such as proteasome and autophagy 
pathways.  Changes in ATF-6α were prevented by calpain inhibitor I, suggesting that the 
concentration of intracellular Ca
2+
 was elevated.  However, despite the importance of 
GRP94 in Ca
2+ 
regulation, neither calpain inhibitor I nor Ca
2+ 
channels blockers prevented 
GRP94 protein changes.  Finally, since GRP94 had been identified in the extracellular 
space as a consequence of acute stress cell death (Basu et al., 2000; Berwin et al., 2001), 
we demonstrated that GRP94 downregulation was blocked in cells pretreated with 
inhibitors of the secretory pathway, geldanamycin and brefeldin.  Using an ELISA assay 
for GRP94 in the supernatant of cells challenged with Aβ, we established that GRP94 
levels were increased in the extracellular medium of cells incubated with Aβ.  Once in the 
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extracellular milieu, stress proteins such as GRP94 might increase stress resistance, after 
binding to stress-sensitive recipient neurons, signal tissue destruction to inflammatory 
cells, and aid in immunosurveillance, by transporting intracellular peptides to distant 
immune cells.  These findings deserve further exploitation as they might open new 
opportunities for alternative therapeutic strategies. 
JNK is an early stress pathway that is activated by the ER pathway IRE1α-
TRAF2-ASK1 (Urano et al., 2000).  Further, JNK activates caspase-12 (Tan et al., 2006).  
We found that in the absence of JNK, through the use of dominant negative forms, Aβ-
induced apoptosis was abrogated in PC12 neuronal-like cells.  We have also confirmed 
that JNK was the proximal stress sensor with peak activation at 2 h, followed by c-Jun 
phosphorylation as well as cell death features.  Most early active JNK was confined to the 
cell nucleus, the most probable location when signaling for cell death (Bjorkblom et al., 
2008).  Notably, we demonstrated that TUDCA inhibited Aβ-induced JNK activation, 
changes in p-c-Jun levels, and JNK nuclear translocation.  By silencing JNK, we 
confirmed that caspase-2 was a specific downstream target of Aβ-induced JNK activation.  
Unsurprisingly, TUDCA inhibited caspase-2 activation as determined by cleavage of its 
specific substrate, the structural Golgi protein golgin-160.  In addition, caspase-2 had a 
Golgi complex subcellular distribution, which in turn was effectively modulated by 
TUDCA.  These results suggest that Aβ-induced apoptotic signals can be transduced at 
the Golgi complex and place this organelle in the centre for development of potential 
therapeutic strategies. 
Our results demonstrating a role for diverse cell organelles in cell death signaling 
has advanced our understanding of AD pathogenesis.  We have demonstrated stress 
sensing and execution of apoptosis by mitochondria of human cerebral endothelial cells, 
when faced with toxic mutant Aβ peptides.  We have also shown that soluble forms of Aβ 
distress the ER, independently of ER stress, and suggested that this response may exist as 
a trigger for immunosurveillance protection.  Finally, we have described the straight 
involvement of the nucleus and Golgi complex during Aβ-induced, JNK-dependent cell 
death.   
The involvement of several organelles in AD pathogenesis, together with the 
large panoply of risk factors suggests that AD may be considered as a "pleiotropic 
disease".  Therefore, not surprisingly, the usual approach of single therapy, selective to a 
target, used to treat AD patients is far from the best solution.  A change has recently been 
made in a tentative to use cocktails of medicines.  This approach is also far from ideal, 
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because it does not account totally for safety concerns.  Thus, the use of a "pleiotropic 
agent", such as TUDCA that modulates several pathways of the disease should the further 
addressed in the future, using relevant animal models of AD. 
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